



US 20160237431A1

(19) **United States**

(12) **Patent Application Publication**
Gomez et al.

(10) **Pub. No.: US 2016/0237431 A1**

(43) **Pub. Date: Aug. 18, 2016**

(54) **INHIBITORS OF CACNA1A/ALPHA1A
SUBUNIT INTERNAL RIBOSOMAL ENTRY
SITE (IRES) AND METHODS OF TREATING
SPINOCEREBELLAR ATAXIA TYPE 6**

Related U.S. Application Data

(60) Provisional application No. 61/882,451, filed on Sep. 25, 2013.

Publication Classification

(71) Applicant: **THE UNIVERSITY OF CHICAGO,**
Chicago, IL (US)

(51) **Int. Cl.**
C12N 15/113 (2006.01)

(72) Inventors: **Christopher M. Gomez,** Chicago, IL
(US); **Xiaofei Du,** Chicago, IL (US)

(52) **U.S. Cl.**
CPC **C12N 15/113** (2013.01); **C12N 2310/11**
(2013.01); **C12N 2310/3233** (2013.01); **C12N**
2320/30 (2013.01); **C12N 2310/314** (2013.01)

(21) Appl. No.: **15/024,492**

(57) **ABSTRACT**

(22) PCT Filed: **Jul. 2, 2014**

The disclosure provides methods of treating polyglutamine diseases, e.g., spinocerebellar ataxia Type 6, in a subject, comprising administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject. Also provided herein are the IRES inhibitors, and pharmaceutical compositions comprising the same.

(86) PCT No.: **PCT/US14/45316**

§ 371 (c)(1),

(2) Date: **Mar. 24, 2016**

FIGURE 1A





FIGURE 1B

FIGURE 1C

FIGURE 1D





FIGURE 1E






FIGURE 1F

FIGURE 1G

FIGURE 1H

FIGURE 2A





FIG. 2B



C

6110nt
 ↓
 pRCTmut1F ATC TAC GCA GCC CC ATG GG.....
 pRCTmut2F ATC TAC GCA GCC AT CC ATG GG.....
 pRCTTF ATC TAC GCA GCC A CC ATG GG.....

FIGURE 2C

D




FIGURE 2D

FIGURE 2E




FIGURE 2F




FIGURE 2G

H




FIGURE 2H

I




FIGURE 2I

J




FIGURE 2J

FIGURE 3A




FIGURE 3B




FIGURE 3C




FIGURE 3D




FIGURE 3E



FIGURE 3F




FIGURE 3G




FIGURE 3H




FIGURE 3I




FIGURE 4A




FIGURE 4B




FIGURE 4C





FIGURE 4D






FIGURE 4E




FIGURE 4F

FIGURE 4G




FIGURE 4H





FIGURE 4I




FIGURE 4J

FIGURE 4K




FIGURE 4L




FIGURE 5A




FIGURE 5B

FIGURE 5C




FIGURE 5D





FIGURE 5E






FIGURE 5H




FIGURE 5G




FIGURE 5F

FIGURE 5I





FIGURE 5J






FIGURE 5K




FIGURE 5L




FIGURE 6A




FIGURE 6B




FIGURE 6C




FIGURE 6D

FIGURE 7A





FIGURE 7B

FIGURE 7C




FIGURE 7D




FIGURE 7E




FIGURE 7F




FIGURE 7H




FIGURE 7G




FIGURE 71




FIGURE 8




FIGURE 9A

FIGURE 9B

FIGURE 9C




FIGURE 10

A




FIGURE 11A




FIGURE 11B




FIGURE 11C




FIGURE 11D




FIGURE 11E




FIGURE 11F




FIGURE 11G




FIGURE 11H




FIGURE 11I



FIGURE 11J




FIGURE 11K




FIGURE 11L




FIGURE 12A




FIGURE 12B




FIGURE 12C




FIGURE 12D




FIGURE 13A




FIGURE 13B




FIGURE 13C




FIGURE 13D

FIGURE 13E





FIGURE 13F






FIGURE 14A




FIGURE 14B




FIGURE 15A




FIGURE 15B




FIGURE 16A




FIGURE 16B




FIGURE 16C




FIGURE 17A




FIGURE 17B




FIGURE 17C




FIGURE 17D




FIGURE 18A





FIGURE 18B






FIGURE 19A




FIGURE 19B




FIGURE 19C




FIGURE 20A




FIGURE 20B




FIGURE 20C




FIGURE 20D

FIGURE 21A




FIGURE 21B





FIGURE 21C




FIGURE 22A




FIGURE 22B

FIGURE 23A





FIGURE 23B




FIG. 24A




FIGURE 24B




FIGURE 24C





FIGURE 24D

FIGURE 25A

DEG Identification at different time point
 FDR=0.05
 Fold Change-1.2



B

$\alpha 1ACT_{WT}$ $\alpha 1ACT_{SCAS}$
 6H 24H 72H 240H 6H 24H 72H 240H




FIGURE 25B

C Go terms analysis for Biology Process





FIGURE 25C

FIGURE 25D

D 24 DEGs Related to Neuron Differentiation



E 17 DEGs Related to Cell Cycle




FIGURE 25E

**INHIBITORS OF CACNA1A/ALPHA1A
SUBUNIT INTERNAL RIBOSOMAL ENTRY
SITE (IRES) AND METHODS OF TREATING
SPINOCEREBELLAR ATAXIA TYPE 6**

**CROSS REFERENCE TO RELATED
APPLICATIONS**

[0001] This application claims the priority benefit of Provisional U.S. Patent Application No. 61/882,451, filed Sep. 25, 2013, which is incorporated by reference in its entirety.

GRANT FUNDING

[0002] This invention was made with government support under Grant No. NS-062771 awarded by the National Institute of Neurological Disorders and Stroke. The government has certain rights in the invention.

**INCORPORATION BY REFERENCE OF
MATERIAL SUBMITTED ELECTRONICALLY**

[0003] Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: 834, 081 kilobytes ACII (Text) file named "47917A_SeqListing," created on Jul. 2, 2014.

BACKGROUND

[0004] Spinocerebellar ataxia type 6 (SCA6), a form of spinocerebellar ataxia (SCA), is a dominantly-inherited neurodegenerative disease characterized by progressive ataxia and Purkinje cell degeneration, associated with CAG repeat expansions in the gene, CACNA1A. SCA6 is a severe neurological disorder, and one of the most common SCAs worldwide (1-6), roughly as prevalent as amyotrophic lateral sclerosis (7-9).

[0005] Initially, patients with SCA6 experience problems with coordination and balance (ataxia). Other early signs and symptoms of SCA6 include speech difficulties, involuntary eye movements (nystagmus), and double vision. Over time, individuals with SCA6 may develop loss of coordination in their arms, tremors, and uncontrolled muscle tensing (dystonia). Signs and symptoms of SCA6 typically begin in a person's forties or fifties but can appear anytime from childhood to late adulthood. Most people with this disorder require wheelchair assistance by the time they are in their sixties. Patients with genetically distinct forms of SCA, including SCA6, become disabled and may progress to severe incapacitation. Many patients die prematurely due to aspiration pneumonia or respiratory failure (10-12). The advent of modern molecular genetics has enabled the confirmed molecular diagnosis and characterization of many distinct forms of SCA (13). The most reliable prevalence estimates of these heterogeneous disorders are on the order of 18-50/100,000 (9, 14). Thus, these disorders create a substantial economic and societal burden (15).

[0006] Current treatment of patients with SCA6 is focused on the treatment of manifestations. For example, acetazolamide is given to patients to eliminate episodes of ataxia, while vestibular suppressants are given to reduce vertigo and/or oscillopsia. Ophthalmology consultation is provided for refractive or surgical management of diplopia. Clonazepam is given for REM sleep disorders. Home modifications are suggested for safety and convenience. Canes, walking sticks, and walkers are prescribed in order to prevent falling. Physical

therapy may also be prescribed to maximize compensation and strength, while speech therapy and communication devices are given for dysarthria. Weighted eating utensils and dressing hooks are suggested, while video esophagrams are provided to identify safest behaviors and consistency of food least likely to trigger aspiration. Feeding assessment when dysphagia becomes troublesome is considered. Furthermore, weight control, as obesity exacerbates ambulation and mobility difficulties, is provided. Moreover, CPAP may be administered to patients for sleep apnea.

[0007] However, no preventive treatment exists for the numerous polyglutamine (polyQ) diseases, including SCA6, and, currently, there are no treatments that target SCA6 itself. Thus, a method of treating SCA6, rather than a method of treating SCA6 manifestations, is needed.

SUMMARY

[0008] Presented herein are data relating to the origin and function of the α 1ACT polypeptide in physiology and disease. It is demonstrated here that α 1ACT is generated from the full-length α 1A transcript by means of a cellular internal ribosomal entry site (IRES) located within the α 1A mRNA, i.e., that the CACNA1A gene is bi-cistronic. The α 1ACT protein containing the normal polyQ tract is a transcription factor that binds and enhances expression of several Purkinje cell (PC)-expressed genes, promotes neurite outgrowth, and partially rescues the CACNA1A knockout phenotype. α 1ACT with expanded polyQ has altered function, reduces viability of cells in vitro, and causes gait impairment and cerebellar cortical atrophy in vivo. Herein, a truly bi-cistronic, dual-function, cellular gene encoding two proteins with completely distinct functions, in this case an ion channel and a transcription factor, is reported. This gene expression strategy demonstrates a novel role for an IRES in coordinating gene expression, as well as a potential therapeutic target for disease modifying therapy.

[0009] The disclosure provides a method of treating a genetic disease in a subject. The method comprises the step of administering to the subject an IRES inhibitor in an amount effective for treating the genetic disease. In exemplary embodiments, the genetic disease is a trinucleotide repeat disorder. In exemplary embodiments, the trinucleotide repeat disorder is a polyglutamine disease. In exemplary aspects, the polyglutamine disease is spinocerebellar ataxia Type 6 (SCA6).

[0010] Accordingly, the disclosure provides a method of treating spinocerebellar ataxia Type 6 (SCA6). The method comprises the step of administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject.

[0011] The disclosure also provides a method of treating a subject with a predisposition to spinocerebellar ataxia Type 6 (SCA6). The method comprises the step of administering to the subject an IRES inhibitor in amount effective for delaying development of SCA6 in the subject.

[0012] IRES inhibitors, as well as pharmaceutical compositions comprising an IRES inhibitor, are provided herein. In exemplary embodiments, the IRES inhibitor is an antisense molecule, e.g., an antisense oligonucleotide or antisense nucleic acid analog. In exemplary aspects, the IRES inhibitor is a nucleic acid analog comprising a 6-membered morpholine ring, in place of the ribose or deoxyribose ring found in RNA or DNA. In exemplary aspects, the nucleic acid analog comprises non-ionic phosphorodiamidate inter-subunit link-

ages in place of anionic phosphodiester linkages found in RNA and DNA. In exemplary aspects, the nucleic acid analog comprises nucleobases (e.g., adenine, cytosine, guanine, thymine, uracil) that are found in RNA and/or DNA.

[0013] Additionally provided herein is a method of identifying a compound with SCA6 therapeutic activity. In exemplary aspects, the method comprises the steps of (i) contacting the compound with a sample comprising a nucleic acid molecule comprising at least a portion of the $\alpha 1A$ mRNA, wherein the portion comprises at least the nucleotide sequence of the IRES of the $\alpha 1A$ mRNA and the coding sequence of $\alpha 1ACT$, (ii) assaying for expression of $\alpha 1ACT$, wherein the compound is identified as a compound with anti-SCA6 therapeutic activity, when expression of $\alpha 1ACT$ mRNA is reduced as compared to a control.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] FIG. 1 relates to the C terminal fragment of $\alpha 1A$ subunit initiating at MIMNEY (amino acids 1960-1964, nucleotide 6114-6128). FIG. 1A represents a Western blot analysis of fractions collected from HiTrap™ DEAE FF anion exchange chromatography. 3xFLAG-tagged $\alpha 1A$ subunit is used as positive control. FIG. 1B represents a Coomassie blue staining of the peak $\alpha 1ACT$ -containing fraction after two-step purification. The arrowhead indicates the 75 kD band identified by mass spectrometry as $\alpha 1ACT$. FIG. 1C represents a Western blot analysis of lysate from $\alpha 1A$ over-expressing cells with anti-FLAG antibody confirms the identity of $\alpha 1ACT$. FIG. 1D represents an LC-MS/MS analysis of in-gel digest of propionylated protein reveals that the starting amino acid sequence of N terminus of the $\alpha 1ACT$ fragment is Met Ile Met Glu Tyr. FIG. 1E is a schematic representation of the constructs with a series of mutations or deletions. FIG. 1F illustrates that an in-frame deletion of the start site of $\alpha 1ACT$ does not abolish the expression of the 75 kD C terminal portion of the FLAG-tagged $\alpha 1A$ protein bearing either normal range (Q11) or pathological range (Q33) of polyQ. FIG. 1G illustrates that expression of the 75 kD $\alpha 1ACT$ C terminal fragment persists after insertion of termination codons at T1937 or P1847 in the FLAG-tagged $\alpha 1A$ subunit, upstream of the start site. FIG. 1H illustrates that deletion of a 534 bp fragment ($\alpha 1Ade1534Q11$), but not deletion of a 185 bp fragment ($\alpha 1Ade1185Q11$) from the $\alpha 1A$ coding region upstream of the $\alpha 1ACT$ eliminates $\alpha 1ACT$ expression, while maintaining expression of full-length $\alpha 1A$ -FLAG. Deletions using encoded Q33 repeat expansions constructs ($\alpha 1Ade1185Q33$ and $\alpha 1Ade1534Q33$) behave similar to the Q11 constructs (see also FIG. 8).

[0015] FIG. 2 relates to CACNA1A mRNA containing an IRES. FIG. 2A is a schematic representation of the constructs pRF and pRCTTF. FIG. 2B illustrates that IRES activity is demonstrated using bi-cistronic vectors. The ratio of Renilla luciferase and firefly luciferase activities was determined and normalized to β -galactosidase activities. FIG. 2C illustrates the sequence of CACNA1A IRES nucleotide inserts CTT, CTmut1 and CTmut2, insertion of 1-2 nucleotides. The three sequences in FIG. 2C are presented in the Sequence Listing as SEQ ID NOS: 167-169 (top sequence to bottom sequence, respectively). FIG. 2D illustrates that the luciferase activities of bi-cistronic vectors bearing nucleotide insertions are determined as in FIG. 2B. FIG. 2E is a schematic representation of the constructs pGL3Basic and pGL3BasicCT. The same DNA fragments as inserted into pRF were subcloned into the promoter-less pGL3Basic construct. FIG. 2F illustrates

Luciferase activities, which are determined as in FIG. 2B. FIG. 2G shows that the raw firefly luciferase activities of two fragments are compared between promoter-less vector pGL3BasicCT and bi-cistronic vector pRCTTF, which suggests 1014 bp fragment contains an IRES. FIG. 2H: Quantitative, real-time reverse transcription-PCR (qRT-PCR) performed using RNA from cells transfected with bi-cistronic vectors as amplified using primers, Ren1, Ren2 and Fire demonstrates no difference in abundance of R-Luc and F-Luc mRNA. (I and J) qRT-PCR performed using RNA extracted from PC12 and HEK293 cells, transfected with $\alpha 1A$ or human cerebellum to compare abundance of amplicons Ex34-35, Ex38-39 and Ex39-40, upstream of the $\alpha 1ACT$ start site relative to amplicons Ex41-42 (I) and Ex41-43 (J), from within the $\alpha 1ACT$ coding region. Data are mean \pm SEM, n>3 (each involving triplicate assays, *p<0.05, **p<0.01). (see also FIG. 9).

[0016] FIG. 3. $\alpha 1ACT$ is a transcription factor that regulates neural gene expression through an AT-rich element (A) ChIP and quantitative real-time PCR verification of DNA sequences identified by ChIP-cloning. PC12 cells were transfected with empty vector or FLAG-tagged $\alpha 1ACT_{WT}$. (B) Relative enrichment was calculated as the ratio between the net intensity of each bound sample normalized to its input sample, and the vehicle control sample normalized to vehicle control input sample (n \geq 3). (C) Enhancer activity of BTG1 gene fragments. Positions of the fragments are indicated. (D) Promoter activity of GRN gene fragments. Positions of the fragments are indicated. (E) Consensus sequence analyzed by CLC main workbench Version 6.5 among the $\alpha 1ACT$ ChIP-targeted sequences. Consensus sequence was predicted and labeled in red. The sequences of FIG. 3E are presented in the Sequence Listing as SEQ ID NOS: 170-174 (top sequence to bottom sequence, respectively). (F) EMSA demonstrates the formation of displaceable nucleoprotein complex with the $\alpha 1ACT$ and BTG1 WT (517-630nt) element. Lane 1 is biotin-labeled BTG1 WT probe. Lanes 2 and 5 show the three major complexes formed between BTG1 probe and $\alpha 1ACT_{WT}$ nuclear protein. Lane 8 shows the fourth complex formed between BTG1 probe and $\alpha 1ACT_{SCA6}$ nuclear protein. (G) EMSA shows that the AT-rich probe (531-553nt) forms three complexes in the absence of competitor. These complexes were displaced by excess unlabeled AT-rich sequence and partially abolished by AT-rich Mut1 and Mut3. The super-shifted bands were only seen in $\alpha 1ACT_{WT}$ -FLAG nuclear extracts treated with FLAG-M2 antibodies, but not in lane of pCDNA3 nuclear extracts. (H) EMSA shows that the TTATAA region is critical for the formation of nucleoprotein complexes with AT-rich element. (I) $\alpha 1ACT_{WT}$ significantly increases BTG1 enhancer activity through intact TTATAA region. Plasmid pRL-TK is used as transfection efficiency control. Data are mean \pm SEM, n \geq 3 (each involving triplicate assays, *p<0.05 vs. control construct) The sequences of FIG. 3I are presented in the Sequence Listing as SEQ ID NOS: 175-178 (top sequence to bottom sequence, respectively). See also FIG. 10.

[0017] FIG. 4. $\alpha 1ACT$ enhances neurite outgrowth by regulating BTG1 expression (A) Relative mRNA expression levels of BTG1, PMCA2, TAF and GRN in PC12 cells transfected with $\alpha 1A_{WT}$, $\alpha 1ACT_{WT}$ or $\alpha 1ACT_{SCA6}$ (n \geq 3). (B and C) Western blot (B) and quantitation of protein expression levels of BTG1 and PMCA2 in PC12 cells transfected with $\alpha 1A_{WT}$, $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ (C). (D) Relative levels of BTG1 mRNA in the cerebellum from two SCA6 patients,

normalized to Pcp2. (E and F) $\alpha 1ACT_{WT}$ enhances neurite outgrowth. Representative low- and high-magnification images of PC12 cells with transiently transfected pcDNA3-FLAG, $\alpha 1A_{WT}$ -FLAG, $\alpha 1ACT_{WT}$ -FLAG and $\alpha 1ACT_{SCA6}$ -FLAG at 24 hr (E) and 72 hr after NGF treatment (F). Cells were labeled for GAP-43 (green) to visualize PC12 cell body and neurites. (G and H) Quantitation of average neurite length and percentage of neuritis per cell (n=200; *p<0.05 versus pcDNA3-FLAG). (I) $\alpha 1ACT_{WT}$ up-regulates BTG1 gene and increases PRMT1/BTG1 protein interaction. (J and K) Silencing of BTG1 expression inhibits $\alpha 1ACT_{WT}$ -enhanced neurite outgrowth. Anti-FLAG staining is shown in red. (L) Quantitation of neurite outgrowth by siBTG1 in transfected cells (n=3, *p<0.05). The blunted effect by $\alpha 1ACT_{SCA6}$ -FLAG was also diminished by BTG1 silencing. Data are mean \pm SEM (see also FIG. 11).

[0018] FIG. 5. $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{WT}$ transgenic mice have improved phenotype and development of cerebellar cortex compared to $\alpha 1A^{-/-}$ mice. (A and B) The genotype (A) and appearance (B) of $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{WT}$ mice. (C) $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{WT}$ mice had slightly greater body weight compared with $\alpha 1A^{-/-}$ mice at age of P14 (*p<0.05). (D) The lifespan of $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{WT}$ mice was significantly improved compared to $\alpha 1A^{-/-}$ (*p<0.05). Some pups survived until age of P30 (n=2, not included in the Figure), while all $\alpha 1A^{-/-}$ pups died before P20. (E-H) $\alpha 1ACT$ expression improves cerebellar cortex and PC dendrites. Low power images of cerebellar ML (E). PC dendrites are labeled for calbindin-28 kDa (green). The thickness of the ML (F), the relative height of dendritic tree (G), and the density (as defined in Methods) of the PC dendritic tree (H) were reduced in $\alpha 1A^{-/-}$ mice and partially corrected in $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{WT}$ mice (100 dendritic trees from 5 mice at each group. Control is set as 1, *p<0.05). (I) Immunolabeling of PFs and PC dendrites using anti-vGlu1 (red) and anti-calbindin (green) antibodies. (J) Immunolabeling of CFs and PC dendrites using anti-vGlu2 (red) and anti-calbindin (green) antibodies. (K and L) Quantitation of CF reach (K) and relative height of dendritic tree (L) (100 CFs, *p<0.05). CF height was measured from the apical pole of PC somata to the tips of vGluT2 labeled CFs. Data are mean \pm SEM (see also FIG. 12).

[0019] FIG. 6. $\alpha 1ACT$ partially restores PF EPSC amplitude but does not affect CF innervation or EPSC properties. (A) PF-EPSC amplitude as a function of stimulus intensity for $\alpha 1A^{-/-}$ (n=9, N=4), $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT$ (n=16, N=6), and WT (n=11, N=3) mice. Top: Typical PF-EPSCs at a stimulus intensity of 45 μ A. (B) Paired-pulse ratios as a function of stimulus interval in $\alpha 1A^{-/-}$, $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT$, and WT mice. Inset shows an overlay of representative traces from all three groups of mice with an interstimulus interval of 20 ms. EPSC1 from $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT$ and WT mice were scaled to match the amplitude of EPSC1 from the $\alpha 1A^{-/-}$ mouse to facilitate comparison. (C) Top: Representative CF-EPSCs elicited while holding at -30 mV. Bottom left: CF-EPSC amplitudes for $\alpha 1A^{-/-}$ (n=10, N=3), $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT$ (n=11, N=3), and WT (n=8, N=3) mice. Bottom right: Paired-pulse depression of CF-EPSCs with 200 ms stimulus interval. (D) Left: representative traces from PCs in $\alpha 1A^{-/-}$ and $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT$ mice exhibiting multiple CF innervation. Right: Percentage of PCs exhibiting either one, two, or three discrete CF steps in $\alpha 1A^{-/-}$ (2 steps: 6/13, 3 steps: 1/13, N=3), $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT$ (2 steps: 5/13, N=3), and WT (2 Steps: 1/9, N=3) mice. All mice were age P16-18. *p<0.05, **p<0.01. Data are mean \pm SEM.

[0020] FIG. 7 $\alpha 1ACT_{SCM}$ is a pathogenic fragment. (A) Representative fluorescence dot blots of FITC-Annexin V and propidium iodide (PI) stained PC12 cells with stably-transfected pcDNA3-FLAG, $\alpha 1ACT_{WT}$ -FLAG and $\alpha 1ACT_{SCA6}$ -FLAG. (B and C) Quantitation of Annexin V and PI positive cells (*p<0.05). (D) Cell death as measured by LDH release assay (*p<0.05). (E) Expression levels of $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCM}$ in cerebellar homogenates by qRT-PCR. (F) Double support of Hind paw was impaired in PC- $\alpha 1ACT_{SCA6}$ transgenic mice compared with PC- $\alpha 1ACT_{WT}$ transgenic mice at age 3-month, 9-month old (*p<0.01). (G and H) Cerebellar cortical atrophy in PC- $\alpha 1ACT_{SCM}$ transgenic mice. Low power images of cerebellar ML in mice at ages of 20-26 months (G) and Quantitation of ML thickness (H) (*p<0.05). PCs dendrites are labeled for calbindin (green). (I) Schematic illustration of expression regulation and function of $\alpha 1ACT$. Data are mean \pm SEM (see also FIG. 13).

[0021] FIG. 8. LC-MS/MS detection of the starting site of $\alpha 1ACT$ fragment (related to FIG. 1). Analysis of in-gel digest protein (The Rockefeller University Protein Resource Center, N.Y.) revealed that the starting amino acid sequence of N terminus of $\alpha 1ACT$ fragment is Met Ile Met Glu Tyr (amino acids 1960-1964, nucleotide 6114-6128) (GenBank accession GI: 187828892, NM_001127222, NP_001120694).

[0022] FIG. 9. Predicted secondary structure of CACNA1A IRES (related to FIG. 2) (A) Optimal secondary structure of human CACNA1A RNA is determined by energy minimization analysis using the mFold (dG=-2821.5 kcal/mol; plt22ps by D. Stewart and M. Zuker, 2010). The CACNA1A IRES 1014T region exhibits several independently folding domains located around the $\alpha 1ACT$ translation initiation site. (B) The amplified image of RNA structure of CACNA1A IRES as determined by mFold. (C) The amplified image of RNA structure of CACNA1A IRES, after deleting 534 bp 5' of the start codon ATG (1960), as determined by mFold. Color coded by observed pairing number (red=high stability, blue=low stability).

[0023] FIG. 10. EMSA shows that the TTATAA region is critical for the formation of nucleoprotein complexes with AT-rich element (related to FIG. 3) Double-stranded, 3' biotin-labeled probes corresponding to the AT-rich element and mutations of AT-rich element (Mut1t, Mut1a, Mut2t, Mut2a, Mut3, Mut4t and Mut4a) were incubated with PC12- $\alpha 1ACT_{WT}$ -Flag nuclear extracts. Mut1t and Mut1a abolished complex II, and Mut2t and Mut2a abolished complex I. Mut4t and Mut4a, combined with Mut1t and Mut2, abolished both complexes I and II. Mut3 had no effect on protein/DNA complexes.

[0024] FIG. 11. $\alpha 1ACT$ induced neurite outgrowth (related to FIG. 4) (A) Immunofluorescence of PC12 cells with transiently transfected pcDNA3-FLAG, $\alpha 1ACT_{WT}$ -FLAG and $\alpha 1ACT_{SCA6}$ -FLAG. Anti-FLAG staining was shown in red and nuclei were stained in blue with DAPI. The GFP protein was co-transfected to visualize PC12 cell body and neurites. The PC12 cells expressing $\alpha 1ACT_{WT}$ -FLAG and $\alpha 1ACT_{SCA6}$ -FLAG showed strong anti-FLAG staining (red) of nuclei (blue) and lighter staining of neurites compared with pcDNA3. (B-D) Quantitation of neurite outgrowth in transfected cells after NGF (50 ng/ml) treatment for 24 hrs, 48 hrs and 72 hrs. The number of cells with neurites, average neurite length and percentage of neurites per PC12 cell were increased in $\alpha 1ACT_{WT}$ -FLAG expressing cells compared to those in cells expressing pcDNA3-FLAG and $\alpha 1ACT_{SCA6}$ -

FLAG at three time points (means \pm SEM, n=200; p<0.01 versus pcDNA3-FLAG). (E) α 1ACT_{WT} induced neurite outgrowth. Expression of both α 1ACT_{WT} and α 1A_{WT} induced neurite outgrowth in PC12 cells. α 1A_{WT}-induced neurite outgrowth could not be blocked by ω -agatoxin, but was blocked by α 1A_{WT} specific siRNA. (F and G) Western blot showed that N-terminal sequence specific α 1A_{WT} siRNA could inhibit the expression of both full-length and C terminus of α 1A_{WT} gene in PC12 cells transfected with α 1A_{WT}-FLAG, but did not inhibit the expression of α 1ACT_{WT} in PC12 cells transfected with α 1ACT_{WT}-FLAG. (H-J) Immunofluorescence showed that N-terminal sequence specific α 1A_{WT} siRNA could block neurite outgrowth in PC12 cells transfected with α 1A_{WT}-FLAG, but not in PC12 cells transfected with α 1ACT_{WT}-FLAG after NGF treatment. (K) Quantitation of α 1A_{WT}-induced neurite outgrowth in PC12 cells. (L) Western blot showed that siRNA inhibited BTG1 gene expression in stable cell lines expressing α 1ACT_{WT}, α 1ACT_{SCA6} and pcDNA3 after siBTG1 at 0 hr, 24 hrs and 36 hrs. Scale bars represent 20 μ M. Data are mean \pm SEM.

[0025] FIG. 12. Relative mRNA expression levels of BTG1, PMCA2, GRN and TAF among α 1A^{-/-} mice, α 1A^{-/-}/PC- α 1ACT_{WT} and control mice (related to FIG. 5) (A-D) α 1A^{-/-}/PC- α 1ACT_{WT} mice restored the mRNA expression of target genes (n \geq 3, *p<0.05). Filled bar is relative to Pcp2 gene. Open bar is relative to β -actin gene. Data are mean \pm SEM.

[0026] FIG. 13. Generation of transgenic mice over-expressing α 1ACT fragment with pathological polyQ (related to FIG. 7) (A) Immunostaining of myc-labeled α 1ACT fragments carrying normal and pathological ranges of polyQ in mouse cerebellum. The anti-myc antibody was labeled in green. Purkinje cells were labeled using antibody to type 1 inositol 1,4,5-triphosphate receptors (IP₃R₁ in red) which, unlike calbindin, does not label the nucleus. (B) Expression levels of α 1ACTWT and α 1ACTSCA6 in cerebellar homogenates by Western blot with anti-Myc antibody (C-F) Relative mRNA expression level of BTG1, PMCA2, GRN and TAF among control and PC- α 1ACT_{SCA6} transgenic mice. Expression of BTG1 and PMCA2 was decreased 30%-40%, and expression of TAF and GRN was decreased 10%-15% in PC- α 1ACT_{SCA6} transgenic mice compared with those in control mice (n>3, *p<0.05). Filled bar is relative to Pcp2 gene. Open bar is relative to β -actin gene. Data are mean \pm SEM.

[0027] FIG. 14. The C terminal fragment of α 1A subunit initiates at MIMYYR (SEQ ID NO: 165) (amino acids 1960-1964, nucleotide 6114-6128) [A.] The eluted fraction from a DEAE column was incubated with anti-FLAG M2 magnetic beads overnight rinsed and eluted with FLAG. The purified proteins were separated by SDS-PAGE and stained with Coomassie blue to identify a 75 kD band (arrow) as α 1ACT. [B.] LC-MS/MS analysis of the protein revealed the starting AA sequence of N terminus of α 1ACT fragment as Met Be Met Glu Tyr (SEQ ID NO: 166) (amino acids 1960-1964, nucleotide 6114-6128) (Genebank GI:187828892, NM_001127222, NP_001120694).

[0028] FIG. 15. α 1A mRNA contains an IRES. [A.] Immunoblot of transfected cell lysates (anti-FLAG) showing 75 kD fragment of full length α 1A_{Q11} persists despite stop codon (α 1A_{stopQ11}) that abolishes full length 250 kD fragment. 75 kD fragment is eliminated with 534 bp deletion that has no effect on full length fragment. 55kD band corresponds to IgG. [B.] Four gene fragments from α 1A cDNA were amplified by PCR and inserted into the bicistronic construct, pRF, to gen-

erate pRCTF and transfected into HEK293 cells with p β -gal control plasmid to detect IRES activity. The ratio of Renilla luciferase (and firefly luciferase activities were determined and normalized to β -galactosidase activity. Data shown are mean \pm SD of three independent experiments (each involving triplicate assays).

[0029] FIG. 16. [A.] Electrophoretic mobility gel shift assays show that α 1ACT_{WT} (Q11) and α 1ACT_{SCA6} (Q33) nuclear extracts (NE) interact with BTG1 3' UTR DNA probe specifically (Complex IV, lanes 5 and 8), although the α 1ACT_{SCA6} complex resists competition suggesting a greater affinity (lane 10). Incubation with anti-FLAG ab caused a supershift (not shown). [B.] EMSA showed that the TTATAA region was critical for the formation of nucleoprotein complexes with 517/600 element. Double-stranded, 3' biotin-labeled probes corresponding to the 517/600 element (WT), mut1, mut2, mut3 and mut4 were incubated with PC12 nuclear extracts. Mut1 abolished complex II. Mut2 abolished complex I. Mut4, combining Mut1 and Mut2, abolished both complexes I and II. Mut3 had no effect on protein/DNA complexes. [C.] Mutated BTG1 targets lose enhancer activity. PC12 cells stably expressing empty vector or α 1ACT were transiently transfected with BTG1630WT, BTG1630mut1, BTG1630mut2, BTG1630mut3 and BTG1630mut4. The data were shown as mean \pm SD of three independent experiments (each involving triplicate assays. *p<0.005 vs. promoter construct). The sequences of FIG. 16C are presented in the Sequence Listing as SEQ ID NOs: 175-178 (top sequence to bottom sequence, respectively).

[0030] FIG. 17. α 1ACT_{WT}(Q11), but not α 1ACT_{SCA6} (Q33) enhances expression of ChIP-targeted genes. [A.] α 1ACT_{WT}, but not α 1ACT_{SCA6}, increases luciferase expression through a 113 bp (630-517) 3' UTR sequence in BTG1. [B.] α 1ACT_{WT}, but not α 1ACT_{SCA6}, increases luciferase expression through a 630 bp (632-1) 5' UTR sequence in granulin (GRN). [C.] Relative RNA expression levels of TAF, BTG1, PMCA2 and GRN in PC12 cells transfected with α 1ACT (n \geq 3, p<0.005). [D.] Relative RNA expression levels of BTG1 relative to endogenous Pcp2 gene in cerebellum from two SCA6 patients (both Q22) compared to control cerebellum.

[0031] FIG. 18. [A.] Quantitation of neurite outgrowth in transiently transfected cells. Cells expressing full length (Q11FLAG) and α 1ACT (5821FLAG) had significantly greater neurite outgrowth than control (PCDNA3). ω -agatoxin did not block neurite outgrowth. [B.] Quantitation of neurite outgrowth in transfected cells. The number of PC12 cells with neurites was increased 2 fold in the cells over-expressing α 1ACT_{WT} over cells expressing pcDNA3. The number of cells with neurites was decreased 20% in PC12 cells over-expressing α 1ACT_{SCA6} compared with PC12 cells expressing pcDNA3 (N=3, P<0.005). [C.] α 1ACT induced neurite outgrowth. Immunofluorescence of PC12 cells with transiently transfected pcDNA3-FLAG, α 1ACT_{WT}-FLAG and α 1ACT_{SCA6}-FLAG. Anti-FLAG staining was shown in red and nucleus was stained blue with DAPI. The GFP protein was co-transfected to visualize PC12 cell body and neurites. The PC12 cells expressing α 1ACT_{WT}-FLAG and α 1ACT_{SCA6}-FLAG show strong anti-FLAG staining (red) of nuclei (blue) and lighter staining of neurites compared with pcDNA3.

[0032] FIG. 19. Purkinje cell-targeted expression of α 1ACT_{WT} partially rescues α 1A^{-/-} CACNA1A phenotype. [A.] Immunofluorescence of CFs in α 1A^{-/-}, α 1A^{-/-}/

$\alpha 1ACT^{tg(Pcp2)}$ and WT mice. Anti-vGlut2 staining was shown in red and the dendrite of Purkinje cells was stained green with Calbindin. The mice were perfused and sacrificed at postnatal day 17. [B.] Upper: Quantitation of Purkinje cells with multiple climbing fibers. Lower: quantitation of relative somatic vs dendritic innervation. [C.] Excitatory postsynaptic currents (EPSCs) of $\alpha 1A^{-/-}$, $\alpha 1A^{-/-}/\alpha 1ACT^{tg(Pcp2)}$ and WT mice, aged 16-17 days. Left: Representative recordings of EPSCs from, paired stimulus protocol. Right: Amplitude of EPSC1 as a function of stimulus intensity.

[0033] FIG. 20. Purkinje cell-directed expression of $\alpha 1ACT$ shows allele-specific pathogenicity of $\alpha 1ACT_{SCA6}$. [A.] Western blot showing equivalent expression of $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{CTSCA6}$ in different lines. [B.] Treadmill analysis of gait shows increasing paw angle variability in 3 and 6 month old mice expressing $\alpha 1ACT_{SCA6}$ compared with WT and $\alpha 1ACT_{WT}$. [C.] Cerebellar cortex of WT, $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ -expressing transgenic mice age 2-2.5 years, stained with calbindin and alexa-488. [D.] Quantitation molecular layer thickness: $n=3$, $p<0.05$.

[0034] FIG. 21. $\alpha 1AQ14$ knockin mice hemizygotes have abnormal cerebellar function and development. [A.] Treadmill (Digigait) assessment shows several abnormal gait parameters in $\alpha 1AQ14/KO$ mice, including paw area variability compared with heterozygous KO mice ($n\geq 3$, $p\leq 0.05$). [B.] and [C.] Innervation of Purkinje cell (green) by climbing fiber (vGlut2, red) is reduced as determined by density (left) and height (right) in $\alpha 1AQ14/KO$ mice compared with heterozygous KO mice.

[0035] FIG. 22 Morpholino, M- $\alpha 1A$, suppresses expression of $\alpha 1ACT$. The underlined sequence, tcacacctca caagtcc[acggacctcaccgtggggaagatct]acgcagcc atg(atg)atca tggagtacta cggcgaca (SEQ ID NO: 7) of the $\alpha 1A$ mRNA was used to design M- $\alpha 1A$. A. Incubation of cells in M- $\alpha 1A$ blocked luciferase activity of the bi-cistronic reporter. B. M- $\alpha 1A$ blocked formation of $\alpha 1ACT$ without affecting $\alpha 1A$.

[0036] FIG. 23A represents a graph of luciferase activity induced in cells treated with miR-1, miR-2, miR-3, or a negative control. FIG. 23B represents a graph of the level of CACNA1A mRNA in cells treated with miR-1, miR-2, miR-3, or a negative control. $n=3$, all data are means+s.e.m.

[0037] FIG. 24A is a set of graphs demonstrating the staining level of propidium iodide (which marks dead or dying cells with compromised membranes) and annexin V (apoptotic cells) of cells transfected with pCDNA3, $\alpha 1ACT_{WT}$, $\alpha 1ACT_{SCA6}$, $\alpha 1ACT^{\Delta 534bp}_{WT}$, or $\alpha 1ACT^{\Delta 534bp}_{SCA6}$.

[0038] FIG. 24B is a graph of demonstrating the % cells positive for propidium iodide staining of cells transfected with pCDNA3, $\alpha 1ACT_{WT}$, $\alpha 1ACT_{SCA6}$, $\alpha 1ACT^{\Delta 534bp}_{WT}$, or $\alpha 1ACT^{\Delta 534bp}_{SCA6}$.

[0039] FIG. 24C is a set of images depicting neurite length at 24 hours or 48 hours of cells transfected with pCDNA3, $\alpha 1ACT_{WT}$, or $\alpha 1ACT^{\Delta 534bp}_{WT}$.

[0040] FIG. 24D is a graph demonstrating neurite length/cell (μm) as a function of time of cells transfected with pCDNA3, $\alpha 1ACT_{WT}$, or $\alpha 1ACT^{\Delta 534bp}_{WT}$.

[0041] FIG. 24E is a graph demonstrating the % of cells with neurites at 24 h or 72 h of cells transfected with pCDNA3, $\alpha 1ACT_{WT}$, or $\alpha 1ACT^{\Delta 534bp}_{WT}$.

[0042] FIG. 25A is an illustration of a comparison of RNA-seq data between cells expressing $\alpha 1ACT_{WT}$ and cells expressing $\alpha 1ACT_{SCA6}$: 37 genes were found in all 4 time points, whereas a number of differentially expressed genes were found at a specific time point. FIG. 25B is a heatmap of

the 37 differentially expressed genes which are at least 1.2 times differentially expressed. The average $\log_{10}FPKM$ values were pruned to be in $[-1.1]$. FIG. 25C is a graph of the gene ontology (GO) term enrichment analysis for biology process of $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ regulated genes. FIGS. 25D and 25E are heatmaps demonstrating temporal expression patterns of genes involved in neuronal differentiation and cell cycle, respectively. $N=3$, $P<0.05$.

DETAILED DESCRIPTION

[0043] Spinocerebellar Ataxia Type 6 (SCA6)

[0044] SCA6 is a neurodegenerative disease (polyQ disorders) caused by expansion of a polyglutamine (polyQ) tract. In SCA6, the polyQ tract expansion is encoded by the 47th exon of the CACNA1A gene. In exemplary aspects, the normal range of polyQ tracts is 4-18, whereas the pathological range of polyQ tracts is 19-33.

[0045] The principal gene product of CACNA1A is the $\alpha 1A$ subunit of the P/Q-type voltage-gated Ca^{2+} channel. Voltage-gated calcium channel genes encode a large family of channel proteins ($\alpha 1$ subunits) that play critical roles in neuronal excitability, transmitter release, muscle contractility and gene expression (Catterall, 2011). Genetic defects of these channels have been implicated in a variety of neurological, cardiac and skeletal muscle disorders (Cain and Snutch, 2011). Diverse mutations in the $\alpha 1A$ subunit, CACNA1A gene, causing either loss or gain of P/Q-type channel function, have been associated with dominantly inherited conditions of migraine, epilepsy, and episodic and progressive ataxia (Rajakulendran et al., 2012). CACNA1A mutations of several types, leading to both loss and gain of channel function, are responsible for several types of neurological diseases, including episodic ataxia type 2, familial hemiplegic migraine, and epilepsy (27-29).

[0046] The presence of the CAG repeat encoding a polyQ tract in the C terminus of the $\alpha 1A$ subunit led to the obvious hypothesis that the polyQ expansion in SCA6 caused a pathological disturbance of P/Q channel function (30, 31). However, several in vitro and in vivo expression studies have failed to demonstrate a consistent effect on channel function (32-36). In particular, two separate studies using CACNA1A knock-in mice with SCA6 repeat expansions failed to demonstrate any change in P/Q channel gating properties in cerebellar neurons (37, 38). Therefore, it is unlikely that SCA6 is a "channelopathy" in the classical sense. That SCA6 was attributed to expansion of polyQ tracts added further complexity to modeling both channel function and disease pathogenesis (Zhuchenko et al., 1997).

[0047] Evidence provided herein suggests that the disease is attributable to expression of a polyQ repeat expansion within a second CACNA1A gene product, $\alpha 1ACT$, that normally serves as a transcription factor (TF) critical for cerebellar cortical development. $\alpha 1ACT$ is a C-terminal peptide encoded by the $\alpha 1A$ mRNA. SCA6-sized polyQ expansions in the $\alpha 1ACT$ TF interrupt its cellular and molecular function, and several studies have shown toxicity of $\alpha 1ACT$ with SCA6-sized polyQ expansions in models. Several laboratories have shown that $\alpha 1ACT$, which contains the polyQ tract, is present as a stable fragment in cultured cells or cerebellar tissues (46-50). This fragment is enriched in cerebellar nuclei, translocated based on nuclear localization signals in the $\alpha 1ACT$ sequence (48). Finally, several groups have shown that the $\alpha 1ACT$ fragment bearing SCA6-expanded

polyQs, unlike the full-length α 1A subunit, is toxic to cultured cells or primary neurons (47-50).

[0048] As shown herein, α 1ACT arises from a gene regulatory mechanism, that is novel for the CACNA1A gene and for ion channel genes in general, in which expression of α 1ACT is under the control of a cryptic cellular internal ribosomal entry site (IRES) within the CACNA1A gene coding region. Based on the data herein, it is hypothesized that the cellular IRES-regulated α 1ACT is required for Purkinje cell development, and that the polyQ-expanded variant, α 1ACT_{SCA6} leads to neurodegeneration.

as being useful in the treatment of other polyQ diseases. Accordingly, the disclosure provides methods of treating a polyglutamine (PolyQ) disease in a subject in need thereof. The methods comprise the step of administering to the subject an IRES inhibitor in an amount effective for treating the polyQ disease in the subject.

[0054] As used herein, the term “polyQ disease” refers to a trinucleotide repeat disorder in which the codon CAG is repeated in the coding region of a gene resulting in a polyQ tract beyond a normal or standard. PolyQ diseases known to date include those listed in the table below.

PolyQ Disease	Gene	No. of PolyQ repeats in Normal State	No. of PolyQ repeats in Pathogenic State
DRPLA (Dentatorubropallidolulysian atrophy)	ATN1 or DRPLA	6-35	49-88
HD (Huntington's disease)	HTT (Huntingtin)	10-35	35+
SBMA (Spinobulbar muscular atrophy or Kennedy disease)	Androgen receptor on the X chromosome.	9-36	38-62
SCA1 (Spinocerebellar ataxia Type 1)	ATXN1	6-35	49-88
SCA2 (Spinocerebellar ataxia Type 2)	ATXN2	14-32	33-77
SCA3 (Spinocerebellar ataxia Type 3 or Machado-Joseph disease)	ATXN3	12-40	55-86
SCA6 (Spinocerebellar ataxia Type 6)	CACNA1A	4-18	21-30
SCA7 (Spinocerebellar ataxia Type 7)	ATXN7	7-17	38-120
SCA17 (Spinocerebellar ataxia Type 17)	TBP	25-42	47-63

Source: “Trinucleotide repeat disorder” on Wikipedia, 2013

[0049] Based at least in part on the data presented herein, the disclosure provides a method of treating SCA6 in a subject in need thereof. The method comprises the step of administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject.

[0050] The disclosure also provides a method of treating a subject with a predisposition to spinocerebellar ataxia Type 6 (SCA6). The method comprises the step of administering to the subject an IRES inhibitor in amount effective for delaying development of SCA6 in the subject. In exemplary aspects, the subject with a predisposition to SCA6 is a subject who has a family history of SCA6. In exemplary aspects, the subject with a predisposition to SCA6 is a subject who has a parent suffering from SCA6. In exemplary aspects, the subject with a predisposition to SCA6 is a subject who has one copy of the altered CACNA1A gene having a number of polyQ tracts in the pathological range. In exemplary aspects, the subject is one who has a number of polyQ tracts in the 47th exon of the CACNA1A gene which is considered pathological (e.g., 19 or more polyQ tracts).

[0051] In exemplary aspects, the subject is a subject who has more than 10 (e.g., more than 11, 12, 13, 14, 15, 16, 17, 18) polyQ tracts in the 47th exon of the CACNA1A gene. In exemplary aspects, the subject is a subject who has more than 15 (e.g., 16, 17, 18) polyQ tracts in the 47th exon of the CACNA1A gene.

[0052] Polyglutamine (PolyQ) Diseases

[0053] Because SCA6 is a polyQ disease, the steps of the method of treating SCA6 provided herein are contemplated

[0055] Besides being encoded by a gene comprising repeated CAG codons, the polyQ proteins involved in polyQ diseases have no structural similarity otherwise. Several polyQ proteins have nuclear functions relating to gene regulation (39). Toxicity in these disorders depends on the flanking protein context of the polyQ tract, and is frequently associated with transport to the nucleus of the full length or a toxic fragment of the mutant protein (40, 41).

[0056] Neurodegenerative Diseases (ND)

[0057] Neurodegenerative diseases are defined as hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral structures of the nervous system. They include diseases such as Alzheimer's Disease and other dementias, Brain Cancer, Degenerative Nerve Diseases, Encephalitis, Epilepsy, Genetic Brain Disorders, Head and Brain Malformations, Hydrocephalus, Stroke, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Huntington's Disease, Prion Diseases, and others.

[0058] There are extensive overlaps between SCA and other neurodegenerative diseases (NDs) (16-19). Although neuronal cell loss is most evident in the regions responsible for the principal clinical presentation of NDs, neurodegeneration is nearly always more widespread (20-23). Moreover, there is an increasing overlap in possible disease mechanisms. For example, there are growing mechanistic genetic overlaps between ALS and SCA2 (24) and SCA6 and epi-

lepsy (25, 26). Thus, insights into molecular pathogenesis in each disease will have a wider impact on understanding neuronal death and dysfunction in other systems.

[0059] The steps of the method of treating SCA6 provided herein are contemplated as being useful in the treatment of other neurodegenerative diseases. Accordingly, the disclosure provides methods of treating a neurodegenerative disease. The method comprises the step of administering to the subject an IRES inhibitor in an amount effective for treating the neurodegenerative disease. In exemplary aspects, the neurodegenerative disease is episodic ataxia type 2, familial hemiplegic migraine, and epilepsy, Alzheimer's Disease and other dementias, Brain Cancer, Degenerative Nerve Diseases, Encephalitis, Epilepsy, Genetic Brain Disorders, Head and Brain Malformations, Hydrocephalus, Stroke, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Huntington's Disease, Prion Diseases, and others. In exemplary aspects, the neurodegenerative disease is SCA6.

[0060] IRES Inhibitors

[0061] The methods of the disclosure comprise the step of administering to a subject an IRES inhibitor. As used herein, the term "IRES" is synonymous with "internal ribosome entry site" and refers to a nucleotide sequence that allows for the initiation of translation in the middle of a messenger ribonucleic acid (mRNA) sequence as part of the greater process of protein synthesis. IRES-mediated translation in exemplary embodiments is considered as "cap-independent" translation. In exemplary aspects, the IRES is located in the 5' untranslated region (5' UTR) of a gene. In alternative aspects, the IRES is located within the middle of a mRNA.

[0062] As used herein, the term "IRES inhibitor" refers to any compound that inhibits IRES-mediated activity, e.g., IRES-mediated translation of an mRNA or IRES protein binding. In exemplary embodiments, the IRES inhibitor is a nucleic acid, a nucleic acid analog, a peptide, a polypeptide, a peptidomimetic, a peptoid, a small molecular weight compound, or the like. In exemplary aspects, the IRES inhibitor is an antisense molecule that binds to mRNA produced by a gene which gene is known to be causative of a particular disease. In exemplary aspects, the antisense molecule is an antisense oligonucleotide comprising deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA). In exemplary aspects, the antisense molecule is an antisense nucleic acid analog comprising a structural analog of DNA and/or RNA. In alternative exemplary aspects, the IRES inhibitor is a small molecular weight compound having a molecular weight of less than about 10 kDa, as measured by, for example, gel filtration chromatography. One skilled in the art will appreciate that a small molecular weight compound can be a non-peptidic compound that is cell-permeable and resistant to degradation. The term "non-peptidic" as used herein refers to not being derived from a protein. The IRES inhibitor may be natural, synthetic, or semi-synthetic or partially synthetic.

[0063] The IRES inhibitor may inhibit any one or more of IRES-mediated activities. In exemplary aspects, the IRES inhibitor inhibits IRES-mediated translation of an mRNA and/or IRES-mediated protein binding. For example, the IRES inhibitor may be a compound which blocks the binding of an IRES trans-acting factor (ITAF) to an IRES. In exemplary aspects, the IRES inhibitor binds to or adjacent to the IRES and effectively blocks the binding of the ITAF to the IRES. In alternative aspects, the IRES inhibitor binds to the ITAF and blocks the binding of the ITAF to the IRES. The

IRES inhibitor may binds to the ITAF within or adjacent to the IRES-binding site of the ITAF, thereby blocking the ITAF's ability to bind to the IRES.

[0064] In additional or alternative embodiments, the IRES inhibitor blocks translation of an mRNA through additional or alternative mechanisms. In exemplary aspects, the IRES inhibitor alters the primary, secondary, and/or tertiary structure of the IRES. In exemplary aspects, the IRES inhibitor effects the change in structure of the IRES by cleaving within the IRES or modifying the chemico-physico attributes of the IRES.

[0065] The IRES inhibitor may provide any level of inhibition of IRES-mediated activity. In exemplary aspects, the IRES inhibitor inhibits at least 10% IRES-mediated activity. In exemplary aspects, the IRES inhibitor achieves at least a 50% inhibition of IRES-mediated activity. In exemplary aspects, the IRES inhibitor achieves at least a 90% inhibition of IRES-mediated activity. In exemplary aspects, the IRES inhibitor inhibits at least 10% IRES-mediated translation. In exemplary aspects, the IRES inhibitor achieves at least a 50% inhibition of IRES-mediated translation. In exemplary aspects, the IRES inhibitor achieves at least a 90% inhibition of IRES-mediated translation. Methods of testing IRES-mediated translation, and thus, methods of inhibiting IRES-mediated translation, are known in the art. See, for example, Du et al., *Cell* 154: 118-133 (2013) and Examples 1 and 2 herein. In exemplary aspects, methods of testing the inhibition of IRES-mediated translation comprises use of one or more bi-cistronic reporter constructs. In exemplary aspects, the IRES inhibitor inhibits at least 10% IRES-mediated protein binding, e.g., IRES-protein binding. In exemplary aspects, the IRES inhibitor achieves at least a 50% inhibition of IRES-protein binding. In exemplary aspects, the IRES inhibitor achieves at least a 90% inhibition of IRES-protein binding. Methods of testing levels of IRES-protein binding are known in the art and include for example electrophoretic mobility shift assay (EMSA). See, e.g., Ausubel, Frederick M. (1994). *Current Protocols in molecular biology*. Chichester: John Wiley & Sons. pp. 12.2.1-11, and Example 1 herein.

[0066] In exemplary aspects, the IRES inhibitor targets an IRES within a viral genome. In exemplary aspects, the IRES inhibitor does not target an IRES within a viral genome. IRESs found within a viral genome are known in the art and include, for example, a picornavirus IRES, aphthovirus IRES, Hepatitis A IRES, Hepatitis C IRES, Pestivirus IRES, Crispavirus IRES, Kaposi's sarcoma associated herpesvirus IRES, and the Marek's disease virus IRES. The IRES inhibitor in exemplary aspects targets an IRES within a poliovirus genome, a rhinovirus genome, an encephalomyocarditis virus genome, a foot-and-mouth disease virus genome, a Hepatitis A virus genome, a Hepatitis C virus genome, a classical swine fever virus genome, a bovine viral diarrhea virus genome, a friend murine leukemia virus genome, a Moloney murine leukemia virus genome, a Rous sarcoma virus genome, a Human immunodeficiency virus genome, a *Plautia stali* intestine virus genome, a *Rhopalosiphum padi* virus genome, a Cricket paralysis virus genome, a Triatoma virus genome, a Kaposi's sarcoma associated herpes virus genome, or a Marek's disease virus genome.

[0067] In exemplary aspects, the IRES inhibitor targets an IRES within a cellular mRNA. In exemplary aspects, the IRES inhibitor does not target an IRES within a cellular mRNA. In exemplary aspects, the cellular mRNA encodes a growth factor, a transcription factor, a translation factor, an

oncogene, a transporter, a receptor, an activator of apoptosis, or a protein localized in neuronal dendrites. In exemplary aspects, the IRES inhibitor targets or does not target an mRNA encoding any one or more of the following proteins: Fibroblast growth factor (FGF-1, FGF-2), Platelet-derived growth factor B (PDGF/c-sis), Vascular endothelial growth factor (VEGF), Insulin-like growth factor 2 (IGF-II), the Antennapedia, Ultrabithorax, MYT-2, NF- κ B repressing factor NRF, AML1/RUNX1, Gtx homeodomain protein, Eukaryotic initiation factor 4G (eIF4G)a, Eukaryotic initiation factor 4G1(eIF4G1)a, Death associated protein 5 (DAPS), c-myc, L-myc, Pim-1, Protein kinase p58PITSLRE, p53, Cationic amino acid transporter Cat-1, Nuclear form of Notch 2, Voltage-gated potassium channel, Apoptotic protease activating factor (Apaf-1), X-linked inhibitor of apoptosis (XIAP), HIAP2, Bcl-xL, Bcl-2, Activity-regulated cytoskeletal protein (ARC), α -subunit of calcium calmodulin dependent kinase II dendrin, Microtubule-associated protein 2 (MAP2), neurogranin (RC3), Amyloid precursor protein, Immunoglobulin heavy chain binding protein (BiP), Heat shock protein 70, (β -subunit of mitochondrial H⁺-ATP synthase, Ornithine decarboxylase, connexins 32 and 43, HIF-1a, APC.

[0068] In exemplary aspects, the IRES inhibitor targets the IRES of a gene associated with a diseased state. In exemplary aspects, the IRES inhibitor targets the IRES of a gene associated with a genetic disorder, e.g., a trinucleotide repeat disorder. In exemplary aspects, the IRES inhibitor targets the IRES of a gene associated with a polyglutamine disease. Genes associated with a polyQ disease are described herein. See, e.g., the table in the section entitled "Polyglutamine Diseases."

[0069] In exemplary aspects, the IRES inhibitor targets the IRES of an mRNA encoding a calcium channel or a transcription factor. In exemplary aspects, the IRES inhibitor targets the IRES of a bi-cistronic mRNA encoding both a calcium channel and a transcription factor. In exemplary aspects, the IRES inhibitor targets the IRES of the α 1A mRNA, which is encoded by the CACNA1A gene. The CACNA1A gene, officially named as the calcium channel, voltage-dependent, P/Q type, alpha 1A subunit gene, is described in the Gene database of the National Center for Biotechnology Information (NCBI) as Gene ID 773. The gene encodes 5 isoforms of the α 1A protein, a voltage-gated calcium channel subunit. Each are provided in the GenBank database as follows: α 1A Isoform 1 (NP_000059); α 1A Isoform 2 (NP_075461.2), α 1A Isoform 3 (NP_001120693.1), α 1A Isoform 4 (NP_001120694.1), and α 1A Isoform 5 (NP_001167551.1). While the IRES is present in all five isoforms, the mRNA encoding Isoforms 1, 3, and 5 do not have the polyQ tract, whereas the mRNA encoding Isoforms 2 and 4 comprise the polyQ tract. In exemplary aspects, the IRES inhibitor targets the IRES of the mRNA of the α 1A Isoform 2 or of the α 1A Isoform 4. The CACNA1A gene also encodes the α 1ACT protein, a transcription factor that coordinates expression of a program of genes involved in neural and Purkinje cell development. The sequence of the nucleic acid encoding the α 1ACT protein is known in the art and is set forth herein as SEQ ID NO: 4.

[0070] In exemplary aspects, the IRES inhibitor blocks binding of the IRES of the α 1A mRNA to an IRES ITAF which binds to the IRES of the α 1A mRNA. In exemplary aspects, the IRES inhibitor binds to an ITAF that binds to the

IRES of the α 1A mRNA. In exemplary aspects, the IRES inhibitor binds to or adjacent to the IRES of the α 1A mRNA.

[0071] In exemplary aspects, the IRES inhibitor is an antisense molecule which permits specific suppression or reduction of expression of the nucleic acid (e.g., the mRNA) encoding the α 1ACT protein. In exemplary aspects, the IRES inhibitor is an antisense molecule which permits specific suppression or reduction of expression of the nucleic acid (e.g., the mRNA) encoding the α 1ACT protein without affecting the expression of the nucleic acid of the α 1A protein. In exemplary aspects, the IRES inhibitor causes specific suppression of translation of the nucleic acid (e.g., the mRNA) encoding the α 1ACT protein without causing degradation of the α 1A mRNA and/or without inhibition of expression of the α 1A protein.

[0072] In exemplary aspects, the antisense molecule can be complementary to the entire coding region of the nucleic acid encoding the α 1ACT protein (SEQ ID NO: 4), or to a portion thereof. The antisense molecule in exemplary aspects is about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45 or about 50 nucleotides in length.

[0073] In exemplary aspects, the antisense molecule is about X to about Y nucleotides in length, wherein X is 10, 11, 12, 13, 14, or 15 and Y is 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. In exemplary aspects, the antisense molecule is about 10 to about 20 nucleotides in length, about 10 to about 21 nucleotides in length, about 10 to about 22 nucleotides in length, about 10 to about 23 nucleotides in length, about 10 to about 24 nucleotides in length, about 10 to about 25 nucleotides in length, about 10 to about 26 nucleotides in length, about 10 to about 27 nucleotides in length, about 10 to about 28 nucleotides in length, about 10 to about 29 nucleotides in length, or about 10 to about 30 nucleotides in length. In exemplary aspects, the antisense molecule is about 11 to about 20 nucleotides in length, about 11 to about 21 nucleotides in length, about 11 to about 22 nucleotides in length, about 11 to about 23 nucleotides in length, about 11 to about 24 nucleotides in length, about 11 to about 25 nucleotides in length, about 11 to about 26 nucleotides in length, about 11 to about 27 nucleotides in length, about 11 to about 28 nucleotides in length, about 11 to about 29 nucleotides in length, or about 11 to about 30 nucleotides in length. In exemplary aspects, the antisense molecule is about 12 to about 20 nucleotides in length, about 12 to about 21 nucleotides in length, about 12 to about 22 nucleotides in length, about 12 to about 23 nucleotides in length, about 12 to about 24 nucleotides in length, about 12 to about 25 nucleotides in length, about 12 to about 26 nucleotides in length, about 12 to about 27 nucleotides in length, about 12 to about 28 nucleotides in length, about 12 to about 29 nucleotides in length, or about 12 to about 30 nucleotides in length. In exemplary aspects, the antisense molecule is about 13 to about 20 nucleotides in length, about 13 to about 21 nucleotides in length, about 13 to about 22 nucleotides in length, about 13 to about 23 nucleotides in length, about 13 to about 24 nucleotides in length, about 13 to about 25 nucleotides in length, about 13 to about 26 nucleotides in length, about 13 to about 27 nucleotides in length, about 13 to about 28 nucleotides in length, about 13 to about 29 nucleotides in length, or about 13 to about 30 nucleotides in length. In exemplary aspects, the antisense molecule is about 14 to about 20 nucleotides in length, about 14 to about 21 nucleotides in length, about 14 to about 22 nucleotides in length, about 14 to about 23 nucleotides in length, about 14 to about 24 nucleotides in length, about 14 to about 25 nucle-

otides in length, about 14 to about 26 nucleotides in length, about 14 to about 27 nucleotides in length, about 14 to about 28 nucleotides in length, about 14 to about 29 nucleotides in length, or about 14 to about 30 nucleotides in length. In exemplary aspects, the antisense molecule is about 15 to about 20 nucleotides in length, about 15 to about 21 nucleotides in length, about 15 to about 22 nucleotides in length, about 15 to about 23 nucleotides in length, about 15 to about 24 nucleotides in length, about 15 to about 25 nucleotides in length, about 15 to about 26 nucleotides in length, about 15 to about 27 nucleotides in length, about 15 to about 28 nucleotides in length, about 15 to about 29 nucleotides in length, or about 15 to about 30 nucleotides in length. In exemplary aspects, the antisense molecule is about 15 to about 30 nucleotides in length or about 20 to 30 nucleotides in length or about 25 to 30 nucleotides in length. In exemplary aspects, the antisense molecule is about 25 nucleotides in length.

[0074] In exemplary aspects, the antisense molecule binds to at least a portion of the sequence of SEQ ID NO: 5 of the α 1A mRNA. SEQ ID NO: 5 is a portion of the sequence of the nucleic acid encoding the α 1ACT protein (known in the art as GenBank Accession No. NM_01127222 and provided herein as SEQ ID NO: 4. SEQ ID NO: 5 is 5101 through 6110 bp of GenBank Accession No. NM_01127222 (SEQ ID NO: 4)). In exemplary aspects, the antisense molecule binds to at least a portion of the sequence of SEQ ID NO: 5 of the α 1A mRNA, wherein the portion is at least 5 contiguous nucleotides (or at least 2 or at least 3 contiguous nucleotides) of SEQ ID NO: 5. In exemplary aspects, the antisense molecule binds to at least 15 contiguous nucleotides of the sequence of SEQ ID NO: 5. In exemplary aspects, the antisense molecule binds to at least 20 contiguous nucleotides of the sequence of SEQ ID NO: 5. In exemplary aspects, the antisense molecule binds to at least 25 contiguous nucleotides of the sequence of SEQ ID NO: 5. In exemplary aspects, the antisense molecule binds to a portion of the α 1A mRNA (and for purposes herein, this portion is termed hereinafter as a target sequence) and the target sequence comprises the ATG start site (i.e., start codon) of the sequence encoding α 1ACT (plus flanking sequence upstream and/or downstream of the ATG start site). The coding sequence of α 1ACT is provided herein as SEQ ID NO: 12 and the α 1A mRNA comprising the coding sequence and the ATG start site is provided herein as SEQ ID NO: 4. In exemplary aspects, the antisense molecule binds to a target sequence of the α 1A mRNA, which target sequence is located upstream or 5' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule binds to a target sequence which is located within the 200 nucleotides immediately upstream or 5' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule binds to a target sequence which is located within the 100 nucleotides immediately upstream or 5' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule binds to a target sequence which is located within the 50 nucleotides immediately upstream or 5' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule binds to a target sequence which is located within the 25 nucleotides immediately upstream or 5' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule binds to a target sequence which is located within the 15 nucleotides immediately upstream or 5' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule

binds to a target sequence of the α 1A mRNA, which target sequence is located downstream or 3' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule binds to a target sequence which is located within the 200 nucleotides immediately downstream or 3' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule binds to a target sequence which is located within the 100 nucleotides immediately downstream or 3' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule binds to a target sequence which is located within the 50 nucleotides immediately downstream or 3' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule binds to a target sequence which is located within the 25 nucleotides immediately downstream or 3' to the ATG start codon of the sequence encoding α 1ACT. In exemplary aspects, the antisense molecule binds to a target sequence which is located within the 15 nucleotides immediately downstream or 3' to the ATG start codon of the sequence encoding α 1ACT.

[0075] In exemplary aspects, the antisense molecule binds to at least a portion of the sequence of SEQ ID NO: 6 of the α 1A mRNA. In exemplary aspects, the antisense molecule binds to at least a portion of the sequence of SEQ ID NO: 6 of the α 1A mRNA, wherein the portion is at least 3 contiguous nucleotides (or at least 5 or at least 2 contiguous nucleotides) of SEQ ID NO: 6. In exemplary aspects, the antisense molecule binds to at least 15 contiguous nucleotides of the sequence of SEQ ID NO: 6. In exemplary aspects, the antisense molecule binds to at least 20 contiguous nucleotides of the sequence of SEQ ID NO: 6. In exemplary aspects, the antisense molecule binds to at least 25 contiguous nucleotides of the sequence of SEQ ID NO: 6. In exemplary aspects, the antisense molecule binds to at least a portion of the sequence of SEQ ID NO: 7 of the α 1A mRNA. In exemplary aspects, the antisense molecule binds to at least a portion of the sequence of SEQ ID NO: 7 of the α 1A mRNA, wherein the portion is at least 2 contiguous nucleotides (or at least 5 or at least 3 contiguous nucleotides) of SEQ ID NO: 7. In exemplary aspects, the antisense molecule binds to the entire sequence of SEQ ID NO: 7.

[0076] In exemplary aspects, the antisense molecule is an antisense oligonucleotide or antisense nucleic acid analog which is complementary to at least a portion of the sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7. The antisense molecule in some aspects is complementary to at least 15 contiguous bases of said sequence. The antisense molecule in some aspects is complementary to at least 20 contiguous bases of the sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7. The antisense molecule in some aspects is complementary to at least 25 contiguous bases of the sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7. In exemplary aspects, the antisense molecule is an antisense oligonucleotide or antisense nucleic acid analog comprising at least 15 contiguous bases of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11, which are complementary sequences of SEQ ID NOs: 5-7, respectively. In exemplary aspects, the antisense molecule is an antisense oligonucleotide or antisense nucleic acid analog comprising at least 15 contiguous bases that differs by not more than 3 bases from a portion of 15 contiguous bases of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11. In exemplary aspects, the antisense molecule is an antisense oligonucleotide or antisense nucleic acid analog comprising at least 15 contiguous

bases that is at least 90% identical to a portion of 15 contiguous bases of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11. In exemplary aspects, the antisense molecule is an antisense oligonucleotide or antisense nucleic acid analog comprising, consisting essentially of, or consisting of SEQ ID NO: 8.

[0077] In exemplary aspects, the antisense molecule binds to at least a portion of the sequence of SEQ ID NO: 56 of the α 1A mRNA. In exemplary aspects, the antisense molecule binds to at least a portion of the sequence of SEQ ID NO: 56 of the α 1A mRNA, wherein the portion is at least 2 contiguous nucleotides (or at least 5 or at least 3 contiguous nucleotides) of SEQ ID NO: 56. In exemplary aspects, the antisense molecule binds to the entire sequence of SEQ ID NO: 56. In exemplary aspects, the antisense molecule binds to at least a portion of the sequence of SEQ ID NO: 57 of the α 1A mRNA. In exemplary aspects, the antisense molecule binds to at least a portion of the sequence of SEQ ID NO: 57 of the α 1A mRNA, wherein the portion is at least 2 contiguous nucleotides (or at least 5 or at least 3 contiguous nucleotides) of SEQ ID NO: 57. In exemplary aspects, the antisense molecule binds to the entire sequence of SEQ ID NO: 57.

[0078] In exemplary aspects, the antisense molecule is an antisense oligonucleotide or antisense nucleic acid analog which is complementary to at least a portion of the sequence of SEQ ID NO: 56 or SEQ ID NO: 57. The antisense molecule in some aspects is complementary to at least 15 contiguous bases of said sequence. The antisense molecule in some aspects is complementary to at least 20 contiguous bases of the sequence of SEQ ID NO: 56 or SEQ ID NO: 57. The antisense molecule in some aspects is complementary to at least 25 contiguous bases of the sequence of SEQ ID NO: 56. In exemplary aspects, the antisense molecule is an antisense oligonucleotide or antisense nucleic acid analog comprising at least 15 contiguous bases of SEQ ID NO: 58 or SEQ ID NO: 59, which are complementary sequences of SEQ ID NOs: 56 and 57, respectively. In exemplary aspects, the antisense molecule is an antisense oligonucleotide or antisense nucleic acid analog comprising at least 15 contiguous bases that differs by not more than 3 bases from a portion of 15 contiguous bases of SEQ ID NO: 58 or SEQ ID NO: 59. In exemplary aspects, the antisense molecule is an antisense oligonucleotide or antisense nucleic acid analog comprising, consisting essentially of, or consisting of SEQ ID NO: 55.

[0079] The antisense molecule can be one which mediates RNA interference (RNAi). As known by one of ordinary skill in the art, RNAi is a ubiquitous mechanism of gene regulation in plants and animals in which target mRNAs are degraded in a sequence-specific manner (Sharp, *Genes Dev.*, 15, 485-490 (2001); Hutvagner et al., *Curr. Opin. Genet. Dev.*, 12, 225-232 (2002); Fire et al., *Nature*, 391, 806-811 (1998); Zamore et al., *Cell*, 101, 25-33 (2000)). The natural RNA degradation process is initiated by the dsRNA-specific endonuclease Dicer, which promotes cleavage of long dsRNA precursors into double-stranded fragments between 21 and 25 nucleotides long, termed small interfering RNA (siRNA; also known as short interfering RNA) (Zamore, et al., *Cell*, 101, 25-33 (2000); Elbashir et al., *Genes Dev.*, 15, 188-200 (2001); Hammond et al., *Nature*, 404, 293-296 (2000); Bern-

stein et al., *Nature*, 409, 363-366 (2001)). siRNAs are incorporated into a large protein complex that recognizes and cleaves target mRNAs (Nykanen et al., *Cell*, 107, 309-321 (2001)). It has been reported that introduction of dsRNA into mammalian cells does not result in efficient Dicer-mediated generation of siRNA and therefore does not induce RNAi (Caplen et al., *Gene* 252, 95-105 (2000); Ui-Tei et al., *FEBS Lett*, 479, 79-82 (2000)). The requirement for Dicer in maturation of siRNAs in cells can be bypassed by introducing synthetic 21-nucleotide siRNA duplexes, which inhibit expression of transfected and endogenous genes in a variety of mammalian cells (Elbashir et al., *Nature*, 411: 494-498 (2001)).

[0080] In this regard, the IRES inhibitor in some aspects mediates RNAi and in some aspects is a siRNA molecule specific for inhibiting the expression of the nucleic acid (e.g., the mRNA) encoding the α 1ACT protein. The term "siRNA" as used herein refers to an RNA (or RNA analog) comprising from about 10 to about 50 nucleotides (or nucleotide analogs) which is capable of directing or mediating RNAi. In exemplary embodiments, an siRNA molecule comprises about 15 to about 30 nucleotides (or nucleotide analogs) or about 20 to about 25 nucleotides (or nucleotide analogs), e.g., 21-23 nucleotides (or nucleotide analogs). The siRNA can be double or single stranded, preferably double-stranded.

[0081] In alternative aspects, the IRES inhibitor is alternatively a short hairpin RNA (shRNA) molecule specific for inhibiting the expression of the nucleic acid (e.g., the mRNA) encoding the α 1ACT protein. The term "shRNA" as used herein refers to a molecule of about 20 or more base pairs in which a single-stranded RNA partially contains a palindromic base sequence and forms a double-strand structure therein (i.e., a hairpin structure). An shRNA can be an siRNA (or siRNA analog) which is folded into a hairpin structure. shRNAs typically comprise about 45 to about 60 nucleotides, including the approximately 21 nucleotide antisense and sense portions of the hairpin, optional overhangs on the non-loop side of about 2 to about 6 nucleotides long, and the loop portion that can be, e.g., about 3 to 10 nucleotides long. The shRNA can be chemically synthesized. Alternatively, the shRNA can be produced by linking sense and antisense strands of a DNA sequence in reverse directions and synthesizing RNA in vitro with T7 RNA polymerase using the DNA as a template.

[0082] Though not wishing to be bound by any theory or mechanism it is believed that after shRNA is introduced into a cell, the shRNA is degraded into a length of about 20 bases or more (e.g., representatively 21, 22, 23 bases), and causes RNAi, leading to an inhibitory effect. Thus, shRNA elicits RNAi and therefore can be used as an effective component of the disclosure. shRNA may preferably have a 3'-protruding end. The length of the double-stranded portion is not particularly limited, but is preferably about 10 or more nucleotides, and more preferably about 20 or more nucleotides. Here, the 3'-protruding end may be preferably DNA, more preferably DNA of at least 2 nucleotides in length, and even more preferably DNA of 2-4 nucleotides in length.

[0083] In exemplary aspects, the antisense molecule is a microRNA (miRNA). As used herein the term "microRNA" refers to a small (e.g., 15-22 nucleotides), non-coding RNA molecule which base pairs with mRNA molecules to silence gene expression via translational repression or target degradation. microRNA and the therapeutic potential thereof are described in the art. See, e.g., Mulligan, *MicroRNA: Express-*

sion, Detection, and Therapeutic Strategies, Nova Science Publishers, Inc., Hauppauge, N.Y., 2011; Bader and Lambers, "The Therapeutic Potential of microRNAs" *Innovations in Pharmaceutical Technology*, pages 52-55 (March 2011)

[0084] In exemplary aspects, the antisense molecule is an antisense oligonucleotide comprising DNA or RNA or both DNA and RNA. In exemplary aspects, the antisense oligonucleotide comprises naturally-occurring nucleotides and/or naturally-occurring internucleotide linkages. The antisense oligonucleotide in some aspects is single-stranded and in other aspects is double-stranded. In exemplary aspects, the antisense oligonucleotide is synthesized and in other aspects is obtained (e.g., isolated and/or purified) from natural sources. In exemplary aspects, the antisense molecule is a phosphodiester oligonucleotide.

[0085] In alternative aspects, the antisense molecule is an antisense nucleic acid analog, e.g., comprising non-naturally-occurring nucleotides and/or non-naturally-occurring internucleotide linkages (e.g., phosphoramidate linkages, phosphorothioate linkages). In exemplary aspects, the antisense nucleic acid analog comprises one or more modified nucleotides, including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosyl-queuosine, inosine, N⁶-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N-substituted adenine, 7-methylguanine, 5-methylammomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueuosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N⁶-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queuosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, 3-(3-amino-3-N-2-carboxypropyl) uracil, and 2,6-diaminopurine.

[0086] In exemplary aspects, the antisense nucleic acid analog comprises non-naturally-occurring nucleotides which differ from naturally occurring nucleotides by comprising a ring structure other than ribose or 2-deoxyribose. In exemplary aspects, the antisense nucleic acid comprises non-naturally-occurring nucleotides which differ from naturally occurring nucleotides by comprising a chemical group in place of the phosphate group.

[0087] In exemplary aspects, the antisense nucleic acid analog comprises or is a methylphosphonate oligonucleotide, which are noncharged oligomers in which a non-bridging oxygen atom is replaced by a methyl group at each phosphorous in the oligonucleotide chain. In exemplary aspects, the antisense nucleic acid analog comprises or is a phosphorothioate, wherein at least one of the non-bridging oxygen atom is replaced by a sulfur at each phosphorous in the oligonucleotide chain.

[0088] In exemplary aspects, the antisense nucleic acid analog is an analog comprising a replacement of the hydrogen at the 2'-position of ribose with an O-alkyl group, e.g., methyl. In exemplary aspects, the antisense nucleic acid analog comprises a modified ribonucleotide wherein the 2' hydroxyl of ribose is modified to methoxy (OMe) or methoxy-ethyl (MOE) group. In exemplary aspects, the antisense nucleic acid analog comprises a modified ribonucleotide

wherein the 2' hydroxyl of ribose is allyl, amino, azido, halo, thio, O-allyl, O—C₁-C₁₀ alkyl, O—C₁-C₁₀ substituted alkyl, O—C₁-C₁₀ alkoxy, O—C₁-C₁₀ substituted alkoxy, OCF₃, O(CH₂)₂SCH₃, O(CH₂)₂—O—N(R¹)(R²), or O(CH₂)—C(=O)—N(R¹)(R²), wherein each of R¹ and R² is independently selected from the group consisting of H, an amino protecting group or substituted or unsubstituted C₁-C₁₀ alkyl. In exemplary aspects, the antisense nucleic acid analog comprises a modified ribonucleotide wherein the 2' hydroxyl of ribose is 2'F, SH, CN, OCN, CF₃, O-alkyl, S-alkyl, N(R¹) alkyl, O-alkenyl, S-alkenyl, or N(R¹)-alkenyl, O-alkynyl, S-alkynyl, N(R¹)-alkynyl, O-alkylenyl, O-Alkyl, alkylenyl, alkaryl, aralkyl, O-alkaryl, or O-aralkyl.

[0089] In exemplary aspects, the antisense nucleic acid analog comprises a substituted ring. In exemplary aspects, the antisense nucleic acid analog is or comprises a hexitol nucleic acid. In exemplary aspects, the antisense nucleic acid analog is or comprises a nucleotide with a bicyclic or tricyclic sugar moiety. In exemplary aspects, the bicyclic sugar moiety comprises a bridge between the 4' and 2' furanose ring atoms. Exemplary moieties include, but are not limited to: —[[C(R_a)(R_b)]_n—, —[C(R_a)(R_b)]_n-0-, —C(R_aR_b)—N(R)-0-or, —C(R_aR_b)-0-N(R)—; 4'-CH₂-2', 4'-(CH₂)₂-2', 4'-(CH₂)₃-2', 4'-(CH₂)-0-2' (LNA); 4'-(CH₂)—S-2'; 4'-(CH₂)₂-0-2' (ENA); 4'-CH(CH₃)-0-2' (cEt) and 4'-CH(CH₂OCH₃)-0-2', 4'-C(CH₃)(CH₃)-0-2', 4'-CH₂—N(OCH₃)-2', 4'-CH₂-0-N(CH₃)-2' 4'-CH₂-0-N(R)-2', and 4'-CH₂-N(R)-0-2', wherein each R is, independently, H, a protecting group, or C₁C₁₂ alkyl; 4'-CH₂—N(R)-0-2', wherein R is H, C1-C12 alkyl, or a protecting group, 4'-CH₂—C(H)(CH₃)-2', 4'-CH₂—C(=CH₂)-2'. Such antisense nucleic acid analogs are known in the art. See, e.g., International Application Publication No. WO 2008/154401, U.S. Pat. No. 7,399,845, International Application Publication No. WO2009/006478, International Application Publication No. WO2008/150729, U.S. Application Publication No. US2004/0171570, U.S. Pat. No. 7,427,672, and Chattopadhyaya, et al, J. Org. Chem., 2009, 74, 118-134). In exemplary aspects, the antisense nucleic acid analog comprises a nucleoside comprising a bicyclic sugar moiety, or a bicyclic nucleoside (BNA). In exemplary aspects, the antisense nucleic acid analog comprises a BNA selected from the group consisting of: α-L-Methyleneoxy (4'-CH₂-0-2') BNA, Aminooxy (4'-CH₂-0-N(R)-2') BNA, β-D-Methyleneoxy (4'-CH₂-0-2') BNA, Ethyleneoxy (4'-(CH₂)₂-0-2') BNA, methylene-amino (4'-CH₂—N(R)-2') BNA, methyl carbocyclic (4'-CH₂—CH(CH₃)-2') BNA, Methyl(methyleneoxy) (4'-CH(CH₃)-0-2') BNA (also known as constrained ethyl or cEt), methylene-thio (4'-CH₂—S-2') BNA, Oxyamino (4'-CH₂—N(R)-0-2') BNA, and propylene carbocyclic (4'-(CH₂)₃-2') BNA. Such BNAs are described in the art. See, e.g., International Patent Publication No. WO 2014/071078.

[0090] In exemplary aspects, the antisense nucleic acid analog comprises a modified backbone. In exemplary aspects, the antisense nucleic acid analog is or comprises a peptide nucleic acid (PNA) containing an uncharged flexible polyamide backbone comprising repeating N-(2-aminoethyl) glycine units to which the nucleobases are attached via methylene carbonyl linkers. In exemplary aspects, the antisense nucleic acid analog comprises a backbone substitution. In exemplary aspects, the antisense nucleic acid analog is or comprises an N3'→P5' phosphoramidate, which results from the replacement of the oxygen at the 3' position on ribose by an amine group. Such nucleic acid analogs are further

described in Dias and Stein, *Molec Cancer Ther* 1: 347-355 (2002). In exemplary aspects, the antisense nucleic acid analog comprises a nucleotide comprising a conformational lock. In exemplary aspects, the antisense nucleic acid analog is or comprises a locked nucleic acid.

[0091] In exemplary aspects, the antisense nucleic acid analog comprises a 6-membered morpholine ring, in place of the ribose or 2-deoxyribose ring found in RNA or DNA. In exemplary aspects, the antisense nucleic acid analog comprises non-ionic phosphorodiamidate intersubunit linkages in place of anionic phosphodiester linkages found in RNA and DNA. In exemplary aspects, the nucleic acid analog comprises nucleobases (e.g., adenine (A), cytosine (C), guanine (G), thymine, thymine (T), uracil (U)) found in RNA and DNA. In exemplary aspects, the IRES inhibitor is a Morpholino oligomer comprising a polymer of subunits, each subunit of which comprises a 6-membered morpholine ring and a nucleobase (e.g., A, C, G, T, U), wherein the units are linked via non-ionic phosphorodiamidate intersubunit linkages. For purposes herein, when referring to the sequence of a Morpholino oligomer, the conventional single-letter nucleobase codes (e.g., A, C, G, T, U) are used to refer to the nucleobase attached to the morpholine ring.

[0092] In exemplary aspects, the Morpholino oligomer binds to at least a portion of the sequence of SEQ ID NO: 5 of the α 1A mRNA. In exemplary aspects, the Morpholino oligomer binds to at least a portion of the sequence of SEQ ID NO: 6 of the α 1A mRNA. In exemplary aspects, the Morpholino oligomer binds to at least a portion of the sequence of SEQ ID NO: 7 of the α 1A mRNA. In exemplary aspects, the Morpholino oligomer is complementary to at least a portion of the sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7. The Morpholino oligomer in some aspects is complementary to at least 15 contiguous bases of said sequence. In exemplary aspects, the Morpholino oligomer comprises at least 15 contiguous bases of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11. In exemplary aspects, the Morpholino oligomer comprises at least 15 contiguous bases that differ by not more than 3 bases from a portion of 15 contiguous bases of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11. In exemplary aspects, the Morpholino oligomer comprises at least 15 contiguous bases that is at least 90% identical to a portion of 15 contiguous bases of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11. In exemplary aspects, the Morpholino oligomer comprises, consists essentially of, or consists of SEQ ID NO: 8.

[0093] In exemplary aspects, the Morpholino oligomer comprises the sequence of SEQ ID NO: 8. In exemplary aspects, the Morpholino oligomer comprises at least 15 contiguous bases of a sequence that (i) differs from SEQ ID NO: 8 by not more than 3 bases (e.g., not more than 4, 5, 6, 7, 8, 9, 10 bases), (ii) is at least 90% (e.g., at least 93%, at least 95%, at least 98%, at least 99%) identical to the sequence set forth in SEQ ID NO: 8, or (iii) is completely complementary to at least a portion of the sequence of SEQ ID NO: 6 or 7.

[0094] In exemplary aspects, the Morpholino oligomer binds to at least a portion of the sequence of SEQ ID NO: 56 of the α 1A mRNA. In exemplary aspects, the Morpholino oligomer binds to at least a portion of the sequence of SEQ ID NO: 57 of the α 1A mRNA. In exemplary aspects, the Morpholino oligomer is complementary to at least a portion of the sequence of SEQ ID NO: 56 or SEQ ID NO: 57. The Morpholino oligomer in some aspects is complementary to at least 15 contiguous bases of said sequence. In exemplary

aspects, the Morpholino oligomer comprises at least 15 contiguous bases of SEQ ID NO: 58 or SEQ ID NO: 59. In exemplary aspects, the Morpholino oligomer comprises at least 15 contiguous bases that differ by not more than 3 bases from a portion of 15 contiguous bases of SEQ ID NO: 58 or SEQ ID NO: 59. In exemplary aspects, the Morpholino oligomer comprises at least 15 contiguous bases that is at least 90% identical to a portion of 15 contiguous bases of SEQ ID NO: 58 or SEQ ID NO: 59. In exemplary aspects, the Morpholino oligomer comprises, consists essentially of, or consists of SEQ ID NO: 55.

[0095] In exemplary aspects, the Morpholino oligomer comprises the sequence of SEQ ID NO: 55. In exemplary aspects, the Morpholino oligomer comprises at least 15 contiguous bases of a sequence that (i) differs from SEQ ID NO: 55 by not more than 3 bases (e.g., not more than 4, 5, 6, 7, 8, 9, 10 bases), (ii) is at least 90% (e.g., at least 93%, at least 95%, at least 98%, at least 99%) identical to the sequence set forth in SEQ ID NO: 55, or (iii) is completely complementary to at least a portion of the sequence of SEQ ID NO: 56 or 57.

[0096] Treatment

[0097] The term "treat" as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complete treatment. Rather, there are varying degrees of treatment of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the present inventive methods can provide any amount, level, or degree of treatment in a subject. Furthermore, the treatment provided by the method of the disclosure may include treatment of one or more conditions or symptoms or signs of the genetic disease, trinucleotide repeat disorder, polyQ disease, or SCA6 being treated. For example, the method of the disclosure may address one or more of: episodes of ataxia, vertigo and/or oscillopsia, diplopia, REM sleep disorders, dysarthria, dysphagia, ambulation and mobility difficulties, sleep apnea, ataxia, speech difficulties, involuntary eye movements (nystagmus), double vision, loss of coordination in their arms, tremors, uncontrolled muscle tensing (dystonia), severe incapacitation, aspiration pneumonia or respiratory failure. Also, the treatment provided by the methods of the disclosure may encompass slowing the progression of the disease or disorder. For example, the treatment may slow the progression of one or more of: episodes of ataxia, vertigo and/or oscillopsia, diplopia, REM sleep disorders, dysarthria, dysphagia, ambulation and mobility difficulties, sleep apnea, ataxia, speech difficulties, involuntary eye movements (nystagmus), double vision, loss of coordination in their arms, tremors, uncontrolled muscle tensing (dystonia), severe incapacitation, aspiration pneumonia or respiratory failure.

[0098] Subjects

[0099] As used herein, the term "subject" is meant any living organism. In exemplary aspects, the subject is a mammal. The term "mammal" as used herein refers to any mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits. It is preferred that the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs). It is further preferred that the mammals are from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses). It is further preferred that the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes). In exemplary aspect, the subject is a human.

[0100] In exemplary embodiments, the human has, is diagnosed with, and/or suffers from a genetic disease, including, any of those known in the art and/or described herein. In exemplary aspects, the subject has, is diagnosed with, and/or suffers from a trinucleotide repeat disorder, such as a polyglutamine disease. In exemplary aspects, the human has, is diagnosed with, and/or suffers from SCA6.

[0101] Antisense Molecules and Pharmaceutical Compositions Comprising the Same

[0102] The disclosure also provides any of the aforementioned IRES inhibitors. In this regard, the disclosure provides any of the aforementioned antisense molecules, e.g., antisense oligonucleotides, antisense nucleic acid analogs, suitable for use in the inventive methods. For purposes herein, in some aspects, the IRES inhibitor, e.g., antisense molecule, is isolated, purified, or not naturally-occurring or synthetic. The term "isolated" as used herein means having been removed from its natural environment. The term "purified" as used herein means having been increased in purity, wherein "purity" is a relative term, and not to be necessarily construed as absolute purity. As used herein, the term "not naturally-occurring" refers to a molecule or compound which is not found in nature or is non-natural. An IRES inhibitor which is not naturally-occurring is "non-naturally occurring." In exemplary aspects, an IRES inhibitor which is not naturally-occurring comprises at least one component which is not found in nature. The non-natural IRES inhibitor may comprise one or more naturally-occurring components but comprises at least one component which is not found in nature. The non-naturally occurring IRES inhibitor in some aspects comprises only naturally occurring components, but the overall structure or arrangement of the components is not found in nature. It is preferred that no insertions, deletions, inversions, and/or substitutions are present in the antisense molecules of the disclosure. However, it may be suitable to comprise one or more insertions, deletions, inversions, and/or substitutions. In exemplary aspects, the antisense molecule comprises a detectable label, such as, for instance, a radioisotope, a fluorophore, or an element particle.

[0103] The antisense molecules of the disclosure can be constructed based on chemical synthesis and/or enzymatic ligation reactions using procedures known in the art. See, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3rd Ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001) and Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons, New York, N.Y. (1994). For example, an antisense molecule can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed upon hybridization (e.g., phosphorothioate derivatives and acridine substituted nucleotides).

[0104] In exemplary aspects, the IRES inhibitor, e.g., antisense molecule, is formulated with one or more pharmaceutically acceptable carriers, diluents, and/or excipients and is provided as part of a pharmaceutical composition. In this regard, the disclosure further provides a pharmaceutical composition comprising any of the IRES inhibitors, e.g., antisense molecules, described herein. The pharmaceutical composition comprises one or more pharmaceutically acceptable carriers, diluents, and/or excipients, and is preferably sterile.

[0105] Depending on the route of administration, the particular IRES inhibitor intended for use, as well as other fac-

tors, the pharmaceutical composition may comprise additional pharmaceutically acceptable ingredients, including, for example, acidifying agents, additives, adsorbents, aerosol propellants, air displacement agents, alkalizing agents, anticaking agents, anticoagulants, antimicrobial preservatives, antioxidants, antiseptics, bases, binders, buffering agents, chelating agents, coating agents, coloring agents, desiccants, detergents, diluents, disinfectants, disintegrants, dispersing agents, dissolution enhancing agents, dyes, emollients, emulsifying agents, emulsion stabilizers, fillers, film forming agents, flavor enhancers, flavoring agents, flow enhancers, gelling agents, granulating agents, humectants, lubricants, mucoadhesives, ointment bases, ointments, oleaginous vehicles, organic bases, pastille bases, pigments, plasticizers, polishing agents, preservatives, sequestering agents, skin penetrants, solubilizing agents, solvents, stabilizing agents, suppository bases, surface IRES inhibitors, surfactants, suspending agents, sweetening agents, therapeutic agents, thickening agents, tonicity agents, toxicity agents, viscosity-increasing agents, water-absorbing agents, water-miscible cosolvents, water softeners, or wetting agents.

[0106] Accordingly, in some embodiments, the pharmaceutical composition comprises any one or a combination of the following components: acacia, acesulfame potassium, acetyltributyl citrate, acetyltriethyl citrate, agar, albumin, alcohol, dehydrated alcohol, denatured alcohol, dilute alcohol, aleuritic acid, alginic acid, aliphatic polyesters, alumina, aluminum hydroxide, aluminum stearate, amylopectin, α -amylase, ascorbic acid, ascorbyl palmitate, aspartame, bacteriostatic water for injection, bentonite, bentonite magma, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, benzyl benzoate, bronopol, butylated hydroxyanisole, butylated hydroxytoluene, butylparaben, butylparaben sodium, calcium alginate, calcium ascorbate, calcium carbonate, calcium cyclamate, dibasic anhydrous calcium phosphate, dibasic dehydrate calcium phosphate, tribasic calcium phosphate, calcium propionate, calcium silicate, calcium sorbate, calcium stearate, calcium sulfate, calcium sulfate hemihydrate, canola oil, carbomer, carbon dioxide, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, β -carotene, carrageenan, castor oil, hydrogenated castor oil, cationic emulsifying wax, cellulose acetate, cellulose acetate phthalate, ethyl cellulose, microcrystalline cellulose, powdered cellulose, silicified microcrystalline cellulose, sodium carboxymethyl cellulose, cetostearyl alcohol, cetrimide, cetyl alcohol, chlorhexidine, chlorobutanol, chlorocresol, cholesterol, chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, chlorodifluoroethane (HCFC), chlorodifluoromethane, chlorofluorocarbons (CFC) chlorophenoxyethanol, chloroxylenol, corn syrup solids, anhydrous citric acid, citric acid monohydrate, cocoa butter, coloring agents, corn oil, cottonseed oil, cresol, m-cresol, o-cresol, p-cresol, croscarmellose sodium, crospovidone, cyclamic acid, cyclodextrins, dextrans, dextrin, dextrose, dextrose anhydrous, diazolidinyl urea, dibutyl phthalate, dibutyl sebacate, diethanolamine, diethyl phthalate, difluoroethane (HFC), dimethyl- β -cyclodextrin, cyclodextrin-type compounds such as Captisol®, dimethyl ether, dimethyl phthalate, dipotassium edentate, disodium edentate, disodium hydrogen phosphate, docusate calcium, docusate potassium, docusate sodium, dodecyl gallate, dodecyltrimethylammonium bromide, edentate calcium disodium, edtic acid, eglumine, ethyl alcohol, ethylcellulose, ethyl gallate, ethyl laurate, ethyl maltol, ethyl oleate, ethylpa-

raben, ethylparaben potassium, ethylparaben sodium, ethyl vanillin, fructose, fructose liquid, fructose milled, fructose pyrogen-free, powdered fructose, fumaric acid, gelatin, glucose, liquid glucose, glyceride mixtures of saturated vegetable fatty acids, glycerin, glyceryl behenate, glyceryl monooleate, glyceryl monostearate, self-emulsifying glyceryl monostearate, glyceryl palmitostearate, glycine, glycols, glycofurol, guar gum, heptafluoropropane (HFC), hexadecyltrimethylammonium bromide, high fructose syrup, human serum albumin, hydrocarbons (HC), dilute hydrochloric acid, hydrogenated vegetable oil, type II, hydroxyethyl cellulose, 2-hydroxyethyl- β -cyclodextrin, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, 2-hydroxypropyl- β -cyclodextrin, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, imidurea, indigo carmine, ion exchangers, iron oxides, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, isotonic saline, kaolin, lactic acid, lactitol, lactose, lanolin, lanolin alcohols, anhydrous lanolin, lecithin, magnesium aluminum silicate, magnesium carbonate, normal magnesium carbonate, magnesium carbonate anhydrous, magnesium carbonate hydroxide, magnesium hydroxide, magnesium lauryl sulfate, magnesium oxide, magnesium silicate, magnesium stearate, magnesium trisilicate, magnesium trisilicate anhydrous, malic acid, malt, maltitol, maltitol solution, maltodextrin, maltol, maltose, mannitol, medium chain triglycerides, meglumine, menthol, methylcellulose, methyl methacrylate, methyl oleate, methylparaben, methylparaben potassium, methylparaben sodium, microcrystalline cellulose and carboxymethylcellulose sodium, mineral oil, light mineral oil, mineral oil and lanolin alcohols, oil, olive oil, monoethanolamine, montmorillonite, octyl gallate, oleic acid, palmitic acid, paraffin, peanut oil, petrolatum, petrolatum and lanolin alcohols, pharmaceutical glaze, phenol, liquified phenol, phenoxyethanol, phenoxypropanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, polacrillin, polacrillin potassium, poloxamer, polydextrose, polyethylene glycol, polyethylene oxide, polyacrylates, polyethylene-polyoxypropylene-block polymers, polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitol fatty acid esters, polyoxyethylene stearates, polyvinyl alcohol, polyvinyl pyrrolidone, potassium alginate, potassium benzoate, potassium bicarbonate, potassium bisulfite, potassium chloride, potassium citrate, potassium citrate anhydrous, potassium hydrogen phosphate, potassium metabisulfite, monobasic potassium phosphate, potassium propionate, potassium sorbate, povidone, propanol, propionic acid, propylene carbonate, propylene glycol, propylene glycol alginate, propyl gallate, propylparaben, propylparaben potassium, propylparaben sodium, protamine sulfate, rapeseed oil, Ringer's solution, saccharin, saccharin ammonium, saccharin calcium, saccharin sodium, safflower oil, saponite, serum proteins, sesame oil, colloidal silica, colloidal silicon dioxide, sodium alginate, sodium ascorbate, sodium benzoate, sodium bicarbonate, sodium bisulfite, sodium chloride, anhydrous sodium citrate, sodium citrate dehydrate, sodium chloride, sodium cyclamate, sodium edentate, sodium dodecyl sulfate, sodium lauryl sulfate, sodium metabisulfite, sodium phosphate, dibasic, sodium phosphate, monobasic, sodium phosphate, tribasic, anhydrous sodium propionate, sodium propionate, sodium sorbate, sodium starch glycolate, sodium stearyl fumarate, sodium sulfite, sorbic acid, sorbitan esters (sorbitan fatty esters), sorbitol, sorbitol solution 70%, soybean oil, sper-

maceti wax, starch, corn starch, potato starch, pregelatinized starch, sterilizable maize starch, stearic acid, purified stearic acid, stearyl alcohol, sucrose, sugars, compressible sugar, confectioner's sugar, sugar spheres, invert sugar, Sugartab, Sunset Yellow FCF, synthetic paraffin, talc, tartaric acid, tartrazine, tetrafluoroethane (HFC), theobroma oil, thimerosal, titanium dioxide, alpha tocopherol, tocopheryl acetate, alpha tocopheryl acid succinate, beta-tocopherol, delta-tocopherol, gamma-tocopherol, tragacanth, triacetin, tributyl citrate, triethanolamine, triethyl citrate, trimethyl- β -cyclodextrin, trimethyltetradecylammonium bromide, tris buffer, trisodium edentate, vanillin, type I hydrogenated vegetable oil, water, soft water, hard water, carbon dioxide-free water, pyrogen-free water, water for injection, sterile water for inhalation, sterile water for injection, sterile water for irrigation, waxes, anionic emulsifying wax, carnauba wax, cationic emulsifying wax, cetyl ester wax, microcrystalline wax, nonionic emulsifying wax, suppository wax, white wax, yellow wax, white petrolatum, wool fat, xanthan gum, xylitol, zein, zinc propionate, zinc salts, zinc stearate, or any excipient in the *Handbook of Pharmaceutical Excipients*, Third Edition, A. H. Kibbe (Pharmaceutical Press, London, UK, 2000), which is incorporated by reference in its entirety. *Remington's Pharmaceutical Sciences*, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), which is incorporated by reference in its entirety, discloses various components used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional agent is incompatible with the pharmaceutical compositions, its use in pharmaceutical compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.

[0107] The pharmaceutical compositions may be formulated to achieve a physiologically compatible pH. In some embodiments, the pH of the pharmaceutical composition may be at least 5, at least 5.5, at least 6, at least 6.5, at least 7, at least 7.5, at least 8, at least 8.5, at least 9, at least 9.5, at least 10, or at least 10.5 up to and including pH 11, depending on the formulation and route of administration. In certain embodiments, the pharmaceutical compositions may comprise buffering agents to achieve a physiological compatible pH. The buffering agents may include any compounds capable of buffering at the desired pH such as, for example, phosphate buffers (e.g., PBS), triethanolamine, Tris, bicine, TAPS, tricine, HEPES, TES, MOPS, PIPES, cacodylate, MES, and others.

[0108] Routes of Administration

[0109] With regard to the disclosure, the IRES inhibitor, pharmaceutical composition comprising the same, may be administered to the subject via any suitable route of administration. The following discussion on routes of administration is merely provided to illustrate exemplary embodiments and should not be construed as limiting the scope in any way.

[0110] Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the IRES inhibitor of the present disclosure dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions. Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfac-

tant. Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch. Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and other pharmacologically compatible excipients. Lozenge forms can comprise the IRES inhibitor of the present disclosure in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the IRES inhibitor of the present disclosure in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to, such excipients as are known in the art.

[0111] The IRES inhibitors of the present disclosure, alone or in combination with other suitable components, can be delivered via pulmonary administration and can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer. Such spray formulations also may be used to spray mucosa. In some embodiments, the IRES inhibitor is formulated into a powder blend or into microparticles or nanoparticles. Suitable pulmonary formulations are known in the art. See, e.g., Qian et al., *Int J Pharm* 366: 218-220 (2009); Adjei and Garren, *Pharmaceutical Research*, 7(6): 565-569 (1990); Kawashima et al., *J Controlled Release* 62(1-2): 279-287 (1999); Liu et al., *Pharm Res* 10(2): 228-232 (1993); International Patent Application Publication Nos. WO 2007/133747 and WO 2007/141411.

[0112] Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The term, "parenteral" means not through the alimentary canal but by some other route such as subcutaneous, intramuscular, intraspinal, or intravenous. The IRES inhibitor of the present disclosure can be administered with a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol or hexadecyl alcohol, a glycol, such as propylene glycol or polyethylene glycol, dimethylsulfoxide, glycerol, ketals such as 2,2-dimethyl-153-dioxolane-4-methanol, ethers, poly(ethyleneglycol) 400, oils, fatty acids, fatty acid esters or glycerides, or acetylated fatty acid glycerides with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.

[0113] Oils, which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty

acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.

[0114] The parenteral formulations in some embodiments contain from about 0.5% to about 25% by weight of the IRES inhibitor of the present disclosure in solution. Preservatives and buffers may be used. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5% to about 15% by weight. Suitable surfactants include polyethylene glycol sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations in some aspects are presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions in some aspects are prepared from sterile powders, granules, and tablets of the kind previously described.

[0115] Injectable formulations are in accordance with the disclosure. The requirements for effective pharmaceutical carriers for injectable compositions are well-known to those of ordinary skill in the art (see, e.g., *Pharmaceutics and Pharmacy Practice*, J. B. Lippincott Company, Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and *ASHP Handbook on Injectable Drugs*, Toissel, 4th ed., pages 622-630 (1986)).

[0116] Additionally, the IRES inhibitors of the disclosure can be made into suppositories for rectal administration by mixing with a variety of bases, such as emulsifying bases or water-soluble bases. Formulations suitable for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.

[0117] It will be appreciated by one of skill in the art that, in addition to the above-described pharmaceutical compositions, the IRES inhibitor of the disclosure can be formulated as inclusion complexes, such as cyclodextrin inclusion complexes, or liposomes.

[0118] In exemplary aspects, wherein the IRES inhibitor is an antisense molecule, the antisense molecule may be formulated into a viral vector or a nonviral vector, either of which are suitable for delivery into humans. Li et al., *Cancer Gene Ther* 8:555-565 (2001) describes methods of targeted gene therapy by non viral vectors. Chen et al., *Mol Ther* describes gene therapy with a lentiviral gene delivery construct. Zhou et al., *J Healthc Eng* 4(2): 223-254 (2013) and Chen et al., *Cardiovasc Ultrasound* 11:11 (2013) describes gene deliver with ultrasound. See, e.g., Chistiakov et al., *Drug Deliv* 19(8): 392-405 (2012) and Juliano et al., *J Drug Target* 21(1): 27-43 (2013) and Southwell et al., *Trends Mol Med* 18(11): 634-643 (2012) and International Patent Application Publication Nos. WO2005/072703, WO1994/023699; WO2010/085665, and WO1998/018811.

[0119] Dosages

[0120] For purposes herein, the amount or dose of the IRES inhibitor administered should be sufficient to effect, e.g., a therapeutic or prophylactic response, in the subject or animal

over a reasonable time frame. For example, the dose of the IRES inhibitor of the present disclosure should be sufficient to treat SCA6 as described herein in a period of from about 1 to 4 minutes, 1 to 4 hours or 1 to 4 weeks or longer, e.g., 5 to 20 or more weeks, from the time of administration. In certain embodiments, the time period could be even longer. The dose will be determined by the efficacy of the particular IRES inhibitor and the condition of the animal (e.g., human), as well as the body weight of the animal (e.g., human) to be treated.

[0121] Many assays for determining an administered dose are known in the art. For purposes herein, an assay, which comprises comparing the extent to which SCA6 is treated upon administration of a given dose of the IRES inhibitor of the present disclosure to a mammal among a set of mammals, each set of which is given a different dose of the IRES inhibitor, could be used to determine a starting dose to be administered to a mammal. The extent to which SCA6 is treated upon administration of a certain dose can be represented by, for example, the extent to which the expression of α 1ACT is reduced. Methods of measuring protein expression are known in the art, including, for instance, the methods described in the EXAMPLES set forth below.

[0122] The dose of the IRES inhibitor of the present disclosure also will be determined by the existence, nature and extent of any adverse side effects that might accompany the administration of a particular IRES inhibitor of the present disclosure. Typically, the attending physician will decide the dosage of the IRES inhibitor of the present disclosure with which to treat each individual patient, taking into consideration a variety of factors, such as age, body weight, general health, diet, sex, IRES inhibitor of the present disclosure to be administered, route of administration, and the severity of the condition being treated. By way of example and not intending to limit the scope of the claimed subject matter, the dose of the IRES inhibitor of the present disclosure can be about 0.0001 to about 1 g/kg body weight of the subject being treated/day, from about 0.0001 to about 0.001 g/kg body weight/day, or about 0.01 mg to about 1 g/kg body weight/day.

[0123] Controlled Release Formulations

[0124] In some embodiments, the IRES inhibitors described herein can be modified into a depot form, such that the manner in which the IRES inhibitor is released into the body to which it is administered is controlled with respect to time and location within the body (see, for example, U.S. Pat. No. 4,450,150). Depot forms of IRES inhibitors of the disclosure can be, for example, an implantable composition comprising the IRES inhibitors and a porous or non-porous material, such as a polymer, wherein the IRES inhibitor is encapsulated by or diffused throughout the material and/or degradation of the non-porous material. The depot is then implanted into the desired location within the body of the subject and the IRES inhibitor is released from the implant at a predetermined rate.

[0125] The pharmaceutical composition comprising the IRES inhibitor in certain aspects is modified to have any type of in vivo release profile. In some aspects, the pharmaceutical composition is an immediate release, controlled release, sustained release, extended release, delayed release, or bi-phasic release formulation. Methods of formulating small molecular weight compounds, peptides, and oligonucleotides or nucleic acid analogs, for controlled release are known in the art. See, for example, Qian et al., *J Pharm* 374: 46-52 (2009) and

International Patent Application Publication Nos. WO 2008/130158, WO2004/033036; WO2000/032218; and WO 1999/040942.

[0126] The instant compositions may further comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect.

[0127] Timing of Administration

[0128] The disclosed pharmaceutical compositions and formulations may be administered according to any regimen including, for example, daily (1 time per day, 2 times per day, 3 times per day, 4 times per day, 5 times per day, 6 times per day), every two days, every three days, every four days, every five days, every six days, weekly, bi-weekly, every three weeks, monthly, or bi-monthly. Timing, like dosing can be fine-tuned based on dose-response studies, efficacy, and toxicity data, and initially gauged based on timing used for other antibody therapeutics.

[0129] Combinations

[0130] In some embodiments, the IRES inhibitors described herein are administered alone, and in alternative embodiments, the IRES inhibitors described herein are administered in combination with another therapeutic agent, e.g., another IRES inhibitor of the disclosure of different type (e.g., structure) or a completely different therapeutic agent.

[0131] In exemplary aspects, the IRES inhibitors described herein are administered in combination with a compound which targets one of the following genes: Bcat1, Bdkrb2, Bmp3, Ces1a, Chst1, Crabp1, Dapk1, Dbh, Foxq1, Gabbr2, Gfra1, Gnai1, Hsd11b1, IL17re, Iqsec3, Mb21d2, Mmp13, Nnat, Npy1r, Ntn1, Pmp22, Podx1, Prkcdp, Ramp1, Rbp4, Reep1, Rgs10, S100a4, S100a5, S100a6, Sema3b, Sgce, Sh3bgr, Smoc2, Tbc1d9, Ugt8, V1d1r. The mRNA encoded by each of these genes are provided in the Sequence Listing as SEQ ID NOS: 64-137. In exemplary aspects, the IRES inhibitors described herein are administered in combination with a compound which targets a gene product encoded by one of these genes.

[0132] In alternative or additional aspects, the IRES inhibitors described herein are administered in combination with a compound which targets one of the following genes, which are related to neuron differentiation: Vgf, Ntn1, S1c11a, Lhx2, Nrp1, Mab2, Ret, Etv4, Btg2, Cspg5, Sptbn4, Rab3a, Lamb2, Ce1sr3, Ntrk1, Mapk8ip3, C1n8, Nnat, Bmp7, Brsk1, Sema5a, P1xna3, Fgfr1. In exemplary aspects, the IRES inhibitors described herein are administered in combination with a compound which targets a gene product encoded by one of these genes.

[0133] In alternative or additional aspects, the IRES inhibitors described herein are administered in combination with a compound which targets one of the following genes, which are related to the cell cycle: Suv39h2, Ndc80, Rad51, Trip13, Cenpf, Ccnb1, SMC4, SMC2, Kif11, Cep55, Kif18a, D1gap5, Lzts2, Katnal1, Mhl1, Mns1, Rps6. In exemplary aspects, the IRES inhibitors described herein are administered in combination with a compound that targets a gene product encoded by one of these genes.

[0134] In addition to the inventive methods comprising administering an IRES inhibitor, provided herein are alternative methods of treating SCA6 in a subject, comprising the step of administering to the subject (I) a compound which targets one or more genes other than the CACNA1A gene, wherein the one or more genes is selected from the group consisting of: Bcat1, Bdkrb2, Bmp3, Ces1a, Chst1, Crabp1,

Dapk1, Dbh, Foxq1, Gabbr2, Gfra1, Gnai1, Hsd11b1, IL17re, Iqsec3, Mb21d2, Mmp13, Nnat, Npy1r, Ntn1, Pmp22, Podx1, Prkcdp, Ramp1, Rbp4, Reep1, Rgs10, S100a4, S100a5, S100a6, Sema3b, Sgce, Sh3bgr, Smoc2, Tbc1d9, Ugt8, V1d1r, Vgf, Ntn1, S1c11a, Lhx2, Nrp1, Mab2, Ret, Etv4, Btg2, Cspg5, Sptbn4, Rab3a, Lamb2, Ce1sr3, Ntrk1, Mapk8ip3, C1n8, Nnat, Bmp7, Brsk1, Sema5a, P1xna3, Fgfr1, Suv39h2, Ndc80, Rad51, Trip13, Cenpf, Ccnb1, SMC4, SMC2, Kif11, Cep55, Kif18a, D1gap5, Lzts2, Katna1, Mhl1, Mns1, and Rps6, or (II) a compound which targets a gene product encoded by said gene.

[0135] Kits

[0136] In some embodiments, the IRES inhibitor is provided as part of a kit or package or unit dose. "Unit dose" is a discrete amount of a therapeutic composition dispersed in a suitable carrier. Accordingly, provided herein are kits comprising an IRES inhibitor of the disclosure. In exemplary aspects, the kit comprises an antisense molecule as described herein.

[0137] In some embodiments, the components of the kit/unit dose are packaged with instructions for administration to a subject. In some embodiments, the kit comprises one or more devices for administration to a subject, e.g., a needle and syringe, a dropper, a measuring spoon or cup or like device, an inhaler, and the like. In some aspects, the IRES inhibitor is pre-packaged in a ready to use form, e.g., a syringe, an intravenous bag, an inhaler, a tablet, capsule, etc. In some aspects, the kit further comprises other therapeutic or diagnostic agents or pharmaceutically acceptable carriers (e.g., solvents, buffers, diluents, etc.), including any of those described herein. In particular aspects, the kit comprises an IRES inhibitor of the disclosure along with the current SCA6 standard of care.

[0138] Screening Methods

[0139] Additionally provided herein is a method of identifying a compound with SCA6 therapeutic activity. In exemplary aspects, the method comprises the steps of (i) contacting the compound with a sample comprising a nucleic acid molecule comprising at least a portion of the α 1A mRNA, wherein the portion comprises at least the nucleotide sequence of the IRES of the α 1A mRNA and the coding sequence of α 1ACT, (ii) assaying for expression of α 1ACT, wherein the compound is identified as a compound with anti-SCA6 therapeutic activity, when expression of α 1ACT mRNA is reduced as compared to a control.

[0140] In exemplary aspects, the control is a control a compound which is known to not interfere with the expression of the α 1ACT mRNA. In exemplary aspects, the control is a vehicle control. In exemplary aspects, when expression of α 1ACT mRNA is reduced by at least 25%, relative to the control level of expression of α 1ACT mRNA, the compound is identified as a compound with anti-SCA6 therapeutic activity. In exemplary aspects, when expression of α 1ACT mRNA is reduced by at least 30% (e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%), relative to the control level of expression of α 1ACT mRNA, the compound is identified as a compound with anti-SCA6 therapeutic activity.

[0141] In exemplary aspects, the nucleic acid molecule in the sample comprises at least a portion of the sequence of SEQ ID NO: 5. In exemplary aspects, the nucleic acid molecule in the sample comprises the coding sequence of α 1ACT comprising the sequence of SEQ ID NO: 12. In exemplary aspects, the nucleic acid molecule in the sample comprises

the sequence of the full length CACNA1A gene. In exemplary aspects, the nucleic acid molecule in the sample comprises the sequence of only a portion of the CACNA1A gene, but the nucleic acid sample comprises at least the IRES and the coding sequence of α 1ACT. In exemplary aspects, the nucleic acid molecule in the sample comprises the sequence of the full length α 1A mRNA, but the nucleic acid sample comprises at least the IRES and the coding sequence of α 1ACT. In exemplary aspects, the nucleic acid molecule in the sample comprises only the IRES and the coding sequence of α 1ACT.

[0142] In exemplary aspects, the sample comprises cells and the cells are engineered to comprise a reporter gene construct which is used to determine whether or not expression of the α 1ACT coding sequence occurs. Many suitable reporter gene constructs are known in the art and include, for example, luciferase, green fluorescent protein (GFP), GUS, beta-galactosidase, chloramphenicol acetyltransferase (CAT), and neomycin phosphotransferase. In exemplary aspects, the cells are engineered to comprise a luciferase reporter. In exemplary aspects, the cells are engineered to comprise a bicistronic gene reporter construct. In exemplary aspects, when the nucleic acid molecule in the sample comprises a full length CACNA1A gene, the reporter construct is a bicistronic gene reporter construct. In exemplary aspects, the bicistronic gene reporter construct is a Renilla-luciferase/Firefly-luciferase (R-Luc/F-Luc) bicistronic reporter construct. A description of an exemplary method of identifying a compound with SCA6 therapeutic activity is described herein in Appendix B.

[0143] In exemplary aspects, the sample does not comprise cells but comprises cell components necessary for in vitro translation. Methods of carrying out in vitro translation assays are known in the art. See, e.g., Kurita et al., *Methods Mol Biol* 905: 311-325 (2012); and Movahedzadeh et al., *Methods in Mol Biol* 235: 247-255 (2003). Following in vitro translation, the method in exemplary aspects comprises methods of assaying the levels of α 1ACT mRNA expression. The method in some aspects comprises assaying for the level of α 1ACT protein. Methods of determining the level of a protein are known in the art and include for instance Western blotting, radioimmunoassay, immunofluorescence, and the like. See, e.g., Green and Sambrook, *Molecular Cloning: A Laboratory Manual* (4th ed.), Coldspring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2012.

[0144] The following examples further illustrate the disclosure but, of course, should not be construed as in any way limiting its scope.

EXAMPLES

[0145] Examples 1 and 2 include information that was published on Jul. 3, 2013, as Du et al., *Cell* 154: 118-133 (2013).

Example 1

[0146] The following experimental procedures and materials were used in Example 2.

Materials and Standard Protocols

[0147] Cells, animals/mouse strains, antibodies, plasmids, and other materials were described in the Extended Experimental Procedures. The detailed protocols used for ChIP, ChIP-based cloning, ChIP-qRT-PCR, EMSA, Luciferase Assays, immunoprecipitation, immunohistochemistry,

immunoblotting, quantitative RT-PCR, electrophysiology and LDH assay are outlined in the Extended Experimental Procedures.

Protein Purification and Mass Spectrometry

[0148] Protein extracts from HEK-293 cells stably transfected with $\alpha 1A$ subunit bearing a Q11 allele were separated via anion exchange chromatography (His Trap FF column) and further purified by ANTI-FLAG M2 affinity purification. $\alpha 1ACT_{WT}$ fragment protein in SDS-PAGE gel was digested in-gel with trypsin and the resulting peptides were then analyzed via LC-MS/MS on an LTQ-Velos-Orbitrap mass spectrometer. See details in the Extended Experimental Procedures.

Immunohistochemistry and Microscopy

[0149] For detailed procedures of immunohistochemistry, antibodies and dilutions were described in the Extended Experimental Procedures. PC12 cells were imaged 0 hr, 24 hrs, 48 hrs and 72 hrs after NGF 24 hrs treatment. Neurites were defined as processes longer than the width of the cell body. For each experiment, cells were imaged. Dendrites were analyzed by employing ImageJ and NeuroJ programs.

Human Tissues

[0150] This study involves specimens from human subjects and was approved by the Institutional Review Board of the

University of Chicago Medical Center. Written consents were obtained from all subjects prior to sample collection.

Plasmids

[0151] All clones were made from human calcium channel, voltage-dependent, P/Q type, $\alpha 1A$ subunit (CACNA1A) cDNA (GenBank accession GI: 187828892, Millipore, Billerica, Mass., USA) as previous described (Kordasiewicz et al., 2006). All FLAG clones were generated with PCR with 3 \times FLAG (Supplemental Table 4 of Appendix A). PCR product and pCDNA3 vector (Invitrogen, Grand Island, N.Y., USA) were digested with BamHI and XbaI. $\alpha 1A_{WT}$, $\alpha 1A_{SCA6}$, $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ cDNA were ligated into the pCDNA3 expression construct. All mutations were performed via PCR (Quick-Change II XL Site-Directed Mutagenesis Kit, Stratagene, La Jolla, Calif., USA). Primers (Table 1) designed for the different BTG1 3'UTR and GRN 5'UTR were amplified from rat genomic DNA (Millipore, Billerica, Mass., USA). PCR products were inserted into pGL3 promoter vector by FseI and XbaI, and into pGL3 basic vector by XhoI and MluI. Primers (Table 1) were designed to amplify different lengths of human $\alpha 1ACT$ 5'-UTR based on identified translation start site and using pCDNA3- $\alpha 1A_{WT}$ -FLAG as a template. Following digestion with EcoRI and NcoI, or MluI and NheI, the fragments were inserted into either the bi-cistronic reporter vector pRF (a gift from Dr. Anne E Willis) or the pGL3 basic vector (Promega, Madison, Wis., USA).

TABLE 1

Primers for Vectors			
Name	Sequence	Vector	SEQ ID NO
CTIREST1RNcoI	5' atacCCATGGtggtgcgtagatcttcc3'	pRF	13
CTIRE889FEcoRI	5' aatGAATTCctcatggctctgatccgca3'	pRF	14
CTIRE1353FEcoRI	5' aatGAATTCtccaggccctcatgcttctc3'	pRF	15
CTIRE1388FEcoRI	5' aatGAATTCtgaattatttc cgcgatgcc3'	pRF	16
CTIREST1RH	5' atacAAGCTTtggtgcgtagatcttcc3'	pGL3Basic	17
CTIRE889FMluI	5' aatACGCGTctcatggctctgatccgca3'	pGL3Basic	18
CTIRE1353FMluI	5' aatACGCGTtccaggccctcatgcttctc3'	pGL3Basic	19
CTIRE1388FMluI	5' aatACGCGTtgaattatttc cgcgatgcc3'	pGL3Basic	20
BTG1517Xba1F	5' cgtaCTAGAGATATAGTCTATGGATGG3'	pGL3promoter	21
BTG1630FseIR	5' GTAGGCCGGCCTCTATCTTGTGC CAGATC3'	pGL3promoter	22
BTG11150FseIR	5' ATAGGCCGGCCTGGCTGGTGCT AACCA3'	pGL3promoter	23
BTG11440FseIR	5' cgcTGGCCGGCCCCAAGATAAGAAACAATT3'	pGL3promoter	24
BTG1517Xba1FDel1	5' cgtaCTAGAGATATAGTCTATGGATGGatcatc tggatagatt3'	pGL3promoter	25

TABLE 1-continued

Primers for Vectors			
Name	Sequence	Vector	SEQ ID NO
BTG1517Xba1FMut1	5' cgt aTCTAGAGATATAGTCTATGGA TGGatcatcGCCTaatgga3'	pGL3pr omoter	26
BTG1517Xba1FMut2	5'cgt aTCTAGAGATATAGTCTATGG ATGGatcatc ttaCGCtga3'	pGL3pr omoter	27
hGRNCP2F	5'ctggccaacatggtgaaac3'	pGL3B asic	28
hGRNCP1B	5'CCGGTTCAA GCGATTCT3'	pGL3B asic	29
hGRNCP2B	5'ccgggttcaa gcgattctc3'	pGL3B asic	30
$\alpha 1$ ACTF for in vitro	5'ataaGGATCCAGCCACCATGCAG AAGACGTA3'	pCDN A3	31
$\alpha 1$ ACTR for in vitro	5'GTATCTAGATTACTTGTTCATCGT CATCCTTGTAGTCGATGTCATGAT CTTTATAATCACCGTCATGGTCTT TGATGTCGCACCAATCATCGTCAG TCTCG	pCDN A3	32
$\alpha 1$ ACTF for in vivo	aattgctagcggatgtccagaagacgggcacatggagt ccg	pTRE2 hyg2	33
$\alpha 1$ ACTR for in vivo	aattatcgatctattagtgatggatggatggatggcaccapTRE2 atcatcgtcactctcgctgtaggg	pTRE2 hyg2	34

Antibodies

[0152] The primary antibodies used in the present study were mouse monoclonal anti-FLAG M2 antibody (clone M2, 1:1000, Sigma Aldrich, St. Louis, Mo., USA), rabbit polyclone anti-BTG1 antibody (1:1000, affinity isolated antibody, Sigma Aldrich), rabbit polyclone anti-PMCA2 (1:1000, affinity isolated antibody, Sigma Aldrich), monoclonal anti-GAP43 antibody (1:1000, Sigma Aldrich), anti- β -actin antibody (1:1000, Abcam, Cambridge, Mass., USA), anti-calbindin-28 kDa (1:250, Abcam), anti-Vglut1 (1:250, Abcam) and anti-Vglut2 (1:250, Abcam). Donkey HRP-conjugated anti-rabbit and anti-mouse IgG were used for secondary antibody detection for western blotting. Goat and donkey AlexaFluor405-, AlexaFluor488-, AlexaFluor555-, AlexaFluor594-, and AlexaFluor647-conjugated anti-mouse, anti-rabbit, anti-goat, and anti-rat IgG antibodies (Invitrogen, Grand Island, N.Y., USA) were used for secondary fluorescence detection for immunocytochemistry and immunohistochemistry.

Animals

[0153] Coding sequence of the C terminus of human calcium channel, voltage-dependent, P/Q type, $\alpha 1A$ subunit carrying both normal range of polyQ ($\alpha 1ACT_{WT}$) and pathological range of polyQ ($\alpha 1ACT_{SCA6}$) were PCR amplified (Supplemental Table 4 of Appendix A) and cloned into pTRE-2hyg2-myc between NheI and ClaI sites. The transgenes were injected into C57BL/6 one-cell embryos and identification of transgenic founders was screened by PCR analysis of tail

genomic DNA. The Pcp2-tTA transgenic mouse in which the tTA expression was driven by the Purkinje cell regulatory region from the murine Pcp2/L7 gene was obtained from Jackson Laboratory. To generate the conditional transgenic mouse models of PC- $\alpha 1ACT_{WT}$ and PC- $\alpha 1ACT_{SCA6}$, the two transgenic lines were crossed to make both genes in a single mouse. The null mouse defective in VDCC $\alpha 1A$ subunit ($\alpha 1A^{-/-}$) was obtained from Dr. Shin (Jun et al., 1999).

[0154] $\alpha 1A^{-/-}$ mice and transgenic mice with an N-terminal myc epitope and expressing the $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ under control of the tetracycline response element in PCP2-tTA were housed in our animal facility. To investigate the importance of expression of the $\alpha 1ACT$ fragment in Purkinje cells to the $\alpha 1A^{-/-}$ phenotype we used the Pcp2 promoter and Tet-off system (Zu et al., 2004) to generate transgenic mice that have selective Purkinje cell expression of $\alpha 1ACT_{WT}$ (Q4) (the smallest $\alpha 1ACT$ polyQ seen in human) and $\alpha 1ACT_{SCA6}$ (Q33) (the largest $\alpha 1ACT$ polyQ seen in human) tagged with an N-terminal myc epitope. We bred transgenic mice (Pcp2-tTA) expressing the tetracycline transactivator protein, tTA (Zu et al., 2004), targeted to Purkinje cells with mice we developed bearing the TRE- $\alpha 1ACT$ transgenes. Use of the Pcp2-tTA line facilitated generation of lines with comparable expression levels selectively in Purkinje cells, and provided the future prospect of pharmacological control of transgene expression, Pcp2-tTA/TRE- $\alpha 1ACT$ (abbreviated, PC- $\alpha 1ACT$) double transgenic mice. To test the role of $\alpha 1ACT$ in cerebellar Purkinje cell development in the absence of $\alpha 1A$ channels, we bred PC- $\alpha 1ACT$ mice with $\alpha 1A^{-/-}$ heterozygous knockout mice and subsequently

crossed these offspring to generate $\alpha 1A^{-/-}$ mice with Purkinje cell-targeted $\alpha 1ACT$ expression ($\alpha 1A^{-/-}/PC-\alpha 1ACT$). Mice with the following genotypes were identified: $\alpha 1A^{-/-}$, $\alpha 1A^{+/-}$, $\alpha 1A^{+/-}/PC-\alpha 1ACT_{WT}$, $A^{+/-}/PC-\alpha 1ACT_{SCA6}$ and $\alpha 1A^{-/-}/PC-\alpha 1ACT_{WT}$. Mouse lines were crossed to get $\alpha 1A^{-/-}/PC-\alpha 1ACT_{WT}$ and $\alpha 1A^{-/-}/PC-\alpha 1ACT_{SCA6}$ double transgenic mice. All animal experiments were approved and carried out in accordance with the regulations and guidelines for the care and use of experimental animals at the Institutional Animal Care and Use Committee of the University of Chicago.

Cell Culture and Established Stable Cell Lines

[0155] HEK-293 cells were maintained in MEME medium (ATCC, Manassas, Va., USA) containing 10% fetal bovine serum in a 37° C., 5% CO₂ incubator. PC12 cells (rat pheochromocytoma) were cultured in F-12K medium (ATCC, Manassas) supplemented with 10% horse serum and 2.5% fetal bovine serum (GIBCO, Grand Island, N.Y., USA) in a 37° C., 5% CO₂ incubator. Cells were transfected with pcDNA3 vectors expressing full-length constructs of the $\alpha 1A$ subunit bearing both Q11 ($\alpha 1A_{WT}$) and Q33 ($\alpha 1A_{SCA6}$) allele, C terminal 3×FLAG tag with Q11 ($\alpha 1ACT_{WT}$ -FLAG), 3×FLAG tagged $\alpha 1ACT$ with Q33 ($\alpha 1ACT_{SCA6}$ -FLAG) and empty pcDNA3 vector when they were <60% confluent using FuGene 6 reagent (Promega, Madison, Wis., USA). Stable cell lines were selected with 150 μ g/ml and 300 μ g/ml G418 (GIBCO) and cloned.

Isolation HEK-293 $\alpha 1ACT_{WT}$ -FLAG Fusion Protein

[0156] HEK-293 cells stable expressing $\alpha 1ACT_{WT}$ were maintained in MEME medium containing 10% fetal bovine serum (FBS) and G418, in a 37° C., 5% CO₂ incubator. For each labeling experiment, cells were harvested at the log phase (50-70% confluence). To obtain the cytosolic lysates of $\alpha 1ACT_{WT}$ from HEK-293 cells, cells were pelleted by centrifugation and then resuspended in the 1×cell lysis buffer (Cell signaling) with proteinase inhibitor cocktail and 1 mM phenylmethanesulfonyl fluoride (PMSF). Cell suspension was incubated on ice for 10 min and lysed by gentle pipetting. The lysates were centrifuged (10,000 rpm, 4° C.) and the supernatant (cytosolic lysate) was carefully transferred into a new tube on ice. Protein concentration was quantified with Promega Coomassie Plus™ Protein Assay Reagent (Promega, Madison, Wis., USA).

[0157] The crude protein lysis was loaded onto a HiTrap™ DEAE FF anion exchange chromatography column at a flow rate of 2.0 mL/min, which had been equilibrated with 20 mM HEPES buffer (pH7.0). The retained protein was eluted with a linear sodium chloride gradient (1-14=15%-80% NaCl in 20 mM Tris-HCl, gradient=5%) in the same buffer. The fraction from each elution was collected and eluted peaks (40% NaCl in 20 mM Tris-HCl, pH=8.0) were detected by western blotting with anti-FLAG antibody. The fractions from eluted peaks were subject to the second step purification.

[0158] Anti-FLAG M2 magnetic beads were washed with 5 packed gel volumes of TBS (1×) twice and used for affinity purification. Enriched fractions (2000 ml) from $\alpha 1ACT_{WT}$ HEK-293 cytosolic lysate were mixed with 150 μ l anti-FLAG M2 magnetic beads, and incubated for overnight at 4° C. The supernatant was removed and the beads were washed with 20 packed cold TBS. The sample was then mixed with Laemml Sample Buffer (BioRad, Hercules, Calif., USA) and 5% (v/v)

2-mercaptoethanol, denatured at 96° C. for 5 min and separated on SDS-PAGE (5-20% Tris-HCl gel, 200 V, 1 hr) in 1× Tris-Glycine-SDS buffer (BioRad, Hercules, Calif., USA). Gel was stained for 2 hrs with GoldBlue (Thermo Fisher Scientific, Waltham, Mass., USA). Stain was discarded and the gel was de-stained with high purity water overnight until bands were observed. Gel was further de-stained using high purity water after which bands were excised and submitted for LD-MS/MS analysis.

Chromatin Immunoprecipitation (ChIP), ChIP-Cloning and ChIP-qRT-PCR

[0159] Anti-FLAG chromatin—immunoprecipitation (ChIP) was performed as Magna ChIP protocol described (Millipore, Billerica, Mass., USA). Target cells were crosslinked by adding of 1% (v/v) of formaldehyde to a cell monolayer in growth medium followed by an incubation for 10 min at 37° C. The crosslinking reaction was stopped by addition of 11% of the suspension volume of an ice cold 1 M solution of glycine. Media was removed and cells were washed twice with cold 1×PBS buffer. The cells were spun down immediately (4 min, 2000 g, 4° C.) and resuspended in cell lysis buffer (Millipore, Billerica, Mass., USA, 2×10⁷ cells per 500 μ l) with protease inhibitor and incubated for 15 min on ice with vortex briefly every 5 min. To shear the chromatin into pieces of a few hundred base pairs, the cell lysate was sonicated using a vibra cell sonifier (Thermo Fisher Scientific, Waltham, Mass., USA). The immunoprecipitation reaction was set up by combining 50 μ l sonicated cell supernatant 10-fold in ChIP dilution buffer, 10 μ g anti-FLAG M2 antibody and 20 μ l of Protein G Magnetic beads for one ChIP reaction. This reaction was rotated overnight at 4° C. The beads were washed five times with wash buffer and TE-buffer using a magnetic particle concentrator (Millipore, Billerica, Mass., USA). The bound chromatin was eluted twice by addition of 50 μ l of ChIP elution buffer to the beads followed by centrifugation. Eluted precipitates were then subjected to overnight digestion with restriction enzyme MboI. Candidate DNA sequences were subsequently recovered by reverse crosslink and proteinase K treatment. Extracted DNAs were cloned into MboI-digested cloning vector for sequencing. To predict the binding site of $\alpha 1ACT$, we performed alignments of ChIP-identified sequences using online software (CLC main workbench Version 6.5). For the ChIP-qRT-PCR, ChIP was performed again and precipitated DNA as template and designed PCR primers for the target genes (Table 2) were used in real-time quantitative PCR.

TABLE 2

Primers for ChIP Verification		
Name	Sequence	SEQ ID NO
BTG1CVF3	5'tgacagtgcc atagtttggga3'	35
BTG1CVR3	5'AAGTGTAATAGTGCAAAATCCCC3'	36
GmCVF1	5'AAGACCATCATGGCCAACAT3'	37
GmCVR1	5'TTGGCTCAACACAACCTCC3'	38

TABLE 2-continued

Primers for ChIP Verification		
Name	Sequence	SEQ ID NO
PMCA2CVF1	5' TCTAGCCCTCCTTGCCCTGAA3'	39
PMCA2CVR1	5' TGGAGGTTGAATTGGAATT3'	40

Transient Transfection

[0160] Transient transfections in HEK293, HeLa and COS-7 cells were performed by using TransIT 1 (Mirus, Pittsburgh, Pa., USA). Transfection in PC12 cells was performed by using Lipofection 2000 (Invitrogen, Grand Island, N.Y., USA), and transfections in SY5Y and N2A cells were performed by using Eugene 6 (Promega, Madison, Wis., USA) according to the manufacturer's instructions. siRNA duplexes (Supplemental Table 4 of Appendix A) were transfected into PC12 cells by using Lipofection2000 (Invitrogen, Grand Island, N.Y., USA) according to the manufacturer's instructions.

Nuclear Protein Extraction, Western Blot and Electrophoretic Mobility Shift Assays (EMSA)

[0161] Nuclear and cytoplasmic proteins were extracted from cell lines using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific). Expression of markers in nuclear and cytoplasmic protein was detected by western blot as described before (Du et al., 2009). Nuclear protein was incubated with biotin-labeled probes described in Table 3, then analyzed on a non-denaturing polyacrylamide gel as described previously (Du et al., 2009). For the supershift, 2 μ g or 4 μ g anti-FLAG antibody was incubated with nuclear protein in binding buffer for 1 hr at room temperature.

TABLE 3

Rat BTG1 probes for EMSA		
Name	Sequence	SEQ ID NO
BTG1 WT probe	631ntGATCTTCACAGCTGTGACATGGTTATCCAT AATCCATCCCCAAGAGGAGCCACCCAAAGCAA AAAATCAAATCTATCCATCCATTATAAGATGATC CATCCATAGACTATAT517nt	138
BTG1-AT-rich probe	553nt TCCATCCATTATAAGATGATCCA	139
BTG1-AT-rich mut1 probe	553nt TCCATCCA g cgTAAGATGATCCA	140
BTG1-AT-rich mut2 probe	553nt TCCATCCATTA g cgGATGATCCA	141
BTG1-AT-rich mut3 probe	553nt TCCATCCATTATAA g cgGATCCA	142
BTG1-AT-rich mut4 probe	553nt TCCATCCA g cggt g caGATCCA	143

TABLE 3-continued

Rat BTG1 probes for EMSA		
Name	Sequence	SEQ ID NO
BTG1-AT-rich mut1a probe	553nt TCCATCCA aaa TAAGATGATCCA	144
BTG1-AT-rich mut2a probe	553nt TCCATCCATTA aaa GATGATCCA	145
BTG1-AT-rich mut4a probe	553nt TCCATCCA aaaaaaaa GATCCA	146
BTG1-AT-rich mut1t probe	553nt TCCATCCA ttt TAAGATGATCCA	147
BTG1-AT-rich mut2t probe	553nt TCCATCCATTA ttt GATGATCCA	148
BTG1-AT-rich mut4t probe	553nt TCCATCCA tttttttt GATCCA	149

Luciferase Assays

[0162] Cells were seeded into 24-well plates in triplicate and co-transfected with pRL-TK (Promega, Madison, Wis., USA) and the reporter pGL3 vector. Twenty-four hours later, luciferase activities were determined using the Dual-Luciferase Assay System as per manufacturer's instructions (Promega). The activities of Firefly and Renilla luciferase in lysates prepared from transfected cells were measured using the Dual-Luciferase Assay System and were measured by using a Wallac 1420 VICTOR 3 V luminometer with a 1 second integration time (Perkin Elmer, Waltham, Mass., USA). The activity of β -galactosidase in lysate prepared from cells co-transfected with p β -Gal was measured using the same reader.

RNA Isolation and Quantitative Real-Time PCR (qRT-PCR)

[0163] Total cellular RNA or cerebellum RNA was isolated by RNeasy mini Kit or RNeasy lipid mini Kit (QIAGEN, Valencia, Calif., USA) according to the manufacturer's instructions. Complementary DNA was generated with SuperScriptIII reverse transcriptase (Invitrogen, Grand Island, N.Y., USA). The forward and reverse primers used in this study were listed in Supplemental Table 4 of Appendix A. Real-time PCR was performed as triplicates on iCycle Real-Time PCR system (Bio-Rad, Hercules, Calif., USA) and repeated at least three times. Each 20 μ l reaction contained 0.1 μ M primers, 4 mM MgCl₂ and SYBR GreenER Supermix (Bio-Rad, Hercules, Calif., USA), and was run under the following conditions: 95°C. 2 min; 95°C. 15 s, 58°C. 45 s for 55 cycles, followed by melting curve. The Ct value is defined as the cycle number at which the fluorescence crosses a fixed threshold above the baseline. As a relative quantification, fold changes were measured using the $\Delta\Delta$ Ct method.

TABLE 4

Primers for RT-PCR		
Name	Sequence	SEQ ID NO
Mouse BTG-1F	5' Gtgtccttca tctccaagtt cc 3'	41
Mouse BTG-1R	5'gaagcctgaacaactcctgact3'	42
Mouse GranulinF	5'ATG CCC CAG GCC TCT TGC TGT3'	43
Mouse GranulinR	5'GGGTAGCTCACAGCAGGTAGA3'	44
Mouse PMCA-2F	5'TGG CAT CAT ATT TAC CCT GCT T3'	45
Mouse PMCA-2R	5' TTTCTTCTTGTCATCTGCATCG3'	46
rBTG-1F	5'gattggactgagcagtcagga3'	47
rBTG-1R	5'tcttaacctgatacagtcctc3'	48
rGRNrt-perF	5'ACTTCCAGCTGCTGCC3'	49
rGRNrt-perR1	5'ATACAGCAGGTGGCGGAG3'	50
rPMCA2rt-perF	5'CTACTGTGGGAAGCTCAGGC3'	51
rPMCA2rt-perR	5'GGGAACCACCTTCTCTCCTC3'	52
rTAF15940F	5'CCCAGGACCAGTGAAGAAAG3'	53
rTAF18086R	5'AAAGAGGAAGGGCAATGAT3'	54
Exon 34-F	5' ACAGTGATGA AGATGAGTTC CAAAT 3'	150
Exon 35-F	5' GATAAGAACT CTGGCATCCT GACTC 3'	151
Exon 35-R	5' ATGAAGGAAACAAAGTAAAAATAAGCA 3'	152
Exon 36-F	5' GTCATCATGGACAACCTTTGAGTACC 3'	153
Exon 36-R	5' AGTCTCGGGTGGGTAAGTCAAAG 3'	154
Exon 38-F	5' GACAACACCGTCCACTTCAAT 3'	155
Exon 38-R	5' AATCTTGATG TCCAGGGCTG T 3'	156
Exon 39-F	5' CCGACAACAGCAGATGGAC 3'	157
Exon 39-R	5' CTAGCGTCTTCTGGGACAGATT 3'	158
Exon 40-F	5' AGAGCAAGGCCAAGAGCTG 3'	159
Exon 40-R	5' CAGCTTCTTGCCCTTGCTCT 3'	160
Exon 41-F	5' GGACACCCCTCATGTTCCAG 3'	161
Exon 42-F	5' GAAAGCGGCTCAAGGAGAG 3'	162
Exon 42-R	5' CGTCTTCTGGAACATCTCCTG 3'	163
Exon 43-R	5' AGTAGCCATCTCTGCCATCT 3'	164

Western Blot

[0164] Immunoblotting was performed on cell extracts and tissues as described previously (Kordasiewicz et al., 2006).

Nuclear and cytoplasmic proteins were extracted from either cell lines or mouse cerebellum using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, Waltham, Mass., USA). 50 µg of total protein or fraction were subjected to SDS-PAGE (6%, 8% or 12% TrisGlycine gel, Invitrogen, Grand Island, N.Y., USA) and transferred to a PVDF membrane (Millipore, Billerica, Mass., USA). The transblotted membrane was blocked with TBST containing 5% nonfat milk for 60 min and then incubated with the primary antibody at 4° C. overnight. The membrane was then probed with HRP-conjugated secondary antibody for 1 hr at room temperature and washed with TBST three times. Finally, the immunoblots were detected using a chemiluminescent substrate (Thermo Scientific Pierce Protein Biology Products, Rockford, Ill., USA) and visualized by autoradiography.

Immunoprecipitation

[0165] The lysates were pre-absorbed with Protein G-magnetic beads (Millipore, Billerica, Mass., USA) and then incubated with the anti-BTG1 in a binding buffer containing 50 mM Tris-Cl (pH7.5), 150 mM NaCl, 5% Glycerol, 1 mM DTT, 0.1% NP-40, 1 mM EDTA and protease inhibitors. The immune complex was captured with Protein G-Magnetic beads and washed as per manufacturers' instructions (Millipore, Billerica, Mass., USA). The immunoprecipitates were eluted with an SDS sample buffer and analyzed by immunoblotting.

Immunolabeling

[0166] Immunohistochemistry was performed as previously reported except as modified below (Kordasiewicz et al., 2006). Briefly, paraffin-embedded sections of perfused brains were de-waxed and rehydrated, then steamed for 20 min in antigen retrieval solution (Reveal; Biocare Medical, Walnut Creek, Calif., USA). Sections were blocked and exposed to primary antibody for 12 hrs at 4° C. After washing, fluorescent secondary antibody in PBS-T (phosphate buffered saline and 0.05% Tween-20) was added for 1 hr at room temperature. Confocal fluorescence microscopy was carried out under a TCS laser scanning microscope (Leica, Buffalo Grove, Ill., USA). Optical sections of 0.4 mm were scanned at the z-axis. Image J was used to quantify the percentage of specific expression of antibody in each sample. Immunocytochemistry of cell cultures was performed in PC12 cells on poly-L-lysine coated cover slips. Cells were fixed for 20min in paraformaldehyde (PFA), washed three times in PBST, permeabilized with methanol-acetone at -20° C. freezer for 15 min, blocked 30min in 10% donkey serum/TBS, incubated in primary antibody for 12 hrs at 4° C., washed three times in TBS, then incubated in secondary antibody either Alexafluor 568 or Alexafluor 488. Images were acquired with a TCS laser scanning microscope (Leica, Buffalo Grove, Ill., USA). All cells were imaged at the same settings. Intensity was determined with the brightest condition exhibiting little saturation (<255).

[0167] Height and density of Purkinje dendrite trees were calculated as previously described (Miyazaki and Watanabe, 2011). Purkinje cells selected for the measurements spanned the molecular layer were well-stained and were not obscured by adjacent cells. The dendritic trees of the captured Purkinje cell image and the area enclosed were outlined and measured using NIH Image J software. The cell body was excluded in

the height measurements. The scale was consistently measured from the point where the cell body narrows into the primary dendrite. Height of the Purkinje cells (perpendicular height) was measured from the cell body in an axis perpendicular to the edge of the molecular layer. Following measurement of height, the identical Purkinje cell was used for density calculation, in which the same fluorescence pixel was used for all the Purkinje cells identified. For both measurements, 50-100 Purkinje cells were analyzed per animal to calculate the mean.

Electrophysiology

[0168] Slice preparation: Experiments were performed on $\alpha 1A^{-/-}$, $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{WT}$, and WT mice age P16-18. The animals were anesthetized with halothane and rapidly decapitated. The cerebellar vermis was then removed and cooled to 4° C. in artificial CSF (ACSF) containing the following (in mM): 124 NaCl, 5 KCl, 1.25 Na_2HPO_4 , 2 $CaCl_2$, 26 $NaHCO_3$, and 10 D-glucose, bubbled with 95% O_2 and 5% CO_2 . Parasagittal slices of the cerebellar vermis (220 μm) were prepared with a vibratome (VT-1000S; Leica Microsystems). Slices were then incubated for at least 1 hr at room temperature (RT) in oxygenated ACSF.

[0169] Somatic whole-cell patch clamp recordings: Slices were held at RT and continuously perfused with ACSF throughout the recordings. Patch-clamp recordings from Purkinje cells were performed using an EPC-10 amplifier (HEKA Electronics, Lambrecht-Pfalz, Germany). Currents were filtered at 3 kHz, digitized at 5-10 kHz, and acquired using Patchmaster software. To record PF EPSCs, patch pipettes (2-5 M Ω) were filled with a solution containing the following (in mM): 120 K-gluconate, 9 KCl, 10 KOH, 3.48 $MgCl_2$, 10 HEPES, 4 NaCl, 4 Na_2ATP , 0.4 Na_3GTP , and 17.5 Sucrose (pH 7.25-7.35). While cells were held in voltage-clamp mode at -80 mV, PF-EPSCs were elicited by a stimulating electrode placed in the upper third of the molecular layer. To record CF EPSCs, patch pipettes (2-5 M Ω) were filled with a solution containing the following (in mM): 100 $CsMeSO_4$, 50 $CsCl$, 1 $MgCl_2$, 0.2 EGTA, 10 HEPES, 2 Na_2ATP , 0.3 Na_3GTP , and 4 mM QX-314 (pH 7.25-7.35). Cells were held in voltage-clamp mode at multiple potentials. CF-EPSCs were elicited by a stimulating electrode placed in the granule cell layer. The presence of multiple CF innervations was ascertained by gradually increasing the stimulus intensity and looking for discrete changes, or steps, in EPSC amplitude, as has been described previously (Hashimoto et al., 2011). Picrotoxin (200 μM ; Sigma-Aldrich, St. Louis, Mo.) was added to the ACSF throughout all recordings.

[0170] Data analysis: Data were analyzed with Excel (Microsoft) and Igor (Wavemetrics). All data are expressed as mean \pm SEM. For statistical analysis of PF and CF EPSCs, we used the unpaired Student's t test.

Cell Death Analysis

[0171] PC12 cells with stably-transfected pcDNA3-FLAG, $\alpha 1ACT_{WT}$ -FLAG and $\alpha 1ACT_{SCA6}$ -FLAG were washed extensively with serum-free, phenol red-free DMEM and an equal number of cells (0.5×10^6) were plated into poly-L-lysine-coated 6-well plates. After 24-h, cells at basal culture conditions were collected and analyzed by flow cytometry with propidium iodide and annexin V-FITC staining. LDH

release assay was also performed on these cells following the manufacturers' instructions (Roche, Indianapolis, Ind., USA).

Statistical Analysis

[0172] Values represent mean \pm standard error of the mean (SEM). Differences between experimental groups were compared by Student's t-test or ANOVA when multiple comparisons were made. For qRT-PCR, error was propagated using standard methods. For histopathology, significance was determined using the Student's t-test. For multiple comparisons, significance was assessed with the Mann-Whitney test. For the cell cycle, significance was analyzed via chi-square testing. Electrophysiological data were analyzed with Excel (Microsoft) or Igor (Wavemetrics).

Example 2

Identification of the C Terminal Fragment of CACNA1A-Encoded $\alpha 1A$ Subunit ($\alpha 1ACT$)

[0173] To identify the N terminal sequence of the $\alpha 1ACT$ fragment, we tagged the full-length human $\alpha 1A$ subunit cDNA bearing normal polyQ (Q11), $\alpha 1A_{WT}$, at its 3' end with a 3 \times FLAG epitope and established HEK293 cell lines stably expressing this ~220 kD $\alpha 1A$ -FLAG fusion protein. The cell line grew normally and stably expressed the 75 kD $\alpha 1ACT$ -FLAG fusion protein. We affinity purified $\alpha 1ACT$ -FLAG from the whole-cell lysate in a two-step procedure. Peak elution fractions (FIG. 1A) collected from anion exchange chromatography (HiTrap™ DEAE FF) were subjected to affinity purification using anti-FLAG M2 magnetic beads. The isolated $\alpha 1ACT$ fragment protein was seen as a unique, 75 kD band (arrowhead) above the heavy chain IgG band on a Coomassie stained SDS-PAGE gel (FIG. 1B and 1C). LC-MS/MS analysis of in-gel digest protein (The Rockefeller University Protein Resource Center, N.Y.) revealed that the amino acid sequence of N terminus of $\alpha 1ACT$ fragment was Met Ile Met Glu Tyr (amino acids 1960-1964, nucleotides 6114-6128, Genbank access GI: 187828892, NM_001127222,) (FIG. 1D and FIG. 8). This sequence, which begins within the IQ-like domain of the full length $\alpha 1A$ subunit and does not overlap with any known protease cleavage site, is a highly homologous sequence in all vertebrate species (Wilkins et al., 1999).

[0174] To investigate the origin of $\alpha 1ACT$ protein fragment, we generated a series of constructs bearing different mutations of the $\alpha 1A$ cDNA, as defined in FIG. 1E, and transfected them into HEK293 cells. Deletion of 534 bps ($\alpha 1A_{\Delta 1534}$ bp) abolished the $\alpha 1ACT$ fragment expression without affecting the expression of the full-length $\alpha 1A$ subunit (FIG. 1H), whereas other mutations of $\alpha 1A$ failed to do so (FIG. 1E-1H). This indicates that the 534 bps fragment upstream of the $\alpha 1ACT$ start site in the $\alpha 1A$ cDNA contains sequences essential for translation of $\alpha 1ACT$. These effects on expression were seen to an equivalent degree with both the $\alpha 1A_{WT}$ and the human $\alpha 1A$ subunit cDNA bearing the pathological polyQ tract (Q33, $\alpha 1A_{SCA6}$)

CACNA1A mRNA Contains an Internal Ribosome Entry Site (IRES)

[0175] We hypothesized that expression of $\alpha 1ACT$ fragment may be mediated by an IRES present within the CACNA1A coding sequence. 2-d structure analyses of the complete $\alpha 1A$ mRNA sequence using an M-fold-based algo-

rithm (Palmenberg and Sgro, 1997; Zuker, 2003) did not identify any canonical type I or type II IRES structures in this region (Baird et al., 2006). However, the region containing nucleotides 5096-6110 sequence was predicted to form a highly complex, stable conformation possessing several stem-loop structures that could represent an area of functional significance for ribosomal binding and interaction with transactivating factors (FIG. 9). This region is highly conserved, from 89.4% in *Bos taurus* to 76.7% in *Danio rerio*.

[0176] To test for IRES activity within this region we inserted DNA segments of different lengths (FIG. 2) from the region 5' to the α 1ACT start site into the bi-cistronic (Renilla luciferase, R-Luc, and firefly luciferase, F-Luc) reporter vector, pRF (FIG. 2A) (Spriggs et al., 2009). Because the coding region for the R-Luc is followed by a stop codon, an increase in F-Luc activity indicates the presence of an upstream IRES that enables re-binding of the dual luciferase transcript to the ribosomal machinery. Expression of pRCT653TF or pRCT1014TF, but not pRCT189TF and pRCT293TF, in HEK293 cells enhanced the activity of the F-Luc approximately 9- and 26-fold (FIG. 2A and 2B). Moreover, insertion of 1 or 2 nucleotides immediately 5' to the ATG codon prior to the F-Luc coding region within the pRF vector eliminated the accumulation of F-Luc (FIG. 2C and 2D). Therefore, the structure of the CACNA1A IRES is highly dependent on initiating translation of the second cistron at a specific codon,

α 1ACT is driven by the presence of a cellular IRES within the α 1A coding region rather than by a cryptic promoter or splicing event.

The Translocated α 1ACT Fragment Binds to Non-Coding Regions of Genes Expressed in Purkinje Cells and Activates Transcription

[0177] Earlier studies indicated that the 75 kD α 1ACT, bearing the normal polyQ tract, was enriched in the nucleus (Ishiguro et al., 2010; Kordasiewicz et al., 2006). To investigate whether α 1ACT_{WT} (Q11) plays a role in gene expression by binding to genomic DNA, we performed chromatin immunoprecipitation-based cloning (ChIP-based cloning) from PC12 cells transfected with α 1ACT-FLAG fusion protein (Methods). Potential target genes identified via ChIP-based cloning and sequencing include GRN (granulin), BTG1 (B-cell translation gene 1), PMCA2 (Ca²⁺ ATPase, plasma membrane 2), ITGA8 (integrin alpha-8 precursor) and TAF1 (TATA box binding protein-associated factor of RNA pol II) (Table 5). Putative interaction between α 1ACT-FLAG fusion protein and cloned DNA segments within the BTG1, PMCA2 and GRN genes was further confirmed by ChIP-qRT-PCR, (FIG. 3A and 3B). Although these genes are not uniquely expressed in PCs, the abundant expression of α 1ACT in PCs suggests that they are part of a PC-specific developmental program.

TABLE 5

The neuronal genes identified by α 1ACT ChIP-cloning				
Name	Short Name	Genebank Accession	Length (bp)	Position
TATA box binding protein-associated factor	TAF1	NG_012771	171	Introns Alu repeat
B-cell translocation gene 1	BTG1	NM_017258	100	3'UTR532-631 nt
Granulin	GRN	NG_007886	153	5'UTR 6793-6930 bp
Ca ²⁺ ATPase, plasma membrane 2	PMCA2	NM_012508	186	5'upstream 9822 bp
Integrin α -8 precursor	ITGA8	EF444991	1227	Intron 22 153367-154427

ATG 1960, as is typical of most IRES activation (Fitzgerald and Semler, 2009; Wilson et al., 2000). To help exclude the possibility that the increased F-Luc activity was due to a change at the RNA level, we inserted the same segments into the promoter-less reporter vector, pGL3Basic. Transfection into HEK293 cells yielded no significant increase of luciferase activity (FIG. 2E-2G), arguing against the presence of a cryptic promoter in these segments. Subsequently, we performed a quantitative real-time PCR (qRT-PCR) on two amplicons within the Renilla ORF and one near the initiation codon of firefly ORF (FIG. 2A). The observed ratio of 1:1 Renilla: Firefly mRNA (FIG. 2H) favors the presence of an IRES, rather than increased transcription of the second reporter via a cryptic promoter, a splicing event or any other increase in mRNA stability. In addition, the qRT-PCR expression ratios for gene fragments (5' to or 3' to the α 1ACT start site) within the α 1A subunit were approximately 1 in untransfected HEK293 or PC12 cells. Lastly, we found equivalent signals from before and after the α 1ACT start site using endogenous α 1A mRNA isolated from human cerebellum (FIGS. 2I and 2J). These results suggest that expression of

[0178] We tested whether α 1ACT regulates gene expression through the target sequences identified in ChIP-based cloning. Within BTG1 3' UTR, we identified an enhancer within the 113 bp sequence that obtained from α 1ACT ChIP-based cloning, using reporter assays with segments spanning three lengths (beginning at nt 517) from the 3' UTR inserted into the pGL3 promoter vector (Du et al., 2009), as shown in FIG. 3C. Importantly, over-expression of α 1ACT_{WT} significantly increased luciferase activity in the BTG1-630 reporter construct, suggesting that BTG1 3'UTR contains an α 1ACT-regulated enhancer element. However, α 1ACT_{SCA6}, bearing the pathological polyQ tract (Q33) failed to increase BTG1 3'UTR-enhanced luciferase expression (FIG. 3C). We obtained similar results from two segments of 5' flanking region in the progranulin gene using the pGL3-basic vector. The α 1ACT_{WT} fragment, but not the Δ 1ACT_{SCA6} fragment, increased expression of the reporters bearing the 1662 bp fragment by 2-fold and the 638 bp fragment by 3.2-fold, respectively (FIG. 3D). Thus, α 1ACT_{WT} has direct gene regulatory effects on at least two target genes, and these are lacking with α 1ACT_{SCA6}.

AT-Rich Element of α 1ACT Binding Site is Essential for the BTG1 Enhancer Activity

[0179] Alignments of ChIP-identified sequences predict two distinct motifs, 1) an AT-rich element, TTATAAAA, and 2) a CA-rich element, CCAA, as potential α 1ACT binding sites (FIG. 3E). The 113 bp BTG1 3' UTR sequence (517-630 bp BTG1 WT, Table 3) contains both consensus sequences. As shown in FIG. 3F by electrophoretic mobility shift assays (EMSA) using the BTG1 WT as probe and nuclear extracts from untreated PC12 cells or from those transfected with α 1ACT_{WT} and α 1ACT_{SCA6}, we observed a component in PC12 cells, caused a significant gel shift (Complex I, II and III). This indicates that the BTG1 3' UTR contains cis-elements reacting with neuron-specific nuclear protein, present in both untransfected and α 1ACT-transfected cells. The three protein complexes with the BTG1 WT probe could be abolished by excess unlabeled BTG1 WT probe, indicating that the binding was specific (Lanes 3 and 4, FIG. 3F). Interestingly, nuclear extracts from α 1ACT_{SCA6}-transfected PC12 cells (Lane 8, FIG. 3F) led to a different migration and pattern of DNA-protein complexes compared to α 1ACT_{WT}-expressing cells (Lane 5, FIG. 3F), with a greater abundance of complex IV in complexes from the α 1ACT_{SCA6}-transfected PC12 cells. This suggests that α 1ACT_{SCA6} has different protein binding pattern from α 1ACT_{WT}.

[0180] To further identify α 1ACT consensus sequences, we used the AT-rich consensus element as a probe in EMSA (Table 3 and FIG. 3G). The AT-rich consensus sequence greatly reduced the formation of the complexes (Lane 7, FIG. 3G), while mutant AT-rich elements only partially reduced the complex formation (Lanes 5 and 6, FIG. 3G). Anti-FLAG antibodies generated a super-shifted complex with nuclear extracts from α 1ACT_{WT}-FLAG expressing cells (Lanes 8 and 9, FIG. 3G). These studies demonstrate that α 1ACT binds to AT-rich element in the BTG1 3' UTR. Finally, we performed EMSA with a series of 3-bp mutations of the TTATAAGAT sequence (Table 3). As shown in FIG. 3H, Mut1 abolished complex II and Mut2 abolished complex I. Mut4, combining Mut1 and Mut2, abolished both complex I and II (FIG. 10). We also mutated the element, TTATAAGT, within the BTG1 630reporter construct (517-630 bp). Constructs 630mut1 and 630mut2 contain 3 bp mutation, while 630mut4 contains both Mut1 and Mut2 substitutions. All three constructs had significantly reduced luciferase activities, both basally and in response to over-expressing of α 1ACT_{WT} compared to BTG1 630 construct (FIG. 3I). These results suggest that TTATAA is the core sequence of AT-rich element that is required to maintain the α 1ACT-regulated BTG1 expression.

The α 1ACT_{WT} (but not α 1ACT_{SCA6}) Increases the Physiological Expression of Target Genes and Enhances Neurite Outgrowth of Differentiating PC12 Cells

[0181] To test for an effect of α 1ACT on endogenous expression of ChIP-identified genes we examined the mRNA and protein levels of TAF, BTG1, PMCA2 and GRN in both cell lines and human cerebellum. Over-expression of normal α 1A_{WT} or α 1ACT_{WT}, but not α 1ACT_{SCA6}, significantly increased the expression of these genes (1.6- to 2.7-fold) in PC12 cells, either compared to empty vector-transfected or α 1ACT_{SCA6}-transfected PC12 cells (FIG. 4A). As shown in FIGS. 4B and 4C, BTG1 and PMCA2 protein expression levels were also increased in α 1A_{WT}- and α 1ACT_{WT}-transfected PC12 cells. Finally, using cerebellar tissues from two SCA6 patients (Q22) and normalizing transcript levels to a

PC specific mRNA, Pcp2, we found that BTG1 gene mRNA expression was decreased compared to the normal control (FIG. 4D).

[0182] Several of the genes regulated by α 1ACT are known to play a role in differentiation of the neuronal phenotype (Baker et al., 2006). We established PC12 cell lines stably expressing 3xFLAG-tagged versions of either the full-length α 1A or the α 1ACT fragment. Upon induction with nerve growth factor (NGF) for 24 hrs, we observed that both α 1A_{WT}-FLAG and α 1ACT_{WT}-FLAG enhanced neurite outgrowth (fraction of cells with neurites) when compared with PC12 cells expressing empty vector (FIG. 4E-4H and FIG. 11A-11D). Importantly, the P/Q channel blocker, ω -agatoxin, had no effect on α 1ACT_{WT}-induced neurite outgrowth (FIG. 11E). Furthermore, blocking the expression of endogenous or transfected full-length α 1A by siRNA, had no effect on α 1ACT_{WT}-enhanced neurite outgrowth in PC12 cells transfected with α 1ACT_{WT}-FLAG (FIG. 11E-11K). These findings suggest that enhanced neurite outgrowth does not depend on functioning channels or the presence of the full channel protein. There was a significant increase in the percentage of cells bearing neurites in cells transfected with α 1A_{WT}-FLAG and α 1ACT_{WT}-FLAG compared to controls after NGF stimulation for 24, 48 and 72 hrs (FIGS. 4E, 4F and 4H). Total neurite lengths were also increased 2 fold in α 1ACT_{WT}-expressing cells compared with controls at each time point (FIG. 4G and FIG. 11A-11D). However, cells expressing α 1ACT_{SCA6}-FLAG had significantly lower percentage of cells with neurites and total neurite length/cell compared with cells expressing α 1ACT_{WT}-FLAG (FIG. 4E-4H and FIG. 11A-11D). Thus, α 1ACT_{SCA6} lacks the normal function of α 1ACT_{WT} in potentiating neurite outgrowth in neuronal cells.

[0183] BTG1 belongs to the BTG/TOB protein family of anti-proliferative genes. Both BTG1 and BTG2 proteins interact with the protein arginine N-methyltransferase (i.e. PRMT1) and positively modulate its activity. The PRMT1/BTG methylation pathway is involved in maintaining neuronal cells in a differentiated state (Berthet et al., 2002). We used BTG1 antibody to immunoprecipitate PRMT1 in PC12 cells stably transfected with α 1ACT_{WT} and α 1ACT_{SCA6}. In α 1ACT_{WT}-expressing cells the quantity of precipitated PRMT1 was increased, while in α 1ACT_{SCA6}-expressing cells precipitated PRMT1 was decreased, consistent with the expression of BTG1 in these two cell types (FIG. 4I). Meanwhile, silencing of BTG1 by small interference RNA (siRNA) blocked the NGF-induced α 1ACT-regulated neurite outgrowth (FIG. 4J-4L and FIG. 11L). These results demonstrate that α 1ACT with normal range polyQ maintains the physiological expression of the BTG1 gene, leading to subsequent interaction of the PRMT1/BTG pathway to mediate neuronal differentiation. Together these observations suggest that the normal α 1ACT acts as a transcription factor through target genes to enhance the neuronal phenotype, and that one effect of the SCA6 polyQ expansion in α 1ACT is to disrupt the properties of the α 1ACT transcription factor.

α 1ACT Partially Rescues the Phenotype of α 1A^{-/-} Mice

[0184] α 1A^{-/-} mice, with targeted disruption of mouse CACNA1A, develop a gross neurological phenotype of seizures, dystonia, and ataxia soon after birth, and die by P18-21 (Jun et al., 1999). To investigate the importance of expression of the α 1ACT fragment in PCs we used the Pcp2 promoter and Tet-off system (Zu et al., 2004) to generate two double transgenic mouse lines, Pcp2-tTA/TRE- α 1ACT (abbrevi-

ated, PC- α 1ACT), expressing at comparable levels either α 1ACT_{WT} (WT=Q4, the smallest α 1ACT polyQ seen in humans) or α 1ACT_{SCA6} (SCA6=Q33, the largest α 1ACT polyQ seen in SCA6) fragments tagged with an N-terminal myc epitope (see Methods). These mice appeared to grow and develop normally and live a full life span. α 1ACT_{SCA6} mice, however, had mild progressive motor problems that were evident using the treadmill (see below).

[0185] To test the role of α 1ACT in cerebellar PC development in the absence of α 1A channels, we bred PC- α 1ACT mice with α 1A^{+/-} heterozygous knockout mice and subsequently crossed these offspring to generate α 1A^{-/-} mice with PC-targeted α 1ACT expression (α 1A^{-/-}/PC- α 1ACT). Curiously we did not identify any mice with α 1A^{-/-}/PC- α 1ACT_{SCA6} genotype, suggesting an impaired viability (FIG. 5A). As expected, α 1A^{-/-} exhibited severe neurological impairment (Jun et al., 1999). Surprisingly, α 1A^{-/-} mice expressing α 1ACT_{WT}, i.e., α 1A^{-/-}/PC- α 1ACT_{WT} mice, had an improved behavioral phenotype relative to α ^{-/-} mice. Although still neurologically impaired, they gained more weight during the first two weeks of postnatal life compared to α ^{-/-} mice (FIGS. 5B and 5C), had improved in-cage mobility (Supplementary video 1), and survived approximately 1 week longer than α 1A^{-/-} mice (FIG. 5D). We reasoned that the improved phenotype of α 1A^{-/-}/PC- α 1ACT_{WT} mouse might be mediated through improved dendritic and synaptic development. Immunofluorescent staining of cerebellar cortex of P16 mice from three groups, WT, α 1A^{-/-} and α 1A^{-/-}/PC- α 1ACT_{WT} mice showed that, as noted previously, PCs of α 1A^{-/-} mice had shortened primary dendrites with premature branching and an immature pattern of parallel fiber (PF) and climbing fiber (CF) synaptic contacts on PC soma and proximal dendrites (Hashimoto et al., 2011) (FIG. 5E-5L). In contrast, PC morphology and afferent innervation of α 1A^{-/-}/PC- α 1ACT_{WT} cells resembled the pattern in WT mice (FIG. 5E-5L). In α 1A^{-/-}/PC- α 1ACT_{WT} mice the thickness of molecular layer (ML), the relative height and density of the dendritic tree were significantly increased, compared to those of α 1A^{-/-} mice ($p < 0.05$) (FIG. 5F-5H). This finding is consistent with our in vitro studies showing that α 1ACT enhances neurite outgrowth.

[0186] We also compared the height of CF innervation between the three mouse groups (FIG. 5J-5L) (Hashimoto and Kano, 2005; Hashimoto et al., 2011). In α 1A^{-/-} mice, most PCs were multi-innervated, and the CF height only reached 65.2 \pm 5.3% of the ML at P16. We found that the CF height was improved in α 1A^{-/-}/PC- α 1ACT_{WT} mice over that of α 1A^{-/-} mice, reaching to 80.7 \pm 4.1% of the ML at P16 ($p < 0.05$). However, α 1A^{-/-}/PC- α 1ACT_{WT} mice exhibited the same three patterns of CF contacts seen with α 1A^{-/-} mice, mono CF on PC dendrites, multiple CF contacts on proximal dendrites, and multiple CF contacts on PC soma (FIG. 5). These results demonstrate that α 1ACT, as a transcription factor, plays an important role in establishing normal dendritic tree morphology in PCs in vivo, but that synapse elimination or selection of dominant innervation requires either P/Q channel function or α 1ACT under its endogenous expression pattern.

[0187] Finally, we examined mRNA levels of TAF, BTG1, PMCA2 and GRN in the three mouse groups. FIG. 12 demonstrates that the expression of these genes was decreased in cerebellar tissue of α 1A^{-/-} mice when compared to normal mice, but was increased 1.5 to 3 fold in α 1A^{-/-}/PC- α 1ACT_{WT} transgenic mice when compared to α 1A^{-/-} mice ($p < 0.05$),

relative to either β -actin or Pcp2 gene expression (FIG. 12A-12D). These results indicate that expression of the α 1ACT target genes is impaired in α 1A^{-/-} mice and is corrected by localized expression of α 1ACT_{WT} in PCs of transgenic mice.

α 1ACT Partially Restores Parallel Fiber EPSC Amplitude but Not Climbing Fiber Mono-Innervation

[0188] To further assess the effect of α 1ACT expression on Purkinje cell synaptic properties, we measured PF excitatory postsynaptic current (PF EPSC) amplitude as a function of stimulus intensity in WT, α 1A^{-/-}, and α 1A^{-/-}/PC- α 1ACT_{WT} mice (P16-18) in cerebellar slice preparations. While PF EPSCs from WT were significantly larger than those from both α 1A^{-/-} ($p < 0.01$, stimulus intensities 20-55 μ A) and α 1A^{-/-}/PC- α 1ACT_{WT} mice ($p < 0.05$), EPSCs from α 1A^{-/-}/PC- α 1ACT_{WT} mice were greater than those from α 1A^{-/-} mice ($p < 0.05$), indicating that α 1ACT expression improves PF synaptic connections (FIG. 6A).

[0189] The inability of α 1ACT to completely restore EPSC amplitudes to WT levels could be explained by the absence of P/Q-type Ca²⁺ channels in PF presynaptic terminals of α 1A^{-/-}/PC- α 1ACT_{WT} mice, as these channels play a critical role in neurotransmitter release at PF-Purkinje cell (PF-PC) synapses (Matsushita et al., 2002; Mintz et al., 1995). We therefore examined the presynaptic release properties of PF-PC synapses in α 1A^{-/-} and α 1A^{-/-}/PC- α 1ACT_{WT} mice by measuring the paired-pulse ratios (PPRs) of PF EPSCs. Large PPRs are indicative of low initial release probabilities, and are a sign of impaired presynaptic function (Zucker and Regehr, 2002). In accordance with observations from mouse models harboring loss-of-function mutations in the CACNA1A gene, α 1A^{-/-} mice exhibited PPRs significantly greater than WT at several stimulus intervals (WT to α 1A^{-/-} mice: $p < 0.01$ for stimulus intervals of 20-100 ms, FIG. 6B) (Liu and Friel, 2008; Matsushita et al., 2002). While α 1ACT expression did lower PPRs closer to WT levels (α 1A^{-/-}/PC- α 1ACT_{WT} to α 1A^{-/-} mice: $p < 0.01$ for stimulus intervals of 20 and 100 ms, $p < 0.05$ for stimulus interval of 50 ms), the measured values were still elevated (WT to α 1A^{-/-}/PC- α 1ACT_{WT}: $p < 0.05$ for stimulus intervals of 20 and 50 ms) (FIG. 6B), suggesting a residual presynaptic deficit.

[0190] We also examined properties of the CF synapse onto Purkinje cells. We observed a reduction in CF EPSC amplitudes and a decrease in the degree of paired-pulse depression in both α 1A^{-/-} and α 1A^{-/-}/PC- α 1ACT_{WT} mice with respect to WT, both of which could also be due to the absence of P/Q-type channels presynaptically (FIG. 6C). Additionally, we investigated whether α 1ACT expression affects the process of CF maturation. During development, Purkinje cells undergo a competitive and activity-dependent elimination of superfluous CF inputs until only one remains. Impairments to this process results in the persistent innervation of Purkinje cells by multiple climbing fibers into adulthood. We found the proportion of Purkinje cells with multiple CF innervations to be increased in both α 1A^{-/-} and α 1A^{-/-}/PC- α 1ACT_{WT} mice compared to WT, a result indicating that actual P/Q-type Ca²⁺ channel function, and not just expression of the C terminus, may be essential for proper CF maturation (Watanabe and Kano, 2011) (FIG. 6D). Our results provide evidence that α 1ACT expression improves the synaptic connections of PFs, but not CFs, onto Purkinje cells.

α 1ACT_{SCA6} Causes Cell Death in vitro and Mediates Ataxia and Cerebellar Cortical Atrophy in Transgenic Mice

[0191] Previous studies have shown that the α 1A C terminus bearing an expanded polyQ tract is toxic relative to WT α 1A C terminus when transiently over-expressed in cultured mammalian cells (Ishiguro et al., 2010; Kubodera et al., 2003). Our flow cytometry results showed that PC12 cells stably expressing α 1ACT_{WT} exhibited equivalent viability to vector control cells, while cells expressing α 1ACT_{SCA6} had approximately a 2-fold increase in cell death ($p < 0.05$, FIG. 7A-7C) (Koopman et al., 1994). Also, LDH release was significantly higher in cells expressing the α 1ACT_{SCA6} compared with that of PC12 cells expressing only pcDNA3 or α 1ACT_{WT} (FIG. 7D). These findings indicate that over-expression of α 1ACT bearing pathological size of polyQ reduces cell viability in cultured mammalian cells.

[0192] Finally, we tested whether over-expression of the SCA6-expanded α 1ACT_{SCA6} fragment in mice would lead to clinical or pathological features resembling SCA6, compared with over-expression of the fragment with normal allele size, α 1ACT_{WT}. Both α 1ACT_{WT} and α 1ACT_{SCA6} can be detected in the nucleus of PCs in the corresponding PC- α 1ACT lines at comparable levels by western blot, RT-PCR and immunostaining (FIG. 7E, FIG. 13A and FIG. 13B). There were no obvious clinical differences between these two lines in young adults, and lifespan was not affected. However, we found that PC- α 1ACT_{SCA6} mice demonstrated significant abnormalities in several gait parameters compared with PC- α 1ACT_{WT} mice using a video-assisted computerized treadmill for gait analysis (DigiGait, Mouse Specifics, Inc) ($p < 0.05$, after post hoc correction). Most importantly, they exhibited an age-dependent increase in shared stance (double support time) of hind limbs, between ages 3 and 9 months, indicating progressive instability during walking ($p < 0.05$, FIG. 7F and Supplementary video 2 and 3) (Matsukawa et al., 2003; Stolze et al., 2002). The gait disturbance never progressed to the level of severe ataxia, although natural changes in weight gain in older mice may have obscured an impact on normal gait activity. The lack of severe ataxia even in 2-year-old mice is not surprising for a model of SCA6, with an age of onset of 43-52 years. Although we found no obvious sign of cell loss in the cerebellum in α 1ACT_{SCA6} mice at approximately 2 years of age, measurement of the ML thickness showed that α 1ACT_{SCA6}-expressing mice have significant thinning of the ML, compared with age-matched α 1ACT_{WT} and WT mice (FIGS. 7G and 7H). Lastly, using RT-PCR to examine the expression levels of ChIP-identified genes TAF, GRN, BTG1 and PMCA2 in cerebellar tissues of 2-year-old PC- α 1ACT_{SCA6} mice compared with age-matched WT mice, we found that the transcript levels of each of the α 1ACT-regulated genes were decreased by between 11% and 34% (FIG. 13C-6F). These findings are the first to demonstrate clinical and pathological changes in an animal model of SCA6 expressing appropriate-sized pathological alleles within a CACNA1A protein.

CACNA1A Contains a Cellular IRES

[0193] Cellular IRESs play an increasingly recognized role in the control of eukaryote gene expression where in many 5' UTRs they provide alternatives to cap-dependent translation initiation during times of cellular stress (Coldwell et al., 2001; Spriggs et al., 2008). IRES sequences have also been detected within the coding regions of some cellular mRNAs, leading to the expression of isoforms or distinct protein prod-

ucts (Cornelis et al., 2000; Ul-Hussain et al., 2008). Together with the present report, these observations suggest that expression of bi-functional genes, particularly those encoding separate transcription factor proteins in the second cistron, may be a newly-recognized strategy for coordinating gene expression programs tied to individual gene products. This could enable the timely expression of a set of genes coincident with the appearance of key proteins during differentiation.

α 1ACT, a CACNA1A-Encoded Transcription Factor Promotes a Neurite Outgrowth Program

[0194] As a transcription factor, the normal α 1ACT enhances the expression of at least three genes, GRN, PMCA2 and BTG1, in PC12 cells and cerebellar tissue, potentiates NGF-mediated neurite outgrowth in PC12 cells, and partially rescues the CACNA1A knockout phenotype. GRN is involved in neurite outgrowth and is critical in maintaining neuronal survival, since loss-of-function mutations of the GRN gene lead to cell death in the frontal and temporal lobes (Baker et al., 2006; Cruts et al., 2006; Van Damme et al., 2008). PMCA2 is highly expressed in the cerebellum, particularly in PCs and throughout the ML and granule cell layer (Zacharias and Kappen, 1999). PMCA2 knock-out mice exhibit vestibular and gait abnormalities and reduced thickness of the cerebellar ML (Kozel et al., 1998). Lack of PMCA2 also dramatically alters PC morphology. PMCA2 is a component of mGluR1-IP3R1 signaling complex, which has been implicated in plasticity at the PF-PC synapse (Kurnellas et al., 2007).

[0195] The PRMT1/BTG methylation pathway is involved in neurogenesis or in maintaining neuronal cells in a differentiated state. The 3' UTR of BTG1 is highly conserved throughout evolution and plays a key role in this pathway (Rouault et al., 1993), consistent with our finding that α 1ACT activates a novel 3' enhancer element of BTG1. Enhanced BTG1/PRMT1-driven arginine methylation partly accounts for the essential role of protein methylation during PC12 differentiation (Cimato et al., 1997), which is in line with findings here that BTG1 knockdown blocks neurite outgrowth. Together these findings suggest that α 1ACT_{WT} is essential for maintenance of neurite outgrowth through gene-specific signaling pathways. It will be of interest to extend our ChIP-based cloning approach using RNA-seq methodology to more completely characterize the normal repertoire of α 1ACT-regulated genes, as well as those bound by α 1ACT_{SCA6}.

[0196] Except for the in vivo studies, the properties of α 1ACT are similar to those demonstrated for the 70 kD fragment, termed CCAT, derived from the Cav1.2 channel, α 1C subunit, which may arise from a similar translational mechanism (Gomez-Ospina et al., 2006). In that case, as well as in ours, the set of genes regulated by these novel transcription factors does not conform to an obvious functional class of proteins, but appears to be involved in elaborating key components of the neuronal phenotype, and in neurogenesis or neurodegeneration, timed with the appearance of Ca²⁺ channel activity.

Phenotype Rescue of α 1A^{-/-} Mice by α 1ACT

[0197] The improved phenotype at behavioral, histological, and electrophysiological levels in α 1A^{-/-}/PC- α 1ACT_{WT} mice is remarkable, particularly because α 1ACT_{WT} expres-

sion, under the control of PC specific promoter, *Pcp2*, was only restored in PCs. Consistent with these findings and our in vitro results, ChIP-identified genes TAF, BTG1, PMCA2 and GRN were down-regulated in $\alpha 1A^{-/-}$ mice, but were increased 1.5 to 3 fold in $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{WT}$ transgenic mice. These results suggest that $\alpha 1ACT$, as a second gene product from CACNA1A, plays an important role in establishing normal morphology and function of PCs.

$\alpha 1ACT$ Expression Improves PF-PC Connections

[0198] PF EPSC amplitudes measured in $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{WT}$ were significantly greater than those observed in $\alpha 1A^{-/-}$ mice, though they were not completely restored to WT levels, presumably due to the importance of P/Q-type Ca^{2+} channel function to neurotransmitter release at PF-PC synapses (Mintz et al., 1995). $\alpha 1ACT$ expression also resulted in a partial reduction of PPRs at this synapse, which was surprising as PPRs generally reflect presynaptic release probabilities, and $\alpha 1ACT$ is present only postsynaptically in $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{WT}$ mice, indicating that factors either directly or indirectly related to the postsynaptic target cell can also influence this parameter. Regardless, the residual elevation of PPRs in $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{WT}$ mice suggests that the incomplete restoration of PF EPSC amplitude is due to a presynaptic deficit in these mice.

[0199] The absence of any discernable effect of $\alpha 1ACT$ expression on CF-EPSCs indicates that actual P/Q-type Ca^{2+} channel function is required for the process of CF maturation, as has been suggested previously (Watanabe and Kano, 2011). Thus, it appears that the phenotypic benefits of $\alpha 1ACT$ expression are due predominantly to the improvement in PF synaptic transmission.

$\alpha 1ACT_{SCA6}$ Abolishes the Normal Function of $\alpha 1ACT$ in Gene Expression Regulation and is Pathogenic in vitro and in vivo

[0200] Compared the properties of the normal $\alpha 1ACT$ protein, $\alpha 1ACT_{WT}$, bearing 4 or 11 glutamines, the $\alpha 1ACT_{SCA6}$ polypeptide had altered binding to the BTG1 enhancer, showing additional DNA-protein complexes, and lacked the capacity to mediate expression via BTG1 and GRN luciferase reporters and impaired expression of these genes in PC12 cells. $\alpha 1ACT_{SCA6}$ also failed to mediate neurite outgrowth when stably expressed in PC12 cells and caused increased cell death. This may explain why we did not obtain any mice with $\alpha 1A^{-/-}$ /PC- $\alpha 1ACT_{SCA6}$ genotype. Mice over-expressing $\alpha 1ACT_{SCA6}$ on a normal background exhibited subtle, but clearly measurable defects in motor functioning. Computerized treadmill gait analysis demonstrated progressive gait impairment with an increase in double limb support, a compensatory reaction to instability during walking. With advanced age $\alpha 1ACT_{SCA6}$ was associated with thinning of the cerebellar cortex. These mice have reduced levels of expression of TAF1, GRN, BTG1 and PMCA2, the targets of $\alpha 1ACT$, relative to endogenous PC transcripts. These studies suggest that, rather than arising from ion channel dysfunction, the pathogenesis of SCA6 more closely resembles the toxic gain-of-function mechanism of the polyQ disorders (La Spada et al., 1991; Palhan et al., 2005; Sopher et al., 2004). This is supported by the lack of disturbed Ca^{2+} channel function in two mouse knockin studies of the SCA6 mutation (Saegusa et al., 2007; Watase et al., 2008). If additional studies further support this Ca^{2+} channel-independent mecha-

nism, the demonstration of selective translation based on an IRES may pave the way for therapies targeted at suppressing the IRES function.

[0201] We have shown that the CACNA1A gene is bicistronic, encoding a newly identified transcription factor, $\alpha 1ACT$, involved with neurite outgrowth and PC maturation, within the *cclA* mRNA. $\alpha 1ACT$ also bears the expanded polyQ tract in SCA6, which interrupts transcription factor function, impairs viability of cultured cells and is pathogenic in transgenic mice. These findings are summarized in the diagram in FIG. 7I.

Example 3

[0202] Additional studies were carried out as described below. Also provided below is a description of an exemplary method of identifying a compound with SCA6 therapeutic activity. It is described as a Renilla luciferase/Firefly luciferase (R-Luc/F-Luc) bicistronic reporter assay.

[0203] Spinocerebellar ataxia type 6 (SCA6) is a dominantly inherited neurodegenerative disease characterized by progressive ataxia and Purkinje cell degeneration, associated with CAG repeat expansions in the gene, CACNA1A. No preventive treatment exists for the numerous polyglutamine (polyQ) diseases including SCA6. Although CACNA1A is known to encode the $\alpha 1A$ subunit of the neuronal P/Q-type voltage-gated Ca^{2+} channel, numerous efforts have failed to implicate expanded polyQ tracts and altered P/Q channel function in SCA6. However, our recent evidence indicates that the disease is attributable to expression of a polyQ repeat expansion within a second CACNA1A gene product, $\alpha 1ACT$, that normally serves as a transcription factor (TF) critical for cerebellar cortical development. SCA6-sized polyQ expansions in the $\alpha 1ACT$ transcription factor interrupt its cellular and molecular function, and the toxicity of $\alpha 1ACT$ with SCA6-sized polyQ expansions has been shown in cellular models and in vivo, as disclosed herein.

[0204] We recently discovered that $\alpha 1ACT$ arises from a gene regulatory mechanism that is novel for the CACNA1A gene and for ion channel genes in general, in which expression of $\alpha 1ACT$ is under the control of a cryptic cellular internal ribosomal entry site (IRES) within the CACNA1A gene coding region. We expect the cellular IRES-regulated $\alpha 1ACT$ to be required for Purkinje cell development, and that the polyQ-expanded variant, $\alpha 1ACT_{SCA6}$, leads to neurodegeneration. The working examples disclosed herein establish that $\alpha 1ACT_{SCA6}$ alters gene expression in a manner expected to contribute to the pathogenesis of SCA6. The disclosures herein also provide a screening strategy for potential IRES-inhibiting compounds as potential therapies.

[0205] Spinocerebellar Ataxias

[0206] Spinocerebellar ataxia type 6 (SCA6), a form of spinocerebellar ataxia (SCA), is a dominantly inherited neurodegenerative disease characterized by progressive ataxia and Purkinje cell degeneration, associated with CAG repeat expansions in the gene, CACNA1A. SCA6 is a severe neurological disorder, and one of the most common SCAs worldwide (1-6), roughly as prevalent as amyotrophic lateral sclerosis (7-9). Patients with genetically distinct forms of SCA, including SCA6, become disabled and may progress to severe incapacitation. Many patients die prematurely due to aspiration pneumonia or respiratory failure (10-12). The advent of modern molecular genetics has enabled the confirmed molecular diagnosis and characterization of the many distinct forms of SCA (13). The most reliable prevalence estimates of

these heterogeneous disorders are on the order of 18-50/100,000 (9, 14). Thus, these disorders create a substantial economic and societal burden (15).

[0207] Insights into ataxia will aid in understanding other neurological disorders. There are extensive overlaps between SCA and other neurodegenerative diseases (NDs) (16-19). Although neuronal cell loss is most evident in the regions responsible for the principal clinical presentation of NDs, neurodegeneration is nearly always more widespread (20-23). Moreover, there is an increasing overlap in possible disease mechanisms. For example, there are growing mechanistic genetic overlaps between ALS and SCA2 (24) and SCA6 and epilepsy (25, 26). Thus, insights into molecular pathogenesis in each disease will have a wider impact on understanding neuronal death and dysfunction in other systems.

[0208] CACNA1A Genes and Disorders

[0209] The principal gene product of CACNA1A is the $\alpha 1A$ subunit of the P/Q-type voltage-gated Ca^{2+} channel. CACNA1A mutations of several types, leading to both loss and gain of channel function, are responsible for several types of neurological diseases, including episodic ataxia type 2, familial hemiplegic migraine, and epilepsy (27-29). The presence of the CAG repeat encoding a polyQ tract in the C terminus of the $\alpha 1A$ subunit led us to the hypothesis that the polyQ expansion in SCA6 caused a pathological disturbance of P/Q channel function (30, 31). However, several *in vitro* and *in vivo* expression studies have failed to demonstrate a consistent effect on channel function (32-36). In particular, two separate studies using CACNA1A knock-in mice with SCA6 repeat expansions failed to demonstrate any change in P/Q channel gating properties in cerebellar neurons (37, 38). Therefore, it is unlikely that SCA6 is a "channelopathy" in the classical sense.

[0210] PolyQ Disorders and Disease

[0211] SCA6 is one of 9 neurodegenerative diseases (polyQ disorders) that are due to an expansion of a CAG repeat encoding a polyQ tract (17-19). These polyQ proteins have no other structural similarity, but several have nuclear functions relating to gene regulation (39). Toxicity in these other disorders depends on the flanking protein context of the polyQ tract, and is frequently associated with transport to the nucleus of the full length or a toxic fragment of the mutant protein (40, 41). SCA6 differs from the other polyQ diseases in at least three respects: (1) The size of the polyQ expansion that leads to SCA6, Q19-33, is small, well within a range of repeat size seen in normal alleles for other polyQ disorders, i.e., SCA1, 2, 3, Huntington's disease, or spinobulbar muscular atrophy (8, 13, 42); (2) The Ca^{2+} channel protein expressing the polyQ tract causing SCA6 has rather restricted expression to neuronal cell types, most abundantly Purkinje cells, while other polyQ proteins are widely expressed outside the central nervous system (CNS) (13, 33, 43-45); and (3) Until recent studies, the polyQ expansion in SCA6 was found on a Ca^{2+} channel subunit, whose only recognized function is mediating Ca^{2+} conductance at the neuronal plasma membrane, while most other polyQ diseases appear to require entry of the pathological polyQ protein into the nucleus (22).

[0212] It has been shown that the C terminus of the $\alpha 1A$ subunit ($\alpha 1ACT$), which contains the polyQ tract, is present as a stable fragment in cultured cells or cerebellar tissues (46-50). We were the first to demonstrate that this fragment is enriched in cerebellar nuclei, translocated based on nuclear localization signals in the $\alpha 1ACT$ sequence (48). Finally, it

has been shown that the $\alpha 1ACT$ fragment bearing SCA6-expanded polyQs, unlike the full-length $\alpha 1A$ subunit, is toxic to cultured cells or primary neurons (47-50). In experiments presented below, we explain both the origin and endogenous function of the $\alpha 1ACT$. We demonstrate that the CACNA1A gene is bicistronic and that the $\alpha 1A$ mRNA contains a cryptic internal ribosomal entry site (IRES) that encodes the $\alpha 1ACT$ protein. We further demonstrate that $\alpha 1ACT$ containing the polyQ tract is a bona fide transcription factor that binds to non-coding regions of several Purkinje cell-expressed genes, enhancing their expression, and mediating neurite outgrowth *in vitro* and partial rescue of the CACNA1A knock-out phenotype *in vivo*. $\alpha 1ACT$ with expanded polyQ has reduced transcription factor and neurite outgrowth function, altered DNA binding, is toxic to cells *in vitro*, and causes impaired motor coordination and cerebellar cortical atrophy *in vivo*.

[0213] The N Terminal Sequence of $\alpha 1ACT$

[0214] Several groups have detected a stable C terminal $\alpha 1ACT$ polypeptide in cells and tissue; however, until now there have been no insights into the origin of this fragment (46-50). We performed a two-step column purification, using DEAE chromatography and anti-FLAG affinity chromatography to obtain a highly enriched preparation of a 75 kD FLAG-tagged $\alpha 1ACT$ fragment produced in cells stably expressing the $\alpha 1A$ subunit C terminally labeled with 3 \times FLAG. With the help of the Proteomics Resource Center at Rockefeller University we subjected the fragment to in-gel N-terminal propionylation and identified the N terminal sequence (start site) of the $\alpha 1ACT$ fragment by mass spectrometry as beginning with MIMYYR (SEQ ID NO: 165), corresponding to codon 1960 of $\alpha 1A$ subunit (FIG. 14).

[0215] $\alpha 1A$ mRNA Contains an IRES

[0216] Insertion of termination codons, either 1847 ($\alpha 1APstopQ11$, FIG. 15A) or 1937 nucleotides, 5' to the $\alpha 1ACT$ start site did not abolish $\alpha 1ACT$ expression, indicating that the $\alpha 1ACT$ fragment could be made separately from the $\alpha 1A$ subunit. To test for the presence of a cryptic internal ribosomal entry site (IRES) upstream of the $\alpha 1ACT$ start site within the $\alpha 1A$ mRNA coding sequence we used a dual-luciferase, bicistronic reporter, pRCTF, consisting of the Renilla luciferase (R-Luc) gene, followed by a stop codon, a polycloning site, and the firefly luciferase (F-Luc) gene (FIG. 15).

[0217] The presence of the stop codon after the R-Luc gene leads to only R-Luc activity. We inserted DNA fragments of four different sizes from the $\alpha 1A$ cDNA (sequences 189, 293, 653 and 1014 nucleotides upstream of the $\alpha 1ACT$ start site) into the cloning site between the luciferase genes. The 189- and 293-nucleotide sequences had no effect on F-Luc expression, while the 653- and 1014-nucleotide sequences increased F-Luc expression by 7-fold and 26-fold over R-Luc expression, respectively. RT-PCR demonstrated no difference in relative abundance of the F-Luc and R-Luc transcripts, excluding possibility of a cryptic promoter. These findings indicate that the $\alpha 1A$ mRNA sequence upstream of $\alpha 1ACT$ start site contains an IRES. Finally, deletion of 534 nucleotides upstream of $\alpha 1ACT$ from $\alpha 1A$ abolishes the $\alpha 1ACT$ fragment without affecting the expression of full-length (-534) $\alpha 1A$ (FIG. 15A).

[0218] $\alpha 1ACT$ Binds to Non-Coding Regions of Cellular Genes through a Consensus Motif

[0219] $\alpha 1ACT$ contains three nuclear localization signals and is enriched in the nucleus of cerebellar neurons and transfected cells (48). To investigate the role of nuclear

α 1ACT we performed ChIP with anti-FLAG antibody using cells expressing recombinant α 1ACT bearing a FLAG tag and cloned the immunoprecipitated DNA using a plasmid vector. We found that α 1ACT bound to non-coding regions of five genes, BTG1, GRN, PMCA2, TAF1 and ITGA8 (Table 6), all known to be expressed in Purkinje cells (63-65). Using the pair wise program, BIND (BONDplus in Biomolecular Interaction Network Database) we predicted the motif, TTATAAAA as an eight-nucleotide consensus sequence common to the five targeted genes. Using electrophoretic mobility shift assays we found that this motif, but not mutations of this motif, was able to effectively compete with two of the gel-shift complexes formed with the BTG1 3' UTR and nuclear extracts of α 1ACT-expressing cells (FIG. 16A,B). Thus α 1ACT fulfils the criteria for a transcription factor.

TABLE 6

Neuronal genes identified by α 1ACT ChIP-cloning				
NAME		GENBANK ACCESSION	LENGTH	POSITION
TATA box binding protein-associated factor	TAF1	NG_012771	171 bp	Introns Aha repeat
B-cell translocation gene 1	BTG1	NM_017258	100 bp	3'UTR532-631
Granulin	GRN	NG_007886	153 bp	5'UTR 6793-6930
Ca++ ATPase, plasma membrane 2	PMCA2	NM_012508	186 bp	5'upstream 9822 bp
Integrin alpha-8 precursor	ITGA8	EF444991	1227	Intron 22 153367-154427

[0220] α 1ACT with Normal PolyQ (but Not α 1ACT with Expanded PolyQ) Enhances Expression Through the Identified Enhancer Elements

[0221] We subcloned three of the target non-coding sequences in Table 6, BTG1 3' UTR (FIG. 17A), GRN 5' UTR (FIG. 17B), and PMCA2 5' UTR (not shown) into the PGL3 luciferase reporter, containing a minimal promoter, and tested for the ability of the α 1ACT to enhance reporter activity. We found that cells transfected with these constructs together with the α 1ACTWT (Q4) plasmid had a 3-5-fold increase in luciferase expression.

[0222] Cells expressing luciferase reporters and α 1ACT_{SCA6} plasmid cloned from an individual with SCA6 exhibited significantly less luciferase expression. PC12 cells expressing α 1ACT_{WT} (Q11) have increased expression of these targeted genes. mRNA isolated from frozen cerebellum from two SCA6 patients had reduced BTG1 mRNA relative to endogenous Pcp2 gene (FIG. 17D). These findings indicate that expanded polyQ in the α 1ACT polypeptide interferes with its transcription factor function.

[0223] α 1ACT with Normal PolyQ (but not α 1ACT with Expanded PolyQ) Enhances Neurite Outgrowth of Differentiating PC12 Cells.

[0224] To test the biological properties of α 1ACT in a cellular system we established stable PC12 cell lines expressing α 1ACT_{WT} (Q11) or α 1ACT_{SCA6} (Q33) fragments, or the corresponding full length α 1A_{WT} and α 1A_{SCA6}, and treated cells with nerve growth factor to induce differentiation into the neuronal phenotype. We found that cells expressing either α 1A_{WT} full length or α 1ACT_{WT} had enhanced neurite outgrowth relative to control plasmid expressing cells. This effect was not blocked by incubation of α 1A_{WT} full length-

expressing cells with the P/Q type Ca²⁺ channel blocker, ω -agatoxin (FIG. 18A). Interestingly cells expressing α 1ACT_{SCA6} had severely diminished neurite outgrowth under the same conditions (FIG. 18B, C). This indicates that expanded polyQ may cause partial loss of transcription factor function in vitro. The relationship of this property to SCA6 pathogenesis remains to be clarified (2, 66).

[0225] α 1ACT Normalizes Purkinje Cell Afferents in α 1A^{-/-} Mice. α 1ACT with Expanded PolyQ do not Yield Viable Mice.

[0226] Homozygous α 1A KO mice (α 1A^{-/-}) are severely neurologically impaired with seizures, dystonia and ataxia, disrupted cerebellar cortical development, and die before 3 weeks of age. To test for the function of α 1ACT in vivo, we asked whether α 1ACT expression restricted only to Purkinje

cells could ameliorate any of the phenotype of the α 1A^{-/-} mice. We generated conditional mutant transgenic mice expressing α 1ACT_{WT} in Purkinje cells using the Pcp2 promoter and the tetracycline transactivator protein (tTA) to target these cells. On a normal CACNA1A background these mice appear normal and have high levels of α 1ACT expressed in nuclei and cytoplasm of Purkinje cells (FIG. 20A). We bred these mice with the α 1A^{+/-} mice to establish mice expressing α 1ACT on a CACNA1A null (α 1A^{-/-}) background. We found that, although still impaired neurologically, the α 1ACT_{WT}/ α 1A^{-/-} mice moved considerably better than their α 1A^{-/-} littermates. More importantly, the cerebellar Purkinje cell morphology and innervation were significantly improved (FIG. 19A,B). The height and branching of Purkinje cell dendrites of α 1ACT_{WT}/ α 1A^{-/-} mice appeared nearly normal. Immuno-histochemical localization of both parallel and climbing fiber afferents using the Vglut1 and Vglut2 antibodies showed essentially a normal pattern of innervation. In comparison, α 1A^{-/-} mice had immature afferent innervation and Purkinje cells with short dendritic trees with abnormal branching (FIG. 19A, B). In electrophysiological studies of cerebellar slice preparations of these mice it was found that, excitatory postsynaptic currents (EPSCs) evoked by parallel fiber stimulation of slices from 17-day-old α 1A^{-/-} mice were extremely depressed with minimal increase with stimulus intensity, EPSCs recorded from α 1ACT_{WT}/ α 1A^{-/-} slices were intermediate in amplitude to those in WT mice of the same age and showed a stronger correlation with stimulus intensity, as in WT mice. Curiously, no transgenic mice expressing α 1ACT_{SCA6} together with α 1A^{-/-} were obtained despite extensive breeding. These findings indicate that the normal α 1ACT terminus expressed in

Purkinje cells plays a key role in maturation of the cerebellar cortex. It is possible that the SCA6-associated $\alpha 1ACT_{SCA6}$ fragment, on a CACNA1A null background, exerts a lethal effect at an early age.

[0227] $\alpha 1ACT_{SCA6}$ Expressed in Purkinje Cells on a Normal CACNA1A Background Causes Impaired Motor Coordination and Thinning of the Cerebellar Molecular Layer.

[0228] Because SCA6 is an autosomal dominant disorder we tested whether over-expression of the SCA6-expanded $\alpha 1ACT_{SCA6}$ fragment would lead to clinical or pathological features resembling SCA6, compared with over-expression of the wild-type $\alpha 1ACT_{WT}$ having the wild-type, typical or normal length CAG repeat.

[0229] We developed several lines of each transgenic, whose expression was targeted based on the *Pcp2* promoter using the tet-off system. Others have found that the *Pcp2*-tTA transgene line provides the most consistent uniform expression of dominant genes under control of the tet responsive element (67). We established two $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ lines with matched levels of expression (FIG. 20A) and compared the phenotypes at different ages. There were no obvious clinical differences between these two lines in young adults. However, using a video-assisted computerized treadmill for gait analysis (Digigait, CleverSys), we measured obvious differences in several gait parameters at ages 3 and 6 months that suggested a progressive gait disturbance consisting of several abnormalities including increased paw angle variability (FIG. 20B).

[0230] The gait disturbance never progressed to the level of severe ataxia over the first year, although natural changes in weight gain may have obscured an impact on normal cage activity. Lifespan was not affected. We looked for pathological changes in the cerebellum at approximately 2 years of age. There was no obvious sign of cell loss or increased markers of apoptosis in $\alpha 1ACT_{SCA6}$ mice. However, measurement of the molecular layer thickness showed that $\alpha 1ACT_{SCA6}$ -expressing mice have significant thinning of the molecular layer, compared with age-matched $\alpha 1ACT_{WT}$ and WT mice (FIG. 20C, D). These findings are the first to demonstrate clinical and pathological changes in an animal model of SCA6 expressing appropriate-sized pathological alleles within a CACNA1A protein. The lack of severe ataxia in 2-year-old mice is not surprising for a model of SCA6, with an age of onset of 43-52 years.

[0231] $\alpha 1AQ14$ Knockin Mice Hemizygotes ($\alpha 1A^{EX47Q14/-}$) Develop Seizures, Dystonia, Ataxia, Stress-Induced Motor Spells and have Disrupted Cerebellar Cortical Development.

[0232] A recent paper describing CACNA1A knockin mice ($\alpha 1A^{EX47Q^n}$), in which the human CACNA1A exon 47 encoding Q14, or expanded polyQ tracts (Q30, Q84), inserted in place of mouse exon 47 failed to identify a C terminal fragment in mouse cerebellar homogenates, using two anti-C terminal antibodies (38). This finding contradicts the observations of several other laboratories (46-50). However, the authors also found that the $\alpha 1A^{EX47Q^n}$ mice have a disturbance in the normal proportions of $\alpha 1A$ mRNA splice-forms. We obtained the $\alpha 1A^{EX47Q^n}$ knock-in mice and confirmed that the $\alpha 1ACT$ C-terminal fragment was undetectable, indicating a problem with expression. Although homozygous $\alpha 1A^{EX47Q14/Q14}$ mice seemed clinically normal, we further analyzed them using a classical genetic complementation experiment: We bred $\alpha 1A^{EX47Q14/Q14}$ mice with $\alpha 1A$ knock-out mice ($\alpha 1A^{-/-}$) and compared phenotypes of 5 mouse lines

($\alpha 1A^{-/-}$, $\alpha 1A^{+/-}$, $\alpha 1A^{EX47Q14/Q14}$, $\alpha 1A^{EX47Q14/+}$ and $\alpha 1A^{EX47Q14/-}$). The $\alpha 1A^{-/-}$ mice exhibited dystonia and ataxia and died by day 21. Unexpectedly, in comparison to $\alpha 1A^{+/-}$, $\alpha 1A^{EX47Q14/Q14}$ and $\alpha 1A^{EX47Q14/+}$ mice, which were all clinically normal, all $\alpha 1A^{EX47Q14/-}$ mice (KIKO mice) (N=21) exhibited a fairly typical CACNA1A mutant phenotype of seizures, dystonia, ataxia and stress-induced motor spells beginning around day 10 until age six months. We determined that $\alpha 1A^{EX47Q14/-}$ mice showed significantly higher frequency and duration of stress-induced spells than all other mice, some lasting 30 minutes (68, 69). Digigait analysis showed abnormalities in several gait parameters, including increased paw area variability (FIG. 21A). These abnormalities appear to reduce with age. Finally, examination of cerebellar histology of KIKO mice revealed a disturbance in both Purkinje cell dendrites and afferent innervation (FIG. 21B, C). Purkinje cell dendrites are shorter, with fewer proximal branches and spine density than in WT mice. In addition, climbing fiber afferents stained with Vglut2 antisera demonstrated an immature or disrupted pattern of contacts with proximal dendrites compared with WT mice. These changes were not seen in either $\alpha 1A^{+/-}$ or $\alpha 1A^{EX47Q14/+}$. These findings indicate some as yet undefined problem with CACNA1A expression in $\alpha 1A^{EX47Q14}$ knock-in mice, relating to species or position effects, that leads to disturbed cerebellar development. Given that these mice have normal P/Q channel function, as judged by cerebellar slice recordings (38), it is likely that the change relates to the alteration in this newly identified role of the CACNA1A gene in cerebellar cortical development. This conclusion is consistent with absence of the $\alpha 1ACT$ and actually supports, rather than contradicts, our findings of the role of the $\alpha 1ACT$ in cerebellar development. Therefore, mice engineered using this knock-in strategy are not appropriate for a SCA6 model.

[0233] Analysis of the SCA6 PolyQ Expansion in $\alpha 1ACT$ in the Transcription Factor ($\alpha 1ACT_{SCA6}$) and Determining if the SCA6 PolyQ Expansion Changes the Gene Binding Patterns and the Expression Patterns of Purkinje Cell Genes

[0234] $\alpha 1ACT_{WT}$ augments PC12 cell neurite outgrowth and binds and enhances expression of a set of Purkinje cell genes through a consensus motif. The $\alpha 1ACT_{SCA6}$ severely blunts neurite outgrowth, has lost the effect on Purkinje cell genes, and causes impaired gait and cerebellar cortical atrophy in vivo. Thus, $\alpha 1ACT_{SCA6}$ may cause SCA6 by its effect on key transcript levels. We hypothesize that the $\alpha 1ACT_{SCA6}$ will have different binding profiles and target gene expression profiles than $\alpha 1ACT_{WT}$.

[0235] We will improve our understanding of the role of $\alpha 1ACT_{WT}$ as a transcription factor and the modified role of $\alpha 1ACT_{SCA6}$ by extending ChIP-cloning studies in PC12-derived lines expressing FLAG-tagged $\alpha 1ACT_{WT}$ protein. This approach already led to the finding that $\alpha 1ACT_{WT}$ binds to several gene targets bearing a consensus motif TTATAA (Table 6 and FIG. 16). It provides a highly pure, cross-linked preparation and employs high affinity antibody for ChIP, and is preferable to switching to a transgenic cerebellar source, which would invite more challenges with purification. The in vivo binding of both $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ in PC12 cells will be detected using ChIP coupled to next generation sequencing (NGS) which will identify the binding profiles in a unbiased and more quantitative fashion than ChIP subcloning. This will be done in the IGSB genome sequencing facility <http://www.igsb.org/services/hgac/>.

[0236] Second, because $\alpha 1ACT_{SCA6}$ -expressing mice develop thinning of the cerebellar molecular layer (FIG. 20D), there may be differences in transcriptome of $\alpha 1ACT_{SCA6}$ and $\alpha 1ACT_{WT}$ Purkinje cells (PCs). We hypothesize that differences in RNA expression patterns will correlate with those of gene occupancy as determined in the ChIP-Seq, and will reveal key affected pathways that underlie the disease. PC-specific RNA will be isolated from these two lines by laser-capture microdissection (LCM), synthesized into cDNA and tagged with linkers for NGS in the IGSB core for an RNA-Seq comparison of gene expression patterns. Mouse groups aged 3 months (clear motor phenotype) and 2 years (clear pathological phenotype) will be used for transcriptome study. RNA-seq is superior to microarray, based on lower background signal, a much greater dynamic range, better quantitation, and more information about splice variants for quantified transcript levels.

[0237] General Procedure and Design

[0238] ChIP and RNA isolation. PC12 cells stably expressing $\alpha 1ACT_{WT}$ or $\alpha 1ACT_{SCA6}$ C-terminally tagged with 3 \times FLAG or background genomic control PC12 cells expressing pCDNA3 vector are again used as a source for ChIP. Chromatin is cross-linked, sonicated and immunoprecipitated by the monoclonal antibody anti-FLAG M2 (Sigma). After recovery of free DNA, the 15-20 ng of ChIP-enriched or control raw DNA is submitted to the IGSB core (70). The transgenic mice expressing $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ aged 3 months and 2 years and background control WT mice are used as source of Purkinje cell RNA. Cerebellums are snap frozen in OCT and 10 μ m sagittal sections are collected on standard LCM slides. After HE staining, PCs easily visualized by phase contrast microscopy are extracted using a laser capture microdissector equipped with a dissecting UV-laser beam (Leica AS LMD <http://pathcore.bsd.uchicago.edu/Home.shtml>). RNA is isolated from 100-150 PCs using PicoPure RNA isolation Components (Applied Biosystems) following the manufacture's instructions. The 2-4 μ g of total RNA is submitted to the IGSB core.

[0239] Preparation of ChIP-seq and mRNA-seq libraries. Sequencing libraries will be prepared with the Illumina ChIP-seq DNA and Illumina TruSeq RNA Sample Prep Kits according to Illumina's instructions in IGSB genome sequencing facility. After adapter ligation, library fragments of ~250 bp are isolated from an agarose gel. The DNA is PCR amplified with Illumina primer for 18 (ChIP-seq) for 15 (RNA-seq) cycles, purified, and loaded on an Illumina flow cell for cluster generation. Libraries are sequenced on Illumina HiSeq2000.

[0240] ChIP-Seq Analysis.

[0241] The bioinformatics support for Illumina runs in the core facility are to convert the raw output into called bases. Filtered reads are mapped to the rat genome (UCSC genome browser assembly m4) using Bowtie. (<http://bowtie-bio.sourceforge.net/index.shtml>). Up to two mismatched base pairs are allowed, and the first 2 base pairs of the read are unused, as they show significant sequence bias for 'C' at the expense of 'T' base pairs. Sequence tags that map to more than one location in the genome are excluded. Peak discovery is performed using Model-based Analysis of ChIP-Seq (MACS). Negative control libraries consisting of input chromatin from PC12 cells expressing pCDNA3 vector is also generated and fed to MACS (<http://liulab.dfci.harvard.edu/MACS/>). The peaks identified from ChIP studies are categorized relative to genomic features such as binding to a pro-

moter, enhancer, exon or intron. In silico analysis of $\alpha 1ACT$ binding sites within peaks are performed by MEME (<http://meme.nbcr.net/meme/intro.html>) using both strands, a minimum occurrence of 50 sites in the data set, and minimum motif size of 8 bases to compare the binding motifs. $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ binding motifs determined by MEME are compared.

[0242] RNA-Seq Analysis of Purkinje Cell-Specific RNA.

[0243] Image analysis and base-calling are done using Illumina Genome Analyzer Pipeline software with default parameters. Filtered reads are mapped to the mouse reference (UCSC genome browser assembly mm9) and a custom splice-junction library based on UCSC known genes using the Cufflinks software. Mapped reads for all six mouse lines are compared with the annotated genes in the RefSeq database. The analysis of the RNA-seq data helps distinguish between up- and down-regulated transcripts, and flagged if Cufflinks finds its expression level to be significantly different by P-value using WT mice as the control. To obtain a global view of the changes in gene expression upon $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$, gene ontology analysis of data will be performed using DAVID software (71).

[0244] As we have shown that $\alpha 1ACT$ is a sequence-specific transcription factor we expect to find a broader array of predominantly Purkinje cell-expressed genes to which $\alpha 1ACT$ binds in the promoter, intron, and 5' and 3' regions through to its cognate DNA sequence motif (72). The expression of $\alpha 1ACT_{WT}$ ChIP-cloned genes is reduced in $\alpha 1ACT_{SCA6}$ cell lines and in SCA6 ataxia cerebellum (FIG. 17D). Therefore, we expect to characterize several more affected genes, enabling the description of the pathways altered by the SCA6-expanded $\alpha 1ACT$. The only other unbiased study of chromatin binding by polyQ proteins was with huntingtin (Htt). Htt does not bind via consensus recognition motif, but occupies several gene promoters in vivo in a polyQ-dependent manner, disturbing gene function (73). Therefore, although the expanded polyQ tract in SCA6 $\alpha 1ACT$ is much smaller than in HD, we anticipate that the $\alpha 1ACT_{SCA6}$ ChIP study will reveal expanded gene occupancy, whose interacting regions may be more widespread, lacking a consensus motif (73).

[0245] For the RNA-seq study, we anticipate that differences (loss or gain of expression of transcripts) will be due to direct pathological effects of $\alpha 1ACT_{SCA6}$ on gene expression, and secondary (compensatory or reactive) changes. The overlapping gene expression profile between ChIP-seq and RNA-seq will be first verified by qRT-PCR and then reporter assay. Alternatively, as in the case of androgen receptor, where polyQ tract length alters its interaction with some transcription co-activators (74), transcript levels in SCA6 may be altered in genes whose ChIP-enrichment is not altered by the expanded polyQ tract.

[0246] Analysis of $\alpha 1ACT$ Expression by CACNA1A IRES and Promoter and Determination of Whether it Reproduces the Normal and Pathological Functions of a 1ACT

[0247] Our $\alpha 1ACT$ transgenics confirm the pathogenicity of $\alpha 1ACT_{SCA6}$ vs $\alpha 1ACT_{WT}$ (FIG. 20), although the model is incomplete due to the restricted expression to Purkinje cells and the use of a non-IRES-based construct. We will generate new $\alpha 1ACT$ lines that include the CACNA1A IRES, preceded by a stop codon to generate $\alpha 1ACT_{WT}$ or $\alpha 1ACT_{SCA6}$ protein by CAP-independent translation. We will use the tet-off expression system to drive conditional expression and a CACNA1A-tTA transgene to generate the correct expres-

sion pattern. This study will confirm our expectations that: (1) The CACNA1A IRES mediates endogenous expression of $\alpha 1$ ACT; (2) $\alpha 1$ ACT_{WT}, expressed under control of the endogenous CACNA1A IRES and promoter will more completely correct the developmental abnormalities of the CACNA1A mutants $\alpha 1A^{-/-}$ and, in particular, $\alpha 1A^{la/la}$ (leaner); and (3) The mutant protein, $\alpha 1$ ACT_{SCA6}, will create an effective model for SCA6. These mice will enable us to explore the involvement of the gene pathways identified in the study described above in more realistic models of $\alpha 1$ ACT expression. More importantly, they will establish an animal model suitable for testing IRES-interacting drugs detected in the study described below that could be potential therapies for SCA6.

[0248] Attempts to generate SCA6 transgenic models have employed three distinct strategies: (1) targeted insertion of the full length $\alpha 1A$ cDNA from a fully-spliced $\alpha 1A$ mRNA encoding a Q28 (or Q13) repeat expansion into the CACNA1A gene (37); (2) targeted insertion of a human exon 47 bearing Q14, Q30 or Q84 repeats into the mouse CACNA1A gene ($\alpha 1A^{EX47Qn}$) (38); and (3) the present strategy, conditional expression of the $\alpha 1$ ACT_{WT} or $\alpha 1$ ACT_{SCA6} selectively in Purkinje cells alone using the Pcp2-tTA tet-off system (FIG. 20) (67, 75, 76).

[0249] Neither of the first two strategies produced any clinical, electrophysiological or pathological changes in mice bearing SCA6-sized alleles. The $\alpha 1A^{EX47Qn}$ mice bearing Q84 super-expansions ($\alpha 1A^{EX47Q84}$), not seen in SCA6 patients, develop protein aggregates and symptoms as older mice (38). However, there is compelling evidence this exon 47 knockin strategy has led to aberrant expression of $\alpha 1A$ splice forms and a hypomorph allele, suggesting that the resultant mice are not a valid model for SCA6 (FIG. 21)(38).

[0250] On the other hand, $\alpha 1$ ACT_{SCA6} mice with Purkinje cell-targeted expression of the $\alpha 1$ ACT_{SCA6} develop motor incoordination and thinning of the cerebellar molecular layer by age 2 years (FIG. 20). Since Q33 is a polyQ tract size seen in SCA6 (77), we believe that this finding supports the role of the free $\alpha 1$ ACTQn in the pathogenesis of SCA6. Further work is necessary in this model to determine whether $\alpha 1$ ACT_{SCA6} acts pathologically through the same genes modulated by $\alpha 1$ ACT_{WT}, and to define the electrophysiological changes that accompany the clinical and pathological abnormalities. However, although these mice demonstrate the pathogenicity of the SCA6-sized $\alpha 1$ ACT in vivo, and provide a model of early cerebellar disease due to an SCA6 disease allele, they are an incomplete model for two reasons: (1) They only express the transgene in Purkinje cells and (2) They do not contain the CACNA1A IRES, as they were made at a time when we believed that the $\alpha 1$ ACT fragment was generated by proteolytic cleavage. Thus, a more accurate model should employ the IRES-generated $\alpha 1$ ACT expressed using the CACNA1A promoter.

[0251] We will use a conditional transgenic system, based on the CACNA1A IRES and the CACNA1A gene in a tet-off system to test these questions. We have already shown that insertion of termination codons in the coding sequence 5' to the $\alpha 1$ ACT start site does not impair the translation of $\alpha 1$ ACT from full length $\alpha 1A$ transcripts expressed transfected cells, as evidence of the CACNA1A IRES (FIG. 15). Therefore, we will generate new transgenic mice that express the full region of the functionally-mapped IRES of the $\alpha 1A$ mRNA (from Met1384) with a stop codon inserted at position 1847, 5' to the $\alpha 1$ ACT start for either the Q4 and Q33 repeats

($\alpha 1$ APstopCT_{WT/SCA6}), under the control of the tetracycline-responsive element (TRE). Transcripts from this transgene will only generate $\alpha 1$ ACT_{WT} or $\alpha 1$ ACT_{SCA6} protein if the IRES functions in vivo. Second, because the CACNA1A 5' UTR gene regions have been effective driving reporter genes in transgenic mice in an endogenous expression pattern (78), we will generate CACNA1A-tTA mice to breed with the TRE- $\alpha 1$ APstopCT_{WT/SCA6} lines to establish mice expressing $\alpha 1$ ACT_{WT} or $\alpha 1$ ACT_{SCA6} in the pattern of the CACNA1A gene. The tet-off system will enable doxycycline suppression of $\alpha 1$ ACT expression. In addition to CACNA1A^{-/-} ($\alpha 1A^{-/-}$), we will also breed these $\alpha 1$ ACT_{WT}-expressing mice with leaner mice CACNA1A^{la/la} ($\alpha 1A^{la/la}$). Breeding with this CACNA1A mutant is the ideal experiment to test the modular nature of the CACNA1A gene products. The leaner mouse CACNA1A mutation affects splicing and deletes the exons encoding the $\alpha 1A$ C-terminus and $\alpha 1$ ACT protein (79, 80) without affecting channel structure. These mice are less severely affected than $\alpha 1A^{-/-}$ mice and often survive to adulthood if supported past weaning (81, 82). We hypothesize that expression of the $\alpha 1$ ACT_{WT} transgene in $\alpha 1A^{la/la}$ mice will correct neurological function more completely than in the complete knockout, $\alpha 1A^{-/-}$ mice.

[0252] General Procedure and Design

[0253] The construct, $\alpha 1$ APstopQ11 (FIG. 15A) that allows expression of the 75 kD $\alpha 1$ ACT_{Q11} despite the presence of a stop codon at position P1847 is used. Expression levels of these proteins are easily detected based on the 3xFLAG C-terminal epitope tag. We will revise the allele size of $\alpha 1$ APstopQ11 to Q4 and Q33, the smallest and largest polyQ repeats recorded in humans, and confirm the continued expression of $\alpha 1$ ACT_{Q4/33} of the correct sizes by transfection into HEK293 cells and western blotting. Subsequently, we will insert these constructs into the pTRE vector and confirm the continued expression in our HEK293 cell line stably expressing tTA. We will generate transgenic mice with the TRE- $\alpha 1$ APstopCT_{Q4/33} constructs. For efficiency we will use donor eggs from Pcp2-tTA mice, (bred in the laboratory), to establish and characterize lines more quickly. We will identify mice with matched levels of Q4 and Q33 transgene expression by western blotting and use backcrosses with the background line (FVB) to confirm single site integration. This initial double transgenic line and expression study will allow prompt testing of hypothesis 1. The CACNA1A IRES mediates endogenous expression of $\alpha 1$ ACT. Finally, to assemble the CACNA1A-tTA minigene we will employ a 1.5 kb region 5' to the coding region of the mouse CACNA1A gene, shown previously to yield correct expression (78). These mice will be bred with the TRE- $\alpha 1$ APstopCT_{Q4/33} mice and offspring genotyped to identify those bearing CACNA1A-tTA and the $\alpha 1$ APstopCT transgenes and not the Pcp2-tTA transgenes. We will then have two sets of new transgenic mice expressing either $\alpha 1$ APstopCT_{Q4} or $\alpha 1$ APstopCT_{SCA6} transgenes under the control of either the Pcp2 promoter or the CACNA1A promoter.

[0254] Characterization of New $\alpha 1$ ACT Mouse Lines.

[0255] We have extensive experience with the generation and characterization of transgenic mouse models of several muscle and cerebellar diseases (83-92). In mice co-expressing Pcp2-tTA or CACNA1A-tTA, $\alpha 1$ APstopCT_{SCA6} mice and $\alpha 1$ APstopCT_{WT} mice, with matched expression levels, will be compared on a normal CACNA1A background at 1, 3, 6, 9, 12, 18 and 24 months of age. In addition, CACNA1A-tTA/ $\alpha 1$ APstopCT_{WT} double transgenic mice will be bred

with $\alpha 1A^{+/-}$ mice and $\alpha 1A^{+/la}$ to determine whether this transgene, expressed more broadly than Purkinje cells alone, can better rescue the $\alpha 1A^{-/-}$ and $\alpha 1A^{la/la}$ phenotypes. The motor behavior, pathology, electrophysiological changes and gene expression studies of these mice will be compared. After full characterization of these lines we will confirm the impact of and recovery from $\alpha 1ACT_{SCA6}$ expression by suppression using doxycycline (67). All animal procedures are in accordance with the guidelines of our Institutional Animal Care and Use Committee.

[0256] Behavioral Characterization.

[0257] For phenotyping, mice are observed at monthly intervals for changes in home cage behavior. Mice are characterized using the Digigait Gait Analysis system, a video-based treadmill, in the University of Chicago Mouse Motor Behavior Core, which has been used extensively (90, 9294). The Digigait utilizes a high speed, high-resolution camera to image the walking mouse ventral view on a motorized transparent treadmill belt. It enables efficient comparison of multiple locomotor parameters, such as paw angle, paw area variability, and stride length and width. The measurements are highly reproducible and sensitive to change, thus amenable to comparison of multiple genetically distinct groups or for studying the effects of treatments. Several of these parameters, including paw area variability, and the stride width, length and frequency variability provide a reproducible and consistent change in the $\alpha 1ACT_{SCA6}$ mice (FIG. 20).

[0258] Pathological Studies.

[0259] Five μ m serial, sagittal paraffin sections are used for immunofluorescence studies (95). For antigen retrieval, sections are incubated in 0.05M borate buffer (pH 8.0), 100° C. for 40 minutes (96). Purkinje cells are labeled with anti-calbindin antibody, and parallel (PF) and climbing (CF) fibers with anti-vGlut1 and vGlut2 antibodies and detected with fluorescent second antibody. A TCS laser scanning confocal fluorescence microscope (SP2, Leica) in the UC microscopy core is used to acquire 0.5 μ m optical z-axis sections. This technique is particularly valuable for the SCA6 model, as it helps identify dendritic and somatic pathology of Purkinje cells, and gives quantifiable measures of the afferent innervation. To quantitate the degree of cerebellar pathology, atrophy and dendritic shrinkage the thickness of molecular layer (primary fissure) is measured in sections stained for calbindin, the ratio of CF height to molecular layer thickness, and the density of CF and PF innervation on confocal images analyzed using image J (NIH image software) (97).

[0260] Electrophysiological Studies.

[0261] Synaptic inputs in cerebellar slice preparations are characterized in detail, the amplitude and kinetics of evoked excitatory postsynaptic currents (EPSCs) at PF Purkinje cell synapses are measured, and mini EPSC amplitudes and frequencies at these synapses are recorded (98). Synaptic responses to CF activation (complex spikes in current-clamp and EPSCs in voltage-clamp) are characterized and the elimination of surplus CFs during development is monitored. Finally, the intrinsic excitability of Purkinje cells is determined by establishing the current input spike output relationship. Briefly, sagittal slices of the cerebellar vermis (250 μ m) are prepared with a vibratome (Leica VT1000S) using ceramic blades, from mice (various ages; focus on P17-35) after decapitation and isoflurane anesthesia. The slices are allowed to recover for at least 1 h, in artificial CSF (ACSF) containing (in mM): 124 NaCl, 5 KCl, 1.25 Na_2HPO_4 , 2 $MgSO_4$, 2 $CaCl_2$, 26 $NaHCO_3$, and 10 D-glucose, bubbled

with 95% O₂ and 5% CO₂, and then transferred to a submerged recording chamber superfused with ACSF (34-35° C.). Whole-cell patch-clamp recordings are performed under visual control using DIC optics and a 40 \times water-immersion objective mounted on a Zeiss Axioskop 2FS microscope. Patch pipettes (3-4 M Ω) are filled with internal saline containing (in mM): 9 KCl, 10 KOH, 120 K-gluconate, 3.48 $MgCl_2$, 10 HEPES, 4 NaCl, 4 Na_2ATP , 0.4 Na_3GTP , and 17.5 sucrose, pH adjusted to 7.25. For CF-EPSC recordings, a cesium gluconate-based internal saline (in mM): 128 CsOH, 111 gluconic acid, 4 NaOH, 10 CsCl, 2 $MgCl_2$, 10 HEPES, 4 Na_2ATP , 0.4 Na_3GTP , and 30 sucrose (pH 7.25) is used. A hyperpolarizing bias current is applied to prevent spontaneous spike activity. For stimulation glass pipettes filled with ACSF are placed in the ML for PF and the granule cell layer for CF. Input resistance (R_i) is measured by injection of hyperpolarizing test currents (200 pA; 100 ms) and calculated from the voltage transient toward the end of current injection (98).

[0262] Gene Expression Studies.

[0263] Based on our gene expression findings in the studies described above, we will isolate total cerebellar RNA and Purkinje cell RNA by LCM, as above, and perform quantitative RT-PCR as in FIG. 17 to measure the expression levels of the genes involved in the pathways affected by the SCA6 mutation. We will also repeat the RNA-seq studies and compare with the results from the *Pcp2*/ $\alpha 1ACT$ mice and the human SCA6 cerebellar RNA to determine whether there are additional genes altered with the more robust phenotype that are common with the human disease.

[0264] Based on our extensive expression studies with these vectors in cultured cells we anticipate that the $\alpha 1ACT$ transcript with the stop codon, $\alpha 1APstopCT_{Q4/33}$, will yield identical levels of expression under control of the *Pcp2*-promoter. We also expect comparable to higher levels with the *CACNA1A-tTA* driver, based on the broader expression pattern of this gene than *Pcp2*. We expect that the $\alpha 1APstopCT_{WT}$ mice will have quantitative rather than qualitative differences in cerebellar pathology, from the $\alpha 1ACT_{SCA6}$ mice, which showed molecular layer (ML) thinning at 2 years (FIG. 20). Specifically, as the disease SCA6 is a late onset cerebellar cortical degeneration, we expect only ML thinning at later ages, rather than Purkinje cell degeneration, similar to early stages of SCA1 mice (97). ML thinning develops between 12 and 15 weeks in SCA1 mice (a more severe SCA) and was seen in homozygous SCA3 mice, both prior to Purkinje cell loss (97, 99). SCA1 mice showed reduced Purkinje cell firing rate and a reduction in the efficiency of the main glutamatergic synapse onto Purkinje cells as measured by PF EPSCs before ataxia (100). In SCA3 knockin mice, Purkinje cells have increased intrinsic excitability, depolarization block and reduced repetitive firing (99). EPSCs recorded in slices may indicate either signs of degeneration, with reduced amplitudes, or compensation with temporal dispersion of PF- or CF-evoked responses after reinnervation. We expect similar changes in gene expression, possibly identifying a pathway more closely associated with changes in SCA6 brains using this genetic strategy.

[0265] Identification of IRES-Directed Molecules that Selectively Suppress $\alpha 1ACT$ Translation, but not $\alpha 1A$ Subunit Expression

[0266] We have used a Renilla (R-Luc)/firefly (F-Luc) luciferase bicistronic reporter assay to show that the *CACNA1A* mRNA contains an IRES within a 1014 nucle-

otide region in the C terminus. The IRES leads to expression of $\alpha 1$ ACT, which bears the polyQ tract. This very efficient reporter assay, which ratios the expression levels of F-Luc and R-Luc, is an ideal tool to confirm the optimal IRES sequence, and subsequently to carry out a high throughput screening assay. We seek to identify compounds that inhibit the function of this cellular CACNA1A IRES. We expect to identify additional compounds that interfere with the production of $\alpha 1$ ACT, without affecting channel function to that may be potential therapies for SCA6.

[0267] Activity of cellular IRES s, including the CACNA1A IRES, varies between cell lines, presumably reflecting differences in the expression of IRES-trans-acting factors (101, 102). To investigate the regulated process of $\alpha 1$ ACT protein synthesis, we will predict the secondary structure of CACNA1A IRES using MFOLD and identify the optimal activity IRES element using pRF bicistronic vector. Subsequently, we will isolate ITAFs by “pull down” using biotin-labeled CACNA1A IRES RNA probes and streptavidin paramagnetic beads, identify them by LC-MS/MS, and verify using EMSA. Drugs designed to specifically target ITAFs might provide a therapeutic strategy. Clarifying the secondary structure of CACNA1A IRES and ITAFs will also provide the evidence for small compound screening in the second part of this study described below.

[0268] Selective suppression of $\alpha 1$ ACT while sparing the $\alpha 1$ A channel subunit will be clearly better tolerated than silencing the entire $\alpha 1$ A Ca^{2+} channel gene, and the viability of adult $\alpha 1A^{la/la}$ (leaner) mice indicates it will be tolerated. Thus, in the second part of this study described below we will develop a high throughput system to identify compounds that can inhibit the activity of CACNA1A IRES, as optimized earlier in this study. We will use HEK293 cells and 384-well plate-based transfection system to screen for potential small-molecule inhibitors that block CACNA1A IRES F-Luc/R-Luc activity ratio. We will optimize the assay by titration of cell density and DMSO concentration, well-to-well, plate-to-plate variation and the Z' factor to arrive the maximal signal-to-noise ratio for the high throughput platform. We will use two compound libraries available in the UC Cellular Screening Center <http://www.igsb.anl.gov/services/csc/>, the Prestwick Chemical Library, which contains 1,120 small molecules and Chem Bridge Express-pick small molecule library of 50,000 molecules, as well as custom design anti-sense oligos. For hit compounds that reduce the F-Luc/R-Luc ratio lower than 50% of pRCTF, we will perform counter screening to eliminate non-specific inhibitors of luciferase enzyme activity by using our PC12 cell lines stably over-expressing the epitope-tagged $\alpha 1$ ACT_{WT} and $\alpha 1$ ACT_{SCA6} subunits.

[0269] Identify the Minimal Active Element and ITAFs

[0270] We have used a Renilla/firefly luciferase bicistronic reporter assay to show that the CACNA1A mRNA contains an IRES within a 1014 nucleotide sequence in the C terminus. Transfecting a variety of cell lines with the pRCT1014TF dual luciferase reporter revealed that the F-Luc/R-Luc ratios ranged from 14 to 45, in SY5Y, N2a, PC12, HEK 293 and Cos7, with the highest activity of F-Luc seen in neuronal cell lines, PC12 and SY5Y, 2 to 1.8-fold greater than in HEK293 cells (not shown). This observation suggests that neuron-specific cellular factors influence the activity of the CACNA1A IRES (103). We will perform deletion mapping to identify the minimal active element of CACNA1A IRES to locate the motifs for ITAFs. We will extend the assay of IRES

activity by designing primers spanning 2 kb within the CACNA1A mRNA 5' of the $\alpha 1$ ACT start site and generating series of DNA fragments for subcloning into the bicistronic vector pRF. These constructs (pRCTF) will be transfected into HEK293 cells and F-Luc/R-Luc luciferase activity ratios compared with pR1014TF (FIG. 15B) to identify the fragment(s) with the highest F-Luc/R-Luc activity ratios. As a confirmatory assay, we will use the FLAG-tagged $\alpha 1A_{WT}$ or $\alpha 1A_{SCA6}$ cDNA expression vectors bearing the same deletions made for pRCTF. We will transfect these internally-deleted $\alpha 1A$ constructs into HEK293 cells and perform immunoblots to compare expression levels of the truncated $\alpha 1$ ACT-3FLAG protein. Finally, we will use the optimal CACNA1A IRES RNA sequences, labeled with biotin, as probes (compared with control GAPDH RNA), and incubate with PC12 cell cytoplasmic extracts, to purify RNA-protein complexes using streptavidin paramagnetic beads. After separating proteins by SDS-PAGE, bands unique to the CACNA1A IRES precipitates, but not to the GAPDH RNA will be excised and identified by LG-MS/MS (93).

[0271] Development of a High Throughput Assay

[0272] The assay is based on R-Luc-F-Luc bicistronic reporter and Dual-Glo Luciferase assay system (Promega). In our preliminary data using transfected HEK293 cells, F-Luc/R-Luc ratio was low with pRF, which lacked the IRES sequence, while there was a 25-fold increase in F-Luc/R-Luc ratio when the CACNA1A IRES was present (pRCTF) (FIG. 15). We have established a transient transfection system in which HEK293 cells can be easily transfected with pRF or pRCTF in 96-well plate and our preliminary data also showed that this assay has maximal signal/noise ratio and excellent Z' factor. We will use the optimized IRES fragment in the pRF luciferase reporter vector identified in this aim (pRCTF), and optimize the transient transfection system in 384-well plates, achieved by titrating the cell density and concentration of two luciferase substrates, and compound incubation time, for sufficient sensitivity to enable the identification of compounds with low potency or efficacy.

[0273] In each assay, two positive controls will be included to evaluate reproducibility. First, the HCV IRES fragment generated from a well-studied HCV IRES construct (H77 strain, nts 40-372) (pRHCVF) will be used as one of the positive controls. HCV IRES inhibitors-quinacrine and acriflavine will be positive controls for the inhibition of pRHCVF. Based on our preliminary screening, anisomycin has the potential to inhibit the activity of CACNA1A IRES pRCTF and will be used as a second positive control. Thus, each 384-well plate will have 366 discrete compounds, six pRHCVF positive controls, three positive pRCTF controls (10 mM anisomycin), and six negative controls (1% DMSO controls) and three wells contain the control vector pRF. To test for inhibition of IRES function, after 24 hrs transfected cells will be cultured with candidate small molecule inhibitors for 10-20 hrs. A pilot screen of Prestwick Chemical Library will be run to validate the pRCTF dual luciferase assay, and followed by Chem Bridge Express-pick small molecule library of 50,000 molecules screening. In parallel, we will design anti-sense oligos to effect steric blockade of downstream translation (Gene tools, Morpholino, <http://www.gene-tools.com/>). R-Luc and F-Luc will be measured by Molecular Devices Analyst GT in the UC Cellular Screening Center <http://www.igsb.anl.gov/services/csc/>. Hit compounds will be defined as those that inhibit pRCTF expression (F-Luc/R-Luc light signal) by 50%.

[0274] We have recently demonstrated that deletion of the IRES-containing region of the $\alpha 1A$ subunit cDNA (with a C terminal epitope tag) eliminates $\alpha 1ACT$ expression seen on immunoblotting, without affecting expression of the full-length $\alpha 1A$ subunit (FIG. 15A). This finding will be further used to eliminate non-specific inhibitors of luciferase enzyme activity as a counter screen. In this screen, we will expose the "IRES intact" $\alpha 1A_{WT}$ and $\alpha 1A_{SCA6}$ -expressing PC12 lines to lead IRES-active compounds detected in the primary screen to assay for their effect on selective suppression of $\alpha 1ACT$ relative to $\alpha 1A$. Cultures will be scaled up to 2 ml cultures and incubated with each concentration of compound for 20 hrs before harvesting for assay by western blot. We will screen for both a selective effect on $\alpha 1ACT$ expression vs $\alpha 1A$ full-length expression. For each hit compound from the counter screen, we will subsequently confirm the presence of a dose-responses relationship to validate the effect and effective dose range using pRCTF dual luciferase assay.

[0275] We expect 0.5%~1% of compounds will decrease the 50% of pRCTF luciferase activity based on the primary screen (104). The optimal RNA sequences involved in IRES function and its related ITAFs will be identified. Counter screen will exclude the non-specific inhibitor and identify specific inhibitors for $\alpha 1ACT$. The effect of lead compounds identified from this screen on cellular and host function will be further studied in our PC12 cell and mouse models. Using our PC12 cell lines stably over-expressing the epitope-tagged $\alpha 1ACT$ and $\alpha 1ACT_{SCA6}$ subunits, that show the allele-specific differences in neurite outgrowth, we will test the effectiveness of identified compounds at preserving the neurite outgrowth effect of $\alpha 1ACT$. In subsequent years, compounds identified as effective in this study will be screened for optimal in vivo properties. The screen will be either employed directly in vivo in our mouse models or optimized with respect to affinity, selectivity and physicochemical properties using medicinal chemistry principles for in vivo use.

Example 4

[0276] This example demonstrates an exemplary method of suppressing $\alpha 1ACT$ expression.

[0277] To confirm the translational basis of $\alpha 1ACT$ production in cells and to demonstrate the ability of selectively suppressing $\alpha 1ACT$ expression for purposes of medical treatment, a morpholino called M- $\alpha 1A$ was designed, made, and tested for the ability to inhibit $\alpha 1ACT$ expression. The inhibition of $\alpha 1ACT$ expression was tested using a dual luciferase (Firefly and Renilla) assay as follows.

[0278] Dual Luciferase (Firefly and Renilla) Assay of Morpholino

[0279] HEK293 cells were transfected using FuGENE® 6 transfection reagent following the manufacturer's protocol (Promega, Madison, Wis.). Two vectors, named PRF and PR1000TF, were used for the transfection. Morpholinos were prepared following the protocol provided by Gene-Tools LLC (Philomath, Oreg.), the company that produces and designs morpholinos (Moultin and Yan, 2008; Summerton 2005). After 24 hours of transfection, the cells were exposed to morpholinos. As a control, a standard oligo purchased from Gene-Tools was used. A morpholino specifically designed to bind to the mRNA to a 25 base pair region downstream of the start codon, named M- $\alpha 1ACT$, was used as a translational block for $\alpha 1ACT$. After 36 hours from the start of transfection, the cells were collected and analyzed for Firefly and Renilla expression via a luciferase assay using a luminometer.

[0280] Western Blotting of Morpholino

[0281] HEK293 cells were transfected by pCDNA3 $\alpha 1A$ following FuGENE® 6 protocol. Morpholinos were prepared following the protocol provided by Gene-Tools LLC. After 24 hours of transfection, the cells were exposed to morpholinos. As a control, a standard oligo purchased from gene-tools was used. A morpholino specifically designed to bind to the mRNA to a 25 base pair region downstream of the start codon, named M- $\alpha 1A$, was used as a translational block for $\alpha 1ACT$. After 36 hours from the start of transfection, the cells were collected and analyzed by western blotting.

[0282] The results of the luciferase assay are shown in FIG. 22A, while the results of the Western blot are shown in FIG. 22B. As shown in FIG. 22A, the exposure of cells to the M- $\alpha 1ACT$ morpholino blocked translation through the IRES, as demonstrated by the reduced ratio of firefly to renilla luciferase activity in the bicistronic reporter assay. As shown in FIG. 22B, exposure to the M- $\alpha 1ACT$ morpholino also reduced levels of $\alpha 1ACT$ protein without affecting levels of $\alpha 1A$.

[0283] The same experiments outlined above are carried out for a different morpholino named M₂- $\alpha 1ACT$. This morpholino has the sequence GCCGGTAGTACTCCATGATCA (SEQ ID NO: 55) and targets the bracketed sequence of: atg(a)[tg]atca tggagtacta cgggc]aga (SEQ ID NO: 56). The bracketed sequence tgatca tggagtacta cgggc is provided herein as SEQ ID NO: 57.

Example 5

[0284] This example describes a study involving miRNAs that target different regions of the CACNA1A mRNA.

[0285] The effects of three miRNAs (miR-1, miR-2, miR-3) on CACNA1A IRES driven translation and on CACNA1A mRNA expression levels were examined by luciferase assay and quantitative RT-PCR analysis, respectively. The miRNAs were predicted to target the sequences within the IRES region. As shown in FIG. 23A, each of the three miRNAs significantly decreased the IRES-driven translation. As shown in FIG. 23B, each of the three miRNAs also reduced the expression levels of CACNA1A mRNA. It is expected that anti-sense oligonucleotides, including chemically modified anti-sense oligonucleotides, that target the IRES region of CACNA1A will be effective in selectively inhibiting the expression of $\alpha 1ACT$ relative to expression of CACNA1A. Accordingly, anti-sense oligonucleotides are contemplated as therapeutics useful in treating SCA6.

Example 6

[0286] This example demonstrates that deletion of CACNA1A IRES blocks $\alpha 1ACT$ effects.

[0287] A stably transformed cell line in which 534 nucleotides of the CACNA1A IRES was deleted was made in order to confirm the role of the IRES in the biological and pathological effects attributed to $\alpha 1ACT$. Cells transfected with pCDNA3, $\alpha 1ACT_{WT}$, $\alpha 1ACT_{SCA6}$, $\alpha 1ACT^{\Delta 534bp}_{WT}$ or $\alpha 1ACT^{\Delta 534bp}_{SCA6}$ were stained with annexin V or propidium iodide to identify apoptotic cells and dead/dying cells, respectively. As shown in FIG. 24A and B, the deletion of the 534 nt sequence of the CACNA1A IRES from the full length pathogenic $\alpha 1A_{SCA6}$ reduces toxicity. This is consistent with translation through the IRES being responsible for cell toxicity. Cells transfected with pCDNA3, $\alpha 1ACT_{WT}$ or $\alpha 1ACT^{\Delta 534bp}_{WT}$ were assayed for neurite length. As shown in

FIGS. 24C-E, cells with the deletion exhibited a reduced neurite length and reduced number of cells containing neurites, relative to the cells with the full length IRES. These data support that the CACNA1A IRES is required for cell toxicity of $\alpha 1A_{SCA6}$ and the neurite outgrowth effect of $\alpha 1A_{WT}$.

Example 7

[0288] This example demonstrates that $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ lead to different gene expression profiles that are involved in a neurogenesis, cell cycle, and cell death pathway.

[0289] $\alpha 1ACT_{WT}$ as a transcription factor augments PC12 cell neurite outgrowth and binds and enhances expression of a set of Purkinje cell genes. The $\alpha 1ACT_{SCA6}$ severely blunts neurite outgrowth, loses the effect on Purkinje cell genes, and causes impaired gait and cerebellar cortical atrophy in vivo. Thus $\alpha 1ACT_{SCA6}$ may cause SCA6 by its effect on key transcript levels. To test the hypothesis that the $\alpha 1ACT_{SCA6}$ leads to different binding profiles and target gene expression profiles than wild-type, RNA-Seq analysis was performed using PC12 cells expressing $\alpha 1ACT_{WT}$, $\alpha 1ACT_{SCA6}$, or pCDNA3 at 6 hours, 24 hours, 72 hours, or 240 hours after plating. At each time point, differentially expressed genes (DEGs) were identified between wild-type- and SCA6-transfected cells. Expression levels of thirty-seven genes differed at all 4 time points and had a time-dependent expression pattern (FIGS. 25A, B). Based on the David functional annotation clustering analysis, the DEGs were found to be significantly involved in cell cycle and cell death, development growth, and neurogenesis and were differentially expressed in a time-dependent manner (FIGS. 25C, D). The change of cell cycle DEGs was more significant at the 6-hour time-point. However, the differences in expression between the $\alpha 1ACT_{WT}$ and $\alpha 1ACT_{SCA6}$ neurogenesis-related DEGs were increased with time.

REFERENCES

[0290] The following represents a listing of the references cited in Examples 1 and 2.

[0291] Baird, S. D., Turcotte, M., Korneluk, R. G., and Holcik, M. (2006). Searching for IRES. *RNA* 12, 1755-1785.

[0292] Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadvnick, A. D., Rollinson, S., et al. (2006). Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* 442, 916-919.

[0293] Berthet, C., Guehenneux, F., Revol, V., Samarut, C., Lukaszewicz, A., Dehay, C., Dumontet, C., Magaud, J. P., and Rouault, J. P. (2002). Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. *Genes to cells: devoted to molecular & cellular mechanisms* 7, 29-39.

[0294] Cain, S. M., and Snutch, T. P. (2011). Voltage-gated calcium channels and disease. *Biofactors* 37, 197-205.

[0295] Catterall, W. A. (2011). Voltage-gated calcium channels. *Cold Spring Harbor perspectives in biology* 3, a003947.

[0296] Cimato, T. R., Ettinger, M. J., Zhou, X., and Aletta, J. M. (1997). Nerve growth factor-specific regulation of protein methylation during neuronal differentiation of PC12 cells. *The Journal of cell biology* 138, 1089-1103.

[0297] Coldwell, M. J., deSchoolmeester, M. L., Fraser, G. A., Pickering, B. M., Packham, G., and Willis, A. E. (2001).

The p36 isoform of BAG-1 is translated by internal ribosome entry following heat shock. *Oncogene* 20, 4095-4100.

[0298] Cornelis, S., Bruynooghe, Y., Denecker, G., Van Huffel, S., Tinton, S., and Beyaert, R. (2000). Identification and characterization of a novel cell cycle-regulated internal ribosome entry site. *Molecular cell* 5, 597-605.

[0299] Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J. J., et al. (2006). Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature* 442, 920-924.

[0300] Du, X., Rosenfield, R. L., and Qin, K. (2009). KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women. *The Journal of clinical endocrinology and metabolism* 94, 2594-2601.

[0301] Fitzgerald, K. D., and Semler, B. L. (2009). Bridging IRES elements in mRNAs to the eukaryotic translation apparatus. *Biochimica et biophysica acta* 1789, 518-528.

[0302] Gomez-Ospina, N., Tsuruta, F., Barreto-Chang, O., Hu, L., and Dolmetsch, R. (2006). The C terminus of the L-type voltage-gated calcium channel Ca(V) 1.2 encodes a transcription factor. *Cell* 127, 591-606.

[0303] Hashimoto, K., and Kano, M. (2005). Postnatal development and synapse elimination of climbing fiber to Purkinje cell projection in the cerebellum. *Neuroscience research* 53, 221-228.

[0304] Hashimoto, K., Tsujita, M., Miyazaki, T., Kitamura, K., Yamazaki, M., Shin, H. S., Watanabe, M., Sakimura, K., and Kano, M. (2011). Postsynaptic P/Q-type Ca²⁺ channel in Purkinje cell mediates synaptic competition and elimination in developing cerebellum. *Proceedings of the National Academy of Sciences of the United States of America* 108, 9987-9992.

[0305] Ishiguro, T., Ishikawa, K., Takahashi, M., Obayashi, M., Amino, T., Sato, N., Sakamoto, M., Fujigasaki, H., Tsuruta, F., Dolmetsch, R., et al. (2010). The carboxy-terminal fragment of alpha(1A) calcium channel preferentially aggregates in the cytoplasm of human spinocerebellar ataxia type 6 Purkinje cells. *Acta neuropathologica* 119, 447-464.

[0306] Jun, K., Piedras-Renteria, E. S., Smith, S. M., Wheeler, D. B., Lee, S. B., Lee, T. G., Chin, H., Adams, M. E., Scheller, R. H., Tsien, R. W., et al. (1999). Ablation of P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit. *Proceedings of the National Academy of Sciences of the United States of America* 96, 15245-15250.

[0307] Koopman, G., Reutelingsperger, C. P., Kuijten, G. A., Keehnen, R. M., Pals, S. T., and van Oers, M. H. (1994). Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. *Blood* 84, 1415-1420.

[0308] Kordasiewicz, H. B., Thompson, R. M., Clark, H. B., and Gomez, C. M. (2006). C-termini of P/Q-type Ca²⁺ channel alpha1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. *Human molecular genetics* 15, 1587-1599.

[0309] Koziel, P. J., Friedman, R. A., Erway, L. C., Yamoah, E. N., Liu, L. H., Riddle, T., Duffy, J. J., Doetschman, T., Miller, M. L., Cardell, E. L., et al. (1998). Balance and hearing deficits in mice with a null mutation in the gene encoding

plasma membrane Ca²⁺-ATPase isoform 2. *The Journal of biological chemistry* 273, 18693-18696.

- [0310] Kubodera, T., Yokota, T., Ohwada, K., Ishikawa, K., Miura, H., Matsuoka, T., and Mizusawa, H. (2003). Proteolytic cleavage and cellular toxicity of the human alpha1A calcium channel in spinocerebellar ataxia type 6. *Neuroscience letters* 341, 74-78.
- [0311] Kurnellas, M. P., Lee, A. K., Szczepanowski, K., and Elkabes, S. (2007). Role of plasma membrane calcium ATPase isoform 2 in neuronal function in the cerebellum and spinal cord. *Annals of the New York Academy of Sciences* 1099, 287-291.
- [0312] La Spada, A. R., Wilson, E. M., Lubahn, D. B., Harding, A. E., and Fischbeck, K. H. (1991). Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. *Nature* 352, 77-79.
- [0313] Liu, S., and Friel, D. D. (2008). Impact of the leaner P/Q-type Ca²⁺ channel mutation on excitatory synaptic transmission in cerebellar Purkinje cells. *The Journal of physiology* 586, 4501-4515.
- [0314] Marqueze-Pouey, B., Martin-Moutot, N., Sakkou-Norton, M., Leveque, C., Ji, Y., Cornet, V., Hsiao, W. L., and Seagar, M. (2008). Toxicity and endocytosis of spinocerebellar ataxia type 6 polyglutamine domains: role of myosin IIb. *Traffic* 9, 1088-1100.
- [0315] Matsukawa, H., Wolf, A. M., Matsushita, S., Joho, R. H., and Knopfel, T. (2003). Motor dysfunction and altered synaptic transmission at the parallel fiber-Purkinje cell synapse in mice lacking potassium channels Kv3.1 and Kv3.3. *The Journal of neuroscience: the official journal of the Society for Neuroscience* 23, 7677-7684.
- [0316] Matsushita, K., Wakamori, M., Rhyu, I.J., Arai, T., Oda, S., Mori, Y., and Imoto, K. (2002). Bidirectional alterations in cerebellar synaptic transmission of tottering and rolling Ca²⁺ channel mutant mice. *The Journal of neuroscience: the official journal of the Society for Neuroscience* 22, 4388-4398.
- [0317] Mintz, I. M., Sabatini, B. L., and Regehr, W. G. (1995). Calcium control of transmitter release at a cerebellar synapse. *Neuron* 15, 675-688.
- [0318] Palhan, V. B., Chen, S., Peng, G. H., Tjernberg, A., Gamper, A. M., Fan, Y., Chait, B. T., La Spada, A. R., and Roeder, R. G. (2005). Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. *Proceedings of the National Academy of Sciences of the United States of America* 102, 8472-8477.
- [0319] Palmenberg, A. C., and Sgro, J. Y. (1997). Topological organization of picornaviral genomes: Statistical prediction of RNA structural signals. *Semin Virol* 8, 231-241.
- [0320] Rajakulendran, S., Kaski, D., and Hanna, M. G. (2012). Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS. *Nature reviews Neurology* 8, 86-96.
- [0321] Rouault, J. P., Samarut, C., Duret, L., Tessa, C., Samarut, J., and Magaud, J. P. (1993). Sequence analysis reveals that the BTG1 anti-proliferative gene is conserved throughout evolution in its coding and 3' non-coding regions. *Gene* 129, 303-306.
- [0322] Saegusa, H., Wakamori, M., Matsuda, Y., Wang, J., Mori, Y., Zong, S., and Tanabe, T. (2007). Properties of human Cav2.1 channel with a spinocerebellar ataxia type 6 mutation expressed in Purkinje cells. *Molecular and cellular neurosciences* 34, 261-270.
- [0323] Scott, V. E., Felix, R., Arikath, J., and Campbell, K. P. (1998). Evidence for a 95 kDa short form of the alpha1A subunit associated with the omega-conotoxin MVIIC receptor of the P/Q-type Ca²⁺ channels. *The Journal of neuroscience: the official journal of the Society for Neuroscience* 18, 641-647.
- [0324] Sopher, B. L., Thomas, P. S., Jr., LaFevre-Bernt, M. A., Holm, I. E., Wilke, S. A., Ware, C. B., Jin, L. W., Libby, R. T., Ellerby, L. M., and La Spada, A. R. (2004). Androgen receptor YAC transgenic mice recapitulate SBMA motor neuropathy and implicate VEGF164 in the motor neuron degeneration. *Neuron* 41, 687-699.
- [0325] Spriggs, K. A., Cobbold, L. C., Ridley, S. H., Coldwell, M., Bottley, A., Bushell, M., Willis, A. E., and Siddle, K. (2009). The human insulin receptor mRNA contains a functional internal ribosome entry segment. *Nucleic acids research* 37, 5881-5893.
- [0326] Spriggs, K. A., Stoneley, M., Bushell, M., and Willis, A. E. (2008). Re-programming of translation following cell stress allows IRES-mediated translation to predominate. *Biology of the cell/under the auspices of the European Cell Biology Organization* 100, 27-38.
- [0327] Stolze, H., Klebe, S., Petersen, G., Raethjen, J., Wenzelburger, R., Witt, K., and Deuschl, G. (2002). Typical features of cerebellar ataxic gait. *Journal of neurology, neurosurgery, and psychiatry* 73, 310-312.
- [0328] Ul-Hussain, M., Zoidl, G., Klooster, J., Kamer-mans, M., and Dermietzel, R. (2008). IRES-mediated translation of the carboxy-terminal domain of the horizontal cell specific connexin Cx55.5 in vivo and in vitro. *BMC molecular biology* 9, 52.
- [0329] Van Damme, P., Van Hoecke, A., Lambrechts, D., Vanacker, P., Bogaert, E., van Swieten, J., Carmeliet, P., Van Den Bosch, L., and Robberecht, W. (2008). Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. *The Journal of cell biology* 181, 37-41.
- [0330] Watanabe, M., and Kano, M. (2011). Climbing fiber synapse elimination in cerebellar Purkinje cells. *The European journal of neuroscience* 34, 1697-1710.
- [0331] Watase, K., Barrett, C.F., Miyazaki, T., Ishiguro, T., Ishikawa, K., Hu, Y., Unno, T., Sun, Y., Kasai, S., Watanabe, M., et al. (2008). Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels. *Proceedings of the National Academy of Sciences of the United States of America* 105, 11987-11992.
- [0332] Wilkins, M. R., Gasteiger, E., Bairoch, A., Sanchez, J. C., Williams, K. L., Appel, R. D., and Hochstrasser, D. F. (1999). Protein identification and analysis tools in the ExPASy server. *Methods Mol Biol* 112, 531-552.
- [0333] Wilson, J. E., Powell, M. J., Hoover, S. E., and Sarnow, P. (2000). Naturally occurring dicistronic cricket paralysis virus RNA is regulated by two internal ribosome entry sites. *Molecular and cellular biology* 20, 4990-4999.
- [0334] Zacharias, D. A., and Kappen, C. (1999). Developmental expression of the four plasma membrane calcium ATPase (Pmca) genes in the mouse. *Biochimica et biophysica acta* 1428, 397-405.
- [0335] Zhuchenko, O., Bailey, J., Bonnen, P., Ashizawa, T., Stockton, D. W., Amos, C., Dobyns, W. B., Subramony, S. H., Zoghbi, H. Y., and Lee, C. C. (1997). Autosomal dominant cerebellar ataxia (SCA6) associated with small poly-

glutamine expansions in the alpha 1A-voltage-dependent calcium channel. *Nature genetics* 15, 62-69.

[0336] Zu, T., Duvick, L. A., Kaytor, M. D., Berlinger, M. S., Zoghbi, H. Y., Clark, H. B., and Orr, H. T. (2004). Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. *The Journal of neuroscience: the official journal of the Society for Neuroscience* 24, 8853-8861.

[0337] Zucker, R. S., and Regehr, W. G. (2002). Short-term synaptic plasticity. *Annual review of physiology* 64, 355-405.

[0338] Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic acids research* 31, 3406-3415.

[0339] Du, X., Rosenfield, R. L., and Qin, K. (2009). KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat storage in women. *The Journal of clinical endocrinology and metabolism* 94, 2594-2601.

[0340] Jun, K., Piedras-Renteria, E. S., Smith, S. M., Wheeler, D. B., Lee, S. B., Lee, T. G., Chin, H., Adams, M. E., Scheller, R. H., Tsien, R. W., et al. (1999). Ablation of P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit. *Proceedings of the National Academy of Sciences of the United States of America* 96, 15245-15250.

[0341] Kordasiewicz, H. B., Thompson, R. M., Clark, H. B., and Gomez, C. M. (2006). C-termini of P/Q-type Ca2+ channel alpha1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. *Human molecular genetics* 15, 1587-1599.

[0342] Miyazaki, T., and Watanabe, M. (2011). Development of an anatomical technique for visualizing the mode of climbing fiber innervation in Purkinje cells and its application to mutant mice lacking GluRdelta2 and Ca(v)2.1. *Anatomical science international* 86, 10-18.

[0343] Zu, T., Duvick, L. A., Kaytor, M. D., Berlinger, M. S., Zoghbi, H. Y., Clark, H. B., and Orr, H. T. (2004). Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. *The Journal of neuroscience: the official journal of the Society for Neuroscience* 24, 8853-8861.

[0344] The following represents a listing of the references cited in Example 3.

[0345] 1. Moseley M L, Benzow K A, Schut L J, Bird T D, Gomez C M, Barkhaus P E, et al. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. *Neurology*. 1998; 51(6):166671.

[0346] 2. Wu Y R, Lin H Y, Chen C M, Gwinn-Hardy K, Ro L S, Wang Y C, et al. Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease. *Clin Genet*. 2004; 65(3):209-14.

[0347] 3. Jayadev S, Michelson S, Lipe H, Bird T. Cambodian founder effect for spinocerebellar ataxia type 3 (Machado-Joseph disease). *J Neurol Sci*. 2006; 250(1-2):110-3.

[0348] 4. Basri R, Yabe I, Soma H, Sasaki H. Spectrum and prevalence of autosomal dominant spinocerebellar ataxia in Hokkaido, the northern island of Japan: a study of 113 Japanese families. *J Hum Genet*. 2007; 52(10): 848-55.

[0349] 5. Klockgether T. The clinical diagnosis of autosomal dominant spinocerebellar ataxias. *Cerebellum*. 2008; 7(2):101-5.

[0350] 6. Wardle M, Majounie E, Muzaimi M B, Williams N M, Morris H R, Robertson N P. The genetic aetiology of late-onset chronic progressive cerebellar ataxia. A population-based study. *J Neurol*. 2009; 256(3):3438.

[0351] 7. Kurtzke J F. Epidemiology of amyotrophic lateral sclerosis. *Adv Neurol*. 1982; 36:281-302.

[0352] 8. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton D W, Amos C, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. *Nature Genetics*. 1997; 15(1):62-9.

[0353] 9. Craig K, Keers S M, Archibald K, Curtis A, Chinnery P F. Molecular epidemiology of spinocerebellar ataxia type 6. *Ann Neurol*. 2004; 55(5):752-5.

[0354] 10. Perlman S L. Spinocerebellar degenerations. *Handb Clin Neurol*. 2011; 100:113-40.

[0355] 11. Klockgether T. Update on degenerative ataxias. *Curr Opin Neurol*. 2011; 24(4):339-45.

[0356] 12. Marelli C, Cazeneuve C, Brice A, Stevanin G, Durr A. Autosomal dominant cerebellar ataxias. *Rev Neurol (Paris)*. 2011; 167(5):385-400.

[0357] 13. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. *Lancet Neurol*. 2010; 9(9):885-94.

[0358] 14. Tsuji S, Onodera O, Goto J, Nishizawa M. Sporadic ataxias in Japan—a population-based epidemiological study. *Cerebellum*. 2008; 7(2):189-97.

[0359] 15. Lopez-Bastida J, Perestelo-Perez L, Monton-Alvarez F, Serrano-Aguilar P. Social economic costs and health-related quality of life in patients with degenerative cerebellar ataxia in Spain. *Mov Disord*. 2008; 23(2): 212-7.

[0360] 16. Shao J, Diamond M I. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. *Hum Mol Genet*. 2007; 16 Spec No. 2:R115-23.

[0361] 17. Bauer P O, Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. *J Neurochem*. 2009; 110(6):1737-65.

[0362] 18. La Spada A R, Taylor J P. Repeat expansion disease: progress and puzzles in disease pathogenesis. *Nat Rev Genet*. 2010; 11(4):247-58.

[0363] 19. He X H, Lin F, Qin Z H. Current understanding on the pathogenesis of polyglutamine diseases. *Neurosci Bull*. 2010; 26(3):247-56.

[0364] 20. Gomez C M, Thompson R M, Gammack J T, Perlman S L, Dobyns W B, Truwit C L, et al. Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. *Ann Neurol*. 1997; 42(6):933-50.

[0365] 21. Koeppe A H. The hereditary ataxias. [Review] [74 refs]. *Journal of Neuropathology & Experimental Neurology*. 1998; 57(6):531-43.

[0366] 22. Havel L S, Li S, Li X J. Nuclear accumulation of polyglutamine disease proteins and neuropathology. *Mol Brain*. 2009; 2:21.

[0367] 23. Pula J H, Towle V L, Staszak V M, Cao D, Bernard J T, Gomez C M. Retinal Nerve Fibre Layer and

- Macular Thinning in Spinocerebellar Ataxia and Cerebellar Multisystem Atrophy. *Neuroophthalmology*. 2011; 35(3):108-14.
- [0368] 24. Elden A C, Kim H J, Hart M P, Chen-Plotkin A S, Johnson B S, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature*. 2010; 466(7310):1069-75.
- [0369] 25. Yalcin O. Genes and molecular mechanisms involved in the epileptogenesis of idiopathic absence epilepsies. *Seizure*. 2011.
- [0370] 26. Rajakulendran S, Kaski D, Hanna M G. Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS. *Nat Rev Neurol*. 2012.
- [0371] 27. Jen J, G. W. Kim G W, R. W. Baloh R W. Clinical spectrum of episodic ataxia type 2. *Neurology*. 2004; 62:17-22.
- [0372] 28. Spacey S D, Materek L A, Szczygielski B I, Bird T D. Two novel CACNA1A gene mutations associated with episodic ataxia type 2 and interictal dystonia. *Arch Neurol*. 2005; 62(2):314-6.
- [0373] 29. Roubertie A, Echenne B, Leydet J, Soete S, Krams B, Rivier F, et al. Benign paroxysmal tonic upgaze, benign paroxysmal torticollis, episodic ataxia and CACNA1A mutation in a family. *J Neurol*. 2008; 255(10):1600-2.
- [0374] 30. Kordasiewicz H B, Gomez C M. Molecular pathogenesis of spinocerebellar ataxia type 6. *Neurotherapeutics*. 2007; 4(2):285-94.
- [0375] 31. Lory P, Mezghrani A. Calcium channelopathies in inherited neurological disorders: relevance to drug screening for acquired channel disorders. *IDrugs*. 2010; 13(7):467-71.
- [0376] 32. Matsuyama Z, Minoru Wakamori, Mori Y, Kawakami H, Nakamura S, Imoto K. Direct Alteration of the P/Q-Type Ca²⁺ Channel Property by Polyglutamine Expansion in Spinocerebellar Ataxia 6. *J. Neurosci*. 1999;RC14:1-5.
- [0377] 33. Restituito S, Thompson R, Charnet P, Gomez C M. The polyglutamine expansion in spinocerebellar ataxia type 6 causes a β subunit-specific enhanced activation of P/Q-type calcium channels in *Xenopus* oocytes. *J. Neurosci*. 2000; 20(17):6394-403.
- [0378] 34. Toru S, Murakoshi T, Ishikawa K, Saegusa H, Fujigasaki H, Uchihara T, et al. Spinocerebellar ataxia type 6 mutation alters P-type calcium channel function. *Journal of Biological Chemistry*. 2000; 275(15):10893-8.
- [0379] 35. Piedras-Renteria E S, Watase K, Harata N, Zhuchenko O, Zoghbi H Y, Lee C C, et al. Increased expression of alpha 1A Ca²⁺ channel currents arising from expanded trinucleotide repeats in spinocerebellar ataxia type 6. *J Neurosci*. 2001; 21(23):9185-93.
- [0380] 36. Chen H, Piedras-Renteria E S. Altered frequency-dependent inactivation and steady-state inactivation of polyglutamine-expanded alpha1A in SCA6. *Am J Physiol Cell Physiol*. 2007; 292(3):C1078-86.
- [0381] 37. Saegusa H, Wakamori M, Matsuda Y, Wang J, Mori Y, Zong S, et al. Properties of human Cav2.1 channel with a spinocerebellar ataxia type 6 mutation expressed in Purkinje cells. *Mol Cell Neurosci*. 2007; 34(2):261-70.
- [0382] 38. Watase K, Barrett C F, Miyazaki T, Ishiguro T, Ishikawa K, Hu Y, et al. Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels. *Proc Natl Acad Sci USA*. 2008; 105(33):11987-92.
- [0383] 39. Riley B E, Orr H T. Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle. *Genes Dev*. 2006; 20(16):2183-92.
- [0384] 40. La Spada A R, Taylor J P. Polyglutamines placed into context. *Neuron*. 2003; 38(5):681-4.
- [0385] 41. Robertson A L, Bottomley S P. Towards the treatment of polyglutamine diseases: the modulatory role of protein context. *Curr Med Chem*. 2010; 17(27):3058-68.
- [0386] 42. Matsuyama Z, Kawakami H, Maruyama H, Izumi Y, Komure O, Uda F, et al. Molecular features of the cag repeats of spinocerebellar ataxia 6 (scab). *Human Molecular Genetics*. 1997; 6(8):1283-7.
- [0387] 43. Ishikawa K, Fujigasaki H, Saegusa H, Ohwada K, Fujita T, Iwamoto H, et al. Abundant expression and cytoplasmic aggregations of alpha 1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6. *Human Molecular Genetics*. 1999; 8(7):1185-93.
- [0388] 44. Koeppen A H. The pathogenesis of spinocerebellar ataxia. *Cerebellum*. 2005; 4(1):62-73.
- [0389] 45. Takahashi T, Katada S, Onodera O. Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going? *J Mol Cell Biol*. 2010; 2(4):180-91.
- [0390] 46. Scott V E, Felix R, Arikath J, Campbell K P. Evidence for a 95 kDa short form of the alpha 1A subunit associated with the omega-conotoxin MVIIC receptor of the P/Q-type Ca²⁺ channels. *J Neurosci*. 1998; 18(2):641-7.
- [0391] 47. Kubodera T, Yokota T, Ohwada K, Ishikawa K, Miura H, Matsuoka T, et al. Proteolytic cleavage and cellular toxicity of the human alpha 1A calcium channel in spinocerebellar ataxia type 6. *Neurosci Lett*. 2003; 341(1):74-8.
- [0392] 48. Kordasiewicz H B, Thompson R M, Clark H B, Gomez C M. C-termini of P/Q-type Ca²⁺ channel α 1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. *Hum Mol Genet*. 2006; 15(10):1587-99.
- [0393] 49. Marqueze-Pouey B, Martin-Moutot N, Sakkou-Norton M, Leveque C, Ji Y, Cornet V, et al. Toxicity and endocytosis of spinocerebellar ataxia type 6 polyglutamine domains: role of myosin IIb. *Traffic*. 2008; 9(7):1088-100.
- [0394] 50. Ishiguro T, Ishikawa K, Takahashi M, Obayashi M, Amino T, Sato N, et al. The carboxy-terminal fragment of alpha(1A) calcium channel preferentially aggregates in the cytoplasm of human spinocerebellar ataxia type 6 Purkinje cells. *Acta Neuropathol*. 2010; 119(4):447-64.
- [0395] 51. Hellen C U, Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. *Genes Dev*. 2001; 15(13):1593-612.
- [0396] 52. Cornelis S, Bruynooghe Y, Denecker G, Van Huffel S, Tinton S, Beyaert R. Identification and characterization of a novel cell cycle-regulated internal ribosome entry site. *Mol Cell*. 2000; 5(4):597605.

- [0397] 53. Lauring A S, Overbaugh J. Evidence that an IRES within the Notch2 coding region can direct expression of a nuclear form of the protein. *Mol Cell*. 2000; 6(4):939-45.
- [0398] 54. Du X L, Wang J, Zhu H, Rinaldo L, Hu Y, Lamar K, Palmenberg A C, Hansel, C, Gomez C. A second cistron in the CACNA1A gene encodes a transcription factor that mediates cerebellar development and SCA6, in preparation.
- [0399] 55. Gomez-Ospina N, Tsuruta F, Barreto-Chang O, Hu L, Dolmetsch R. The C terminus of the L-type voltage-gated calcium channel Ca(V) 1.2 encodes a transcription factor. *Cell*. 2006; 127(3):591-606.
- [0400] 56. Barbado M, Fablet K, Ronjat M, De Waard M. Gene regulation by voltage-dependent calcium channels. *Biochim Biophys Acta*. 2009; 1793(6):1096-104.
- [0401] 57. Hibino H, Pironkova R, Onwumere O, Rousset M, Charnet P, Hudspeth A J, et al. Direct interaction with a nuclear protein and regulation of gene silencing by a variant of the Ca2+-channel beta 4 subunit. *Proc Natl Acad Sci USA*. 2003; 100(1):307-12.
- [0402] 58. Latchman D S. Transcription-factor mutations and disease. *N Engl J Med*. 1996; 334(1):28-33.
- [0403] 59. Yang Y X, Latchman D S. Nurrl transcriptionally regulates the expression of alpha-synuclein. *Neuroreport*. 2008; 19(8):867-71.
- [0404] 60. Egly J M, Coin F. A history of TFIIH: two decades of molecular biology on a pivotal transcription/repair factor. *DNA Repair (Amst)*. 2011; 10(7):714-21.
- [0405] 61. Adkins N L, Georgel P T. McCP2: structure and function. *Biochem Cell Biol*. 2011; 89(1):1-11.
- [0406] 62. Shoubridge C, Fullston T, Gecz J. ARX spectrum disorders: making inroads into the molecular pathology. *Hum Mutat*. 2010; 31(8):889-900.
- [0407] 63. Daniel R, He Z, Carmichael K P, Halper J, Bateman A. Cellular localization of gene expression for progranulin. *J Histochem Cytochem*. 2000; 48(7):999-1009.
- [0408] 64. Su A I, Wiltshire T, Batalov S, Lapp H, Ching K A, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. *Proc Natl Acad Sci USA*. 2004; 101(16):6062-7.
- [0409] 65. Empon R M, Garside M L, Knopfel T. Plasma membrane Ca2+ ATPase 2 contributes to short-term synapse plasticity at the parallel fiber to Purkinje neuron synapse. *J Neurosci*. 2007; 27(14):3753-8.
- [0410] 66. Li S H, Cheng A L, Li H, Li X J. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin. *J Neurosci*. 1999; 19(13):5159-72.
- [0411] 67. Zu T, Duvick L A, Kaytor M D, Berlinger M S, Zoghbi H Y, Clark HB, et al. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. *J Neurosci*. 2004; 24(40):8853-61.
- [0412] 68. Fureman B E, Jinnah H A, Hess E J. Triggers of paroxysmal dyskinesia in the calcium channel mouse mutant tottering. *Pharmacol Biochem Behav*. 2002; 73(3):631-7.
- [0413] 69. Weisz C J, Raikie R S, Soria-Jasso L E, Hess E J. Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. *J Neurosci*. 2005; 25(16):4141-5.
- [0414] 70. Du X, Rosenfield R L, Qin K. KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women. *J Clin Endocrinol Metab*. 2009; 94(7):2594-601.
- [0415] 71. Huang da W, Sherman B T, Lempicki R A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc*. 2009; 4(1):44-57.
- [0416] 72. Pepke S, Wold B, Mortazavi A. Computation for ChIP-seq and RNA-seq studies. *Nat Methods*. 2009; 6(11 Suppl):522-32.
- [0417] 73. Benn C L, Sun T, Sadri-Vakili G, McFarland K N, DiRocco DP, Yohrling G J, et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. *J Neurosci*. 2008; 28(42):10720-33.
- [0418] 74. Li X, Zhu C, Tu W H, Yang N, Qin H, Sun Z. ZMIZ1 preferably enhances the transcriptional activity of androgen receptor with short polyglutamine tract. *PLoS One*. 2011; 6(9):e25040.
- [0419] 75. Boy J, Schmidt T, Wolburg H, Mack A, Nuber S, Bottcher M, et al. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. *Hum Mol Genet*. 2009; 18(22):4282-95.
- [0420] 76. Wang A, Das P, Switzer R C, 3rd, Golde T E, Jankowsky J L. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. *J Neurosci*. 2011; 31(11):4124-36.
- [0421] 77. Yabe I, Sasaki H, Matsuura T, Takada A, Wakisaka A, Suzuki Y, et al. Scali mutation analysis in a large cohort of the Japanese patients with late-onset pure cerebellar ataxia. *Journal of the Neurological Sciences*. 1998; 156(1):89-95.
- [0422] 78. Takahashi E, Ino M, Miyamoto N, Nagasu T. Expression analysis of P/Q-type Ca2+ channel alpha 1A subunit mRNA in olfactory mitral cell in N-type Ca2+ channel alpha 1B subunit gene-deficient mice. *Neurosci Lett*. 2004; 359(1-2):37-40.
- [0423] 79. Fletcher C F, Lutz C M, O'Sullivan T N, Shaughnessy J J, Hawkes R, Frankel W N, et al. Absence of epilepsy in tottering mutant mice is associated with calcium channel defects. *Cell*. 1996; 87(4):607-17.
- [0424] 80. Lau F C, Abbott L C, Rhyu L T, Kim D S, Chin H. Expression of calcium channel alpha1A mRNA and protein in the leaner mouse (tgla/tgla) cerebellum. *Brain Res Mol Brain Res*. 1998; 59(1):93-9.
- [0425] 81. Sidman R L, Appel S H, Fullier J F. Neurological Mutants of the Mouse. *Science*. 1965; 150(3695):513-6.
- [0426] 82. Herrup K, Wilczynski S L. Cerebellar cell degeneration in the leaner mutant mouse. *Neuroscience*. 1982; 7(9):2185-96.
- [0427] 83. Gomez C M, Bhattacharyya B B, Charnet P, Day J W, Labarca C, Wollmann R W, et al. A transgenic mouse model of the slow-channel syndrome. *Muscle and Nerve*. 1996; 19:79-87.

- [0428] 84. Gomez C M, Maselli R, Gundeck J E, Chao M, Day J W, Tamamizu S, et al. Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction. *Journal of Neuroscience*. 1997; 17(11):4170-9.
- [0429] 85. Bhattacharyya B J, Day J, Gundeck J E, Leonard S, Wollmann R W, Gomez C. Desensitization of Mutant Acetylcholine Receptors in Transgenic Mice Reduces the Amplitude of Synaptic Currents. *Synapse*. 1997; 27(4):367-77.
- [0430] 86. Gomez C, Maselli R, Groshong J G, Zayas R, Wollmann R L, Thierry Cens T, et al. Active Calcium Accumulation Underlies Severe Weakness In A Panel Of Mice With Slow-Channel Syndrome. *J. Neuroscience*. 2002; 22(15):6447-57.
- [0431] 87. Vohra B P, Groshong J S, Zayas R, Wollmann R L, Gomez C M. Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model. *Neurobiol Dis*. 2006; 23(2):462-70.
- [0432] 88. Groshong J S, Spencer M J, Bhattacharyya B J, Kudryashova E, Vohra B P, Zayas R, et al. Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome. *J Clin Invest*. 2007; 117(10):2903-12.
- [0433] 89. Zayas R, Groshong J S, Gomez C M. Inositol-1,4,5-triphosphate receptors mediate activity-induced synaptic Ca²⁺ signals in muscle fibers and Ca²⁺ overload in slow-channel syndrome. *Cell Calcium*. 2007; 41(4):343-52.
- [0434] 90. Zhu H, Bhattacharyya B J, Lin H, Gomez C M. Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals. *J Neurosci*. 2011; 31(43):15269-83.
- [0435] 91. Zhu H, Gomez C. Further evidence for the role of Ins(1,4,5)P3R1 in regulating subsynaptic gene expression and neuromuscular transmission. *Channels*. 2012; 6(1):1-4.
- [0436] 92. Traka M, Millen K J, Collins D, Elbaz B, Gomez C M, Popko B. A missense mutation in the cerebellar hypoplasia, mental retardation & quadrupedal locomotion (CAMRQ2) disease protein WDR81 causes Purkinje cell degeneration and photoreceptor cell loss in the mouse. submitted.
- [0437] 93. Amende I, Kale A, McCue S, Glazier S, Morgan J P, Hampton T G. Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. *J Neurorehabil*. 2005; 2:20.
- [0438] 94. Li S, Kim J E, Budel S, Hampton T G, Strittmatter S M. Transgenic inhibition of Nogo-66 receptor function allows axonal sprouting and improved locomotion after spinal injury. *Mol Cell Neurosci*. 2005; 29(1):2639.
- [0439] 95. Sillitoe R V, Hawkes R. Whole-mount immunohistochemistry: a high-throughput screen for patterning defects in the mouse cerebellum. *J Histochem Cytochem*. 2002; 50(2):235-44.
- [0440] 96. Kim S H, Kook M C, Shin Y K, Park S H, Song H G. Evaluation of antigen retrieval buffer systems. *J Mol Histol*. 2004; 35(4):409-16.
- [0441] 97. Clark H B, Burright E N, Yunis W S, Larson S, Wilcox C, Hartman B, et al. Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. *Journal of Neuroscience*. 1997; 17(19):7385-95.
- [0442] 98. Belmeguenai A, Hosy E, Bengtsson F, Pedroarena C M, Piochon C, Teuling E, et al. Intrinsic plasticity complements long-term potentiation in parallel fiber input gain control in cerebellar Purkinje cells. *J Neurosci*. 2010; 30(41):13630-43.
- [0443] 99. Shakkottai V G, do Carmo Costa M, Dell'Orco J M, Sankaranarayanan A, Wulff H, Paulson H L. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. *J Neurosci*. 2011; 31(36):13002-14.
- [0444] 100. Hourez R, Servais L, Orduz D, Gall D, Millard I, de Kerchove d'Exaerde A, et al. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. *J Neurosci*. 2011; 31(33):11795-807.
- [0445] 101. Mitchell S A, Spriggs K A, Coldwell M J, Jackson R J, Willis A E. The Apaf-1 internal ribosome entry segment attains the correct structural conformation for function via interactions with PTB and unr. *Mol Cell*. 2003; 11(3):757-71.
- [0446] 102. Stoneley M, Willis A E. Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression. *Oncogene*. 2004; 23(18):3200-7.
- [0447] 103. King H A, Cobbold L C, Willis A E. The role of IRES trans-acting factors in regulating translation initiation. *Biochem Soc Trans*. 2010; 38(6):1581-6.
- [0448] 104. Novac O, Guenier A S, Pelletier J. Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. *Nucleic Acids Res*. 2004; 32(3):902-15.

SEQUENCE LISTING

The patent application contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (<http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20160237431A1>). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

What is claimed is:

1. A method of treating spinocerebellar ataxia Type 6 (SCA6) in a subject in need thereof, comprising the step of administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject.

2. A method of treating a subject with a predisposition to spinocerebellar ataxia Type 6 (SCA6), comprising the step of administering to the subject an IRES inhibitor in an amount effective for delaying development of SCA6 in the subject.

3. The method of claim **1** or **2**, wherein the IRES inhibitor binds to the α 1A mRNA.

4. The method of claim **3**, wherein the IRES inhibitor binds upstream of the start codon of the coding sequence encoding α 1ACT of the α 1A mRNA, optionally, wherein the IRES inhibitor binds within 100 bp upstream of the start codon of the coding sequence encoding α 1ACT of the α 1A mRNA.

5. The method of claim **3**, wherein the IRES inhibitor binds to the IRES of the α 1A mRNA.

6. The method of any one of claims **3** to **5**, wherein the IRES inhibitor binds to at least a portion of the sequence of SEQ ID NO: 5.

7. The method of any one of claims **3** to **6**, wherein the IRES inhibitor binds to at least a portion of the sequence of SEQ ID NO: 6.

8. The method of any one of claims **3** to **7**, wherein the IRES inhibitor binds to at least a portion of the sequence of SEQ ID NO: 7.

9. The method of claim **3**, wherein the IRES inhibitor binds downstream of the start codon of the coding sequence encoding α 1ACT of the α 1A mRNA, optionally, wherein the IRES inhibitor binds within 100 bp downstream of the start codon of the coding sequence encoding α 1ACT of the α 1A mRNA.

10. The method of any one of the preceding claims, wherein the IRES inhibitor is an antisense molecule.

11. The method of claim **10**, wherein the antisense molecule comprises at least 15 contiguous nucleobases of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11.

12. The method of claim **11**, wherein the antisense molecule comprises at least 25 contiguous nucleobases of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11.

13. The method of claim **10**, wherein the antisense comprises at least 15 contiguous nucleobases of a sequence that (i) differs from SEQ ID NO: 9 by not more than 3 nucleobases or (ii) is at least 90% identical to the sequence set forth in SEQ ID NO: 9.

14. The method of claim **10**, wherein the antisense molecule comprises at least 15 contiguous nucleobases of a sequence that (i) differs from SEQ ID NO: 10 by not more than 3 nucleobases or (ii) is at least 90% identical to the sequence set forth in SEQ ID NO: 10.

15. The method of claim **10**, wherein the antisense molecule comprises at least 15 contiguous nucleobases of a sequence that (i) differs from SEQ ID NO: 11 by not more than 3 nucleobases or (ii) is at least 90% identical to the sequence set forth in SEQ ID NO: 11.

16. The method of any one of claims **13** to **15**, comprising at least 25 contiguous nucleobases of the sequence.

17. The method of any one of claims **10** to **16**, wherein the antisense molecule is an antisense oligonucleotide comprising nucleotides, wherein each nucleotide comprises a nucleobase and either deoxyribose or ribose.

18. The method of any one of claims **10** to **16**, wherein the antisense molecule is an antisense nucleic acid analog.

19. The method of claim **18**, wherein the antisense nucleic acid analog comprises a 6-membered morpholine ring.

20. The method of claim **18** or **19**, wherein the antisense nucleic acid analog comprises non-ionic phosphorodiamidate intersubunit linkages.

21. The method of any one of claims **18** to **20**, wherein the antisense nucleic acid analog comprises a combination of nucleobases comprising at least adenine, cytosine, guanine, and either thymine or uracil.

22. The method of any one of the preceding claims, wherein the IRES inhibitor blocks binding of the IRES of the α 1A mRNA to an IRES Trans-Acting Factor.

23. The method of claim **22**, wherein the IRES inhibitor binds to an IRES Trans-Acting Factor that binds to the IRES of the α 1A mRNA.

24. An antisense molecule comprising at least 15 contiguous nucleobases of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11.

25. The antisense molecule of claim **24**, comprising at least 25 contiguous nucleobases of SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11.

26. An antisense molecule comprising at least 15 contiguous nucleobases of a sequence that (i) differs from SEQ ID NO: 9 by not more than 3 nucleobases or (ii) is at least 90% identical to the sequence set forth in SEQ ID NO: 9.

27. An antisense molecule comprising at least 15 contiguous nucleobases of a sequence that (i) differs from SEQ ID NO: 10 by not more than 3 nucleobases or (ii) is at least 90% identical to the sequence set forth in SEQ ID NO: 10.

28. An antisense molecule comprising at least 15 contiguous nucleobases of a sequence that (i) differs from SEQ ID NO: 11 by not more than 3 nucleobases or (ii) is at least 90% identical to the sequence set forth in SEQ ID NO: 11.

29. The antisense molecule of any one of claims **26** to **28**, comprising at least 25 contiguous nucleobases of the sequence.

30. The antisense molecule of any one of claims **24** to **29**, wherein the antisense molecule is an antisense oligonucleotide comprising nucleotides comprising deoxyribose or ribose.

31. The antisense molecule of any one of claims **24** to **29**, wherein the antisense molecule is an antisense nucleic acid analog.

32. The antisense molecule of claim **31**, wherein the antisense nucleic acid analog comprises a 6-membered morpholine ring.

33. The antisense molecule of claim **31** or **32**, wherein the antisense nucleic acid analog comprises non-ionic phosphorodiamidate intersubunit linkages.

34. The antisense molecule of any one of claims **30** to **33**, comprising a combination of nucleobases comprising at least adenine, cytosine, guanine, and either thymine or uracil.

35. A pharmaceutical composition comprising the antisense molecule of any one of claims **24** to **34** and a pharmaceutically acceptable carrier, excipient, or diluent.

36. A kit comprising the antisense molecule of any one of claims **24** to **34** and a device for administration to a subject.

37. A method of identifying a compound with SCA6 therapeutic activity, comprising the steps of (i) contacting the compound with a sample comprising a nucleic acid molecule comprising at least a portion of the α 1A mRNA, wherein the portion comprises at least the nucleotide sequence of the IRES of the α 1A mRNA and the coding sequence of α 1ACT, and (ii) assaying for expression of α 1ACT, wherein the com-

pound is identified as a compound with anti-SCA6 therapeutic activity when expression of α 1ACT mRNA is reduced compared to a control.

38. The method of claim **37**, wherein the nucleic acid molecule comprises at least a portion of the sequence of SEQ ID NO: 5.

39. The method of claim **37** or **38**, wherein the coding sequence of α 1ACT comprises the sequence of SEQ ID NO: 12.

40. The method of any one of claims **37** to **39**, wherein the sample comprises proteins for in vitro translation.

41. The method of any one of claims **37** to **40**, wherein the sample comprises cells transfected with a bicistronic gene reporter construct.

42. The method of claim **41**, wherein the sample comprises cells transfected with a Renilla-luciferase/Firefly-luciferase (R-Luc/F-Luc) bicistronic reporter construct.

* * * * *